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                                               Abstract 
Modulation of inflammation in the reduction of intra 
hepatic resistance 
In cirrhosis, there is a dichotomy in the haemodynamic abnormality in the intra hepatic 
and splanchnic circulation, as a result of an imbalance between vasoactive agents. In the 
intra-hepatic circulation, there is vasoconstriction secondary to endothelial dysfunction 
and vasodilatation in the splanchnic circulation which is provoked by a multitude of 
mechanisms. Inflammation has been also implicated in propagation of the haemodynamic 
abnormalities of portal hypertension in patients with acute on chronic liver failure 
(ACLF).  
The studies conducted in this thesis aim to understand how modulating inflammation 
leads to the reduction of intra hepatic resistance. In the first part of the thesis, I validated 
the bile duct ligated rat model for my studies. I establish ADRA2a adrenergic receptor as 
the target receptor in this model to treat portal hypertension. I was able to show that a 
specific ADRA2a adrenergic receptor antagonist was able to improve the haemodynamic 
and inflammatory parameters. This strategy was also able to improve the function of the 
immune cells in this model. This provided a proof-of-concept for ADRA 2a adrenergic 
receptor as a target for intervention in ACLF to reduce inflammation and thereby reduce 
portal pressure. 
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In the second section of the thesis, I studied the role of arginine in the modulation of portal 
hypertension in a bile duct ligated rat model of cirrhosis. Thereafter, I showed a significant 
lowering of portal pressure in a BDL model of cirrhosis by L-Arginine supplementation 
via modulation of the NO-ADMA-DDAH and inflammatory pathway. The findings from 
this study provides the basis for novel agents for the treatment of portal hypertension. 
.The studies conducted within the remit of this thesis provides valuable insight into the 
pathophysiology of portal hypertension and alludes to an alternative management strategy 
for portal hypertension. 
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                                 Chapter 1 
Modulation of inflammation in the reduction of intra 
hepatic resistance 
1.1 Introduction 
The first published description of cirrhosis of the liver was in 1817 by Samuel Black of 
Newry, Ireland. The caption of this paper is: “Dissections of Two Habitual Drunkards ”. 
The case was observed in 1808 and the paper read in 1816. It has been published in the 
“Transactions of the Association of Fellows and Licentiates of the King’s and Queen’s 
College of Physicians in Ireland”, Dublin (1817), Vol. I, pp. 56-62.  Wherein, he describes 
the post mortem findings of the liver of a journeyman baker, who had a significant alcohol 
history. He states that the liver was shrunken to about a third of the size, was hard and 
rigid and dark in colour. He commented that there were numerous tubercle with variable 
size and this was also found on the liver parenchyma. 
From this early description of cirrhosis, it has become the eighteenth most common cause 
of death in the world and seventh in Europe (WHO data).In data published by the Office 
of National Statistics, cirrhosis of the liver is the second most common cause of death in 
male patients aged between 34 to 55 years accounting for about ten percent of deaths. And 
even more significantly, the second most common cause of death in female patients in the 
age group of 24 to 55 years is cirrhosis of the liver accounting up to eight percent of the 
total deaths. 
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Fig 1: National Audit Office data: Standardized mortality rate for chronic disease  
in UK 
In another set of data published by the National Audit office, it is clear that while most 
other  cause of death is going down in the United Kingdom, the death rate from cirrhosis 
has gone up significantly as shown in Figure 1. As a consequence of this increase in 
mortality and morbidity associated with cirrhosis in the UK the increase in chronic liver 
disease poses particular problems with respect significant costs to the public both in terms 
of treatment and in loss of productivity. The impact of increase incidence notably alcohol 
intake, obesity and type 2 diabetes both here in the UK and globally implies that these 
problems are likely to increase in the future. 
The incidence of cirrhosis has been estimated by several studies but all these studies 
calculated the numbers from the death certification figures. These figures may therefore 
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over-estimate the actual number of patients with cirrhosis. In a recent study from 
Nottingham, the incidence of cirrhosis was calculated after extrapolation of data from the 
general practice research database.  
It is estimated in these studies estimate 76 per 100,000 people were living with cirrhosis 
in 2001 and there is a 45% increase in the incidence of cirrhosis in the last decade, majority 
of them attributable to alcohol. Disease progression with cirrhosis among this mainly 
ambulatory population was rapid with a rate of decompensation in people with 
compensated disease of 5% per year and 1 in 10 dying in the first year following diagnosis. 
This figure increased to 25% of people dying within one year for those with 
decompensated disease. Mortality in subjects with compensated and decompensated 
cirrhosis was 93.4 and 178.0 per 1000 person years compared with only 19.2 per 1000 
person years in the general control population. Following adjustment for age and sex 
people with compensated and decompensated disease were respectively 5 and 10 times 
more likely to die than the general population (1). The statistical data presented above 
implies that the burden of liver disease will continue to challenge us to find strategies to 
improve the outcome in the next century. 
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1.2 The Pathophysiology of Portal hypertension 
Portal hypertension is the most common haemodynamic abnormality caused by cirrhosis 
of the liver in the western world (2). The onset of portal hypertension heralds the 
beginning of complications such as variceal bleeding, ascites, hepatorenal syndrome, 
spontaneous bacterial peritonitis and hepatic encephalopathy, which in turn results in 
increased morbidity and mortality. It is defined as the pathological increase of portal 
venous pressure to above 10-12 mmHg from the normal value of 5 mmHg. The portal 
venous pressure is measured by assessing the gradient between the wedged hepatic 
pressures to the free hepatic venous pressure via a transjugular route as the portal vein is 
inaccessible. The formulae used to calculate the hepatic venous pressure gradient is (3) 
HVPG = WHVP - FHVP 
The correction is required to adjust the increased intra-abdominal pressure to provide an 
accurate measurement of the portal venous pressure. The actual pressure in the portal vein 
is measured by the principles governing any pressure difference between two points, by 
applying the Ohm’s Law: 
RQP 
 
Where the delta change in pressure between any two points in the portal vein is determined 
by the rate of blood flow and the resistance applied by the wall of the vein in that section. 
 Although it is a surrogate measurement of portal venous pressure, it has been shown to 
have excellent clinical co-relation. A reduction of hepatic venous pressure gradient below 
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12 mmHG or a reduction of less than 20% from the baseline has been shown to reduce 
the incidence of variceal bleeding to less than 10% (4), (5). Recently, there has been a 
suggestion that there may be other benefits of reduction of portal pressure other than just 
lowering portal pressure, which improves the survival of patients with portal hypertension 
(6). Although there has been a great improvement in the understanding of the 
pathophysiology of portal hypertension, there is still an unmet need for the development 
of a treatment strategy for portal hypertension. 
The classical view of portal hypertension suggested that the increased resistance to portal 
blood flow to the liver is the main determinant in the propagation and maintenance of 
portal hypertension. This has been the basis of the treatment modalities available up to 
now. This  includes non-selective beta blocker (propanolol, nadolol) for the prevention of 
primary  (7) and secondary episodes of variceal bleeding (8) and short acting intravenous 
drugs like somastatin and its analogues and terlipressin (9) for the treatment of acute 
variceal bleeding which effectively reduced the splanchnic blood flow. However, recent 
evidence suggest that reduction of the splanchnic blood flow may not be the most 
appropriate treatment for certain stages of refractory ascites and can even have deleterious 
outcome (10). 
There has been a gradual paradigm shift in the understanding of the pathophysiology of 
portal hypertension. Clinicians and scientists are beginning to arrive at a consensus that 
intrahepatic resistance to portal blood flow is the initiating factor in the development of 
portal hypertension. Correction of this aspect is more likely to improve the severe 
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haemodynamic abnormality and prognosis associated with clinically significant portal 
hypertension. 
1.2.1 Increased portal blood flow resistance: 
In portal hypertension, there is an increase in the resistance to the portal blood flow. This 
can be due to the increase in intrahepatic resistance as well as resistance generated by the 
co-lateral porto-systemic circulation. 
1.2.1.1  Intra hepatic resistance: 
The normal liver is a very compliant vascular organ whereby it can accommodate increase 
in portal blood blow, without any detrimental effect. The intra hepatic vascular tree is able 
to dilate appropriately in response to the increased blood flow as seen in the context of 
postprandial increase in portal blood flow. The main site of resistance in a normal liver 
has been suggested to be at the hepatic sinusoids, terminal hepatic venules and portal 
venules.  However as the portal pressure remains within the normal level of 4-8 mmHg, 
there is no real significance to the resistance (11). 
However, this compliance is not seen in portal hypertension. Intrahepatic resistance (IHR) 
was classically thought to be as a result of the mechanical effects of cirrhosis including 
fibrosis, thrombosis and nodule formation which leads to abnormal architecture of the 
sinusoidal space and hence distortion to the laminar flow of blood (12). The exact site of 
intra hepatic resistance is variable and can change according to etiological factors and 
disease process. Chronic hepatitis appears to have both pre-sinusoidal and sinusoidal 
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vascular abnormalities which contribute towards the increased resistance (13) where as 
there is abnormal architecture in the sinusoidal and post sinusoidal site (14), when liver 
injury is caused by ischaemia. As the disease progresses, there is terminal vein fibrosis, 
reduction in sinusoidal space by enlarging hepatocyte and deposition of collagen in the 
space of disse, all of which contribute to the increased vascular resistance. Thus, at the 
beginning of research into this area, the importance was given to the anatomical 
abnormalities as the most important cause of portal hypertension. There is some emerging 
evidence that anatomical architectural deformities can be corrected by treatment of 
underlying condition like treatment of Hepatitis C (15) 
The seminal paper by Mittal and Groszmann in 1984 gave the first indication into the 
presence of a modifiable component in the intra hepatic vasculature (16). Bhathal and 
Grossman in 1985 confirmed this perspective and led to the theory of presence of a 
pharmacologically modifiable vascular element in addition to the mechanical factors that 
influence intra hepatic resistance (17). A significant body of research has evolved since 
then to understand and apply this principle to modify intra hepatic resistance as a 
treatment of portal hypertension. 
It has been estimated that this dynamic and reversible component of intrahepatic 
resistance may account for about 30-40% of the total resistance in the cirrhotic liver. 
These include vascular smooth muscle cells present in the intra hepatic vasculature (18) 
activated hepatic stellate cells and hepatic myofibroblasts (19, 20) that may distort the 
regenerative nodule within the fibrous septa. In addition to these factors, there is also an 
imbalance between the intrahepatic vasoactive agents. Angiotensin II, endothelin I, 
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adrenergic stimulation are some of the agents which propagate the vasoconstriction of the 
intra hepatic microcirculation (21), (22). On the other hand, Nitric oxide, CO, H2S are 
some of the vasodilators present in the intra hepatic circulation. Normally, vascular tone 
is maintained by a delicate balance between the vasoconstrictors and vasodilators. 
Endothelial dysfunction (ED) implicate a loss of function of numerous activities of the 
endothelium (23), mainly characterised by impairment of the production and release of 
endothelium driven vasodilatory factors including NO (24), (25).  Endothelial dysfunction 
is thought to be a key event in the development of distinct human vascular diseases, 
including liver cirrhosis, hypertension, diabetes and atherosclerosis. Reduced NO 
bioavailability makes a major contribution to endothelial dysfunction and is mainly due 
to reduced NO production or increased NO breakdown due to the chemical reaction with 
oxidant radicals (26). The hepatic vascular bed of cirrhotic liver exhibits ED and is now 
considered to play a key role in the initiation and advancement of liver cirrhosis.  
As a result, there is an abundance of vasoconstrictors and a lack of vasodilators especially 
nitric oxide (NO) ((27), (25),(28) , (29)) which leads to intrahepatic vasoconstriction and 
increased resistance. NO, in particular has been shown to have a potent vasodilator 
function and plays an important role in maintaining the vascular tone in normal livers 
(16). The deficiency of NO is due to the loss of activity of endothelial Nitric Oxide 
Synthetase, which is the rate-limiting enzyme in the synthesis of NO. Although the protein 
expression of eNOS remains same or increases, there is loss of activity, which suggest 
that there is a post translational modification in the eNOS protein, hence leading to its 
inactivation (25). Among the culprits for this modification that may influence hepatic 
eNOS activity is reduction in the akt mediated phosphorylation of eNOS and increased 
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expression of caveolin I (30), (28). Furthermore, eNOS may be unable to synthesize NO 
in the presence of oxidative stress which depletes the essential co-factor like 
tetrahydrobiopterin which are essential for the oxidation process to take place for NO 
synthesis (31) leading to uncoupling of the eNOS protein. There has been recent interest 
in the elevated levels of the endogenous inhibitor Asymmetrical Dimethyl Arginine 
(ADMA), which leads to inhibition of eNOS, thus leading to decrease NO production 
(32). In addition, there is scavenging of the produced NO by reactive oxygen species 
which can be prevented by the use of anti-oxidants (33) (34) 
The hepatic stellate cells located in the sinusoids with perisinusoidal and inter cellular 
branching acquire contractile properties and modulate intra hepatic resistance 
dynamically (35). They synthesize collagen and form a myofibrobalst like matrix around 
the sinusoids and terminal hepatic venules in cirrhotic livers and have been shown to have 
an enhanced response to endothelins (36). The endocannabinoid system has also been 
implicated in the activation of hepatic stellate cells and cannabinoid receptor CB1 
upregulation is associated with fibrogenesis of the liver and some associated metabolic 
effects like insulin resistance and dyslipidaemia (37). 
Thus, in summary, there is a combination of reversible dynamic component and 
irreversible components, which lead to increase in intra hepatic resistance. 
1.2.1.2  Portosystemic collateral resistance 
Portosystemic collaterals are formed as a result of portal hypertension as a means to 
decompress the portal circulation by diverting blood to the systemic circulation by 
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opening up of unopened and new blood vessels. However, the resistances present in these 
vessels are still more than normal vascular resistance, therefore, they contribute to the 
overall resistance of blood flow. 
1.2.2 Splanchnic vasodilatation 
The other important phenomenon occurs in the systemic circulation in cirrhosis is 
splanchnic vasodilatation. This is associated with an increase flow in the splanchnic 
circulation, which contributes to the propagation and maintenance of portal hypertension 
(38). This is manifested by the classical phenomenon of vascular hyporeactivity  to vaso 
constrictors which can be corrected by removal of the endothelium (39) and 
overproduction of NO. The importance of this overproduction of NO is implicated by the 
fact that a non-specific inhibition of NOS leads to the correction of the haemodynamic 
abnormalities in the splanchnic circulation (40). The main enzyme responsible for this 
increased NO production is endothelial Nitric Oxide Synthetase (eNOS). This is proven 
by the increased protein expression (41) and activity of eNOS (42) and excessive 
production of NO by the pulsatile flow and shear stress generated activation of the eNOS 
enzyme (43). Although there is good evidence to suggest that eNOS is the main enzyme 
responsible for the NO overproduction (44) there is evidence that the upregulation of 
eNOS prior to onset of the hyperdynamic circulation suggesting that there may be other 
factors involved in the increased production of NO (45). In 1991, Moncada and colleagues 
showed that endotoxemia present in liver cirrhosis model caused  upregulation of 
inducible Nitric Oxide Synthetase (iNOS) which acted as a source of increased NO 
production and resulting in the hyperdynamic circulation (46). Subsequently it has been 
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shown that selective inhibition of iNOS does not abrogate the hyperdynamic circulation 
and vascular hyporesponsiveness to vasoconstrictors (47), thus suggesting that iNOS 
production may not have a direct effect on splanchnic vascular regulation. Furthermore, 
it has been shown in several studies that there is a causal relationship between 
endotoxemia and NO production (48) (49). There is also suggestion that neuronal NOS 
(nNOS) normally found in the neurons and vascular smooth muscle cells is upregulated 
in the mesenteric arteries (50)and aorta and takes part in the progression and maintenance 
of hyperdynamic circulation of cirrhosis (51).Several other factors have been implicated 
in the upregulation of the eNOS enzyme and among them, the presence of co-factors like 
Calcium, Calmodulin and tetrahydyobiopterin, which is increased by circulating 
endotoxin are important (52). Among the positive regulators, Heat Shock Protein 90 
(Hsp90) (53) and akt phosphorylation contributes to the splanchnic eNOS activation (54). 
The portal pressure can also dictate the amount of splanchnic dilatation as a rise in portal 
pressure increases the shear stress which leads to increase phosphorylation of eNOS via 
the akt/protein kinase B pathway (44).Vascular Endothelial Growth Factor (VEGF) is one 
of the most important potent inducer of angiogenesis and eNOS phosphorylation via the 
akt pathway and it helps to propagate and maintain the hyperdynamic circulation in 
cirrhosis(55). There is also some suggestion from the literature that the alteration of the 
eNOS protein from its normal sub-cellular location near the golgi body to the plasma 
membrane make it more able to produce NO and may be related to the endothelial 
dysfunction in the splanchnic vasculature noted in cirrhosis (56). Furthermore, recently it 
has been shown that eNOS is negatively regulated by S-nitrosylated, which means 
addition of a NO group to a thiol side chain to a cystiene residue (57) 
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Among other molecules that have been implicated in the splanchnic vasodilation in 
cirrhosis is carbon monoxide (CO), which is a byproduct of the Heme Oxygenase (HO) 
pathway through which there is activation of soluble Guanylate Cyclase (sGC) in the 
vascular smooth muscle cells leading to vasodilatation and hyperdynamic circulation (58). 
Prostacylin I, derived from the cycloxygenase pathway has been found be increase in 
cirrhosis and acts on the adenyl cyclase to induce vasodilatation (59). There is also a 
suggestion of involvement of the endocannabinoid system in the splanchnic vasodilatation 
as it already known that anandamide, a cannabinoid receptor 1 (CB1) receptor agonist is 
elevated in cirrhosis and participates in vasodilatation of the mesenteric vessels but there 
is an ongoing controversy whether its mechanism involves NO or not (60). A growing 
body of evidence also suggests the involvement of Hydrogen Sulphide (H2S) in the 
vasodilatation of the aorta and mesentery via the opening of the kATP  channel and 
independent of the cGMP pathway (61), (62). Another molecule that has been shown to 
be involved in the propagation of the hyperdynamic circulation is the pro-inflammatory 
cytokine TNFα, although there is still some controversy about the exact mechanism 
involved. The proof that it is implicated in this process is given by the study using 
thalidomide, an anti-TNFα agent in portal hypertensive rats which abrogates the 
hyperdynamic circulation (63). It has been suggested that TNFα induces synthesis of 
tetrahydrobiopterin, which is an essential co-factor of eNOS in the synthesis of NO (64) 
and it is also implicated in the induction of iNOS in the aorta to play a part in the 
maintenance of the hyperdynamic circulation (65).Lastly, another molecule that has been 
found to be increased in cirrhosis is adrenomedullin, which is an endogenous potent 
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vasodilatory peptide, which is thought to be working through the cGMP and the akt 
phosphorylation pathways (66, 67) 
In addition to arterial hypotension, there is also volume expansion, which helps to 
maintain the hyperdynamic circulation. Peripheral vasodilatation leads to activation of the 
baroreceptors and volume receptors which in turn activate the neurohumoral system and 
the renin angiotensin system. The consequence is absorption of salt and water from the 
kidneys leading to increased plasma volume. This increased plasma volume and 
peripheral vasodilatation leads to increased splanchnic blood flow. In cirrhosis, the 
increased blood flow leads to aggravation of the intra hepatic resistance, which is already 
increased as result of intra hepatic endothelial dysfunction. 
In summary, the intra hepatic resistance is the initiator of portal hypertension and the 
splanchnic vasodilatation and consequent increased blood flow to the liver maintains and 
propagates portal hypertension. There is an imbalance between the vasodilators and 
vasoconstrictors in the intra hepatic and splanchnic circulation with opposing effects. 
There has been multiple factors which have been implicated in the pathogenesis of portal 
hypertension, nitric oxide being one of the most important factor influencing this process. 
The modulation of nitric oxide remains an important strategy to decrease intra hepatic 
resistance and various strategies have already been applied to increase the availability of 
NO in the intra hepatic circulation.  
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1.3 The impact of Inflammation on portal hypertension 
The onset of portal hypertension is the defining event in the clinical course of a cirrhotic 
patient (68). It is associated with the development of complication from portal 
hypertension which include variceal bleeding, ascites, spontaneous bacterial peritonitis 
and hepatic encephalopathy. All of these complications are associated with poor outcome. 
Portal hypertension in cirrhosis is propagated by two components. Splanchnic 
vasodilatation is caused by reduced systemic vascular resistance and results in increased 
blood flow to the liver. The primary haemodynamic change is recognised to be the 
increased intra hepatic resistance (IHR). IHR has two important component. One is 
termed as the fixed component, which is as a result of architechtural distortion due to 
nodule formation and microthrombi. However, it is being increasingly recognised that the 
intra hepatic vascular tone and the contractility are a significant component of IHR. The 
splanchnic vasodilatation and hyperdynamic circulation associated with portal 
hypertension in cirrhosis is thought to be a compensatory mechanism as a consequence of 
the increased intra hepatic resistance. 
Pro inflammatory cytokines have been shown to be elevated in liver cirrhosis (69). 
Lemmers et al showed that progressive elevation of IL-6 levels were found in patients 
with cirrhosis and alcoholic hepatitis as compared to normal controls. The levels of pro 
inflammatory cytokines have been shown to have been increased in alcoholic hepatitis 
(70). In a more recent study by our group, we have shown that TNFα is an important 
mediator of portal and systemic haemodynamic derangement in alcoholic hepatitis. In this 
study, Dr.Mookerjee shows that the plasma TNFα level was directly related to the severity 
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of liver disease i.e. it was highest in the group of patients with alcoholic hepatitis as 
compared to the cirrhotic patients. In the same study, an anti TNFα agent (Infliximab) was 
used in all ten patients as a one off bolus dose and the patients were assessed at 24 hours 
and on the day of discharge. The portal pressure was significantly reduced after 24 hours 
of administration of infliximab and it remained low at the time of discharge. The systemic 
vascular resistance was increased and there was improvement in the hepatic and renal 
blood flow. This study provides proof of the role of TNFα as a pro inflammatory cytokine 
in the propagation of portal hypertension (71). 
Acute on chronic liver failure is a recently described clinical syndrome wherein there is 
acute deterioration of liver function precipitated by superimposed liver injury or 
superadded infection. The definition and natural history of this clinical syndrome has been 
established in the recently concluded European consortium study CANONIC study where 
the ACLF patients were differentiated from patients with acute decompensation by the 
presence of one or more organ failure, presence of high systemic inflammatory response 
and high mortality within 28 days of admission. In fact the high systemic inflammatory 
response was identified as the key precipitating factor in the pathogenesis of this 
syndrome. (72).Studies in patients with acute severe alcoholic hepatitis have shown that 
they have a higher portal pressure as compared to decompensated cirrhosis (73). 
1.3.1 The impact of inflammation on intra hepatic resistance 
Cirrhosis is characterized by architectural distortion resulting in resistance to sinusoidal 
blood flow. This is primarily caused by nodule formation and scarring of the liver. 
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However increasingly increased vascular tone because of an imbalance between the 
vasoactive agents is being implicated as a more important aspect of increase intra hepatic 
resistance in portal hypertension. Nitric oxide (NO) has been demonstrated to be a key 
regulator of intrahepatic vascular tone, and NO production from endothelial nitric oxide 
synthase (eNOS) in the sinusoidal endothelial cell (SEC) is decreased in cirrhosis (16), 
(27).NO modulates the vascular tone by acting on the smooth muscle cells. Intra hepatic 
resistance is also regulated by activated hepatic stellate cells, which adapt a 
myofibroblastic phenotype upon activation. Activated HSC also played a key role in the 
development of angiogenesis leading to intra hepatic shunting and vascular collateral 
formation. 
 
Hepatic innate immune signaling also has a role in the propagation of increased intra 
hepatic resistance. It plays a part in both increased fibrosis and vascular tone. The role of 
Pathogen associated molecular pattern (PAMP) in the progression of fibrosis has been 
shown in rodent models where in various knockout of the Toll Like Receptor (TLR) 
pathway such as CD14, Liposaccharide Binding Protein (LBP), MYd88, TIR-domain-
containing adapter-inducing interferon-β (TRIF) have shown reduction in fibrosis in Bile 
duct ligated (BDL) and Carbon tetrachloride (CCL4) model ((74), (75)). These pathways 
have been demonstrated as Kupffer Cell (KC) independent processes. However, in 
advanced liver disease, hepatic stellate cells (HSC) play a more active role in the 
development of hepatic inflammation and oxidative stress, which in turn increases the 
intra hepatic vascular tone. The upregulation of the TLR signaling pathway promotes the 
production of pro inflammatory cytokines which include TNFα , IL6 and IL8, initiating 
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both hepatic and systemic inflammation (76). Another downstream effect of HSC 
activation is production of Reactive Oxygen Species (ROS). Oxidative stress leads to 
impaired production of NO via multiple pathways. ROS directly reacts with NO to 
produce peroxynitrate and other reactive nitrogen species ROS leads to direct eNOS 
dysfunction by ‘uncoupling’ and inhibition of phosphorylation and increase in the 
formation of eNOS inhibitors. (77).Plasma level of NOS inhibitor ADMA are raised in 
cirrhosis and further raised in patients with Alcoholic Hepatitis (78).In addition, hepatic 
expression of eNOS inhibitor caveolin-1 and eNOS trafficking protein NOSTRIN are 
increased in alcoholic hepatitis as compared to decompensated cirrhotic patients. These 
proteins will reduce eNOS activity and in turn NO production (79) 
  
Hepatocye cell death through oxidative injury will activate local innate immune pathways 
by way of Damage Associated Molecular Pattern (DAMPs).These protein are responsible 
for the introduction of ‘sterile inflammation’ through the TLR pathway as well (80).There 
is cross talk between the PAMPs and the DAMPs as bacterial LPS stimulates DAMP 
proteins like HMGB1 which activate both pathways (81). Therefore, local liver injury 
propagated by bacterial translocation and activation of the innate immune pathway 
through the TLR pathway leads to further inflammation and oxidative stress. This leads 
to significant intra hepatic vascular dysfunction and thereby propagates the progression 
of portal hypertension. 
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1.3.2 The impact of inflammation in the splanchnic circulation 
The forward theory of portal hypertension suggests that there is splanchnic vasodilatation 
and reduction in the systemic vascular resistance with resultant increased portal venous 
inflow to the liver. As opposed to the intra hepatic circulation, there is excess NO in the 
splanchnic circulation and reduced responsiveness of the mesenteric circulation to 
vasoconstrictors. In a recent study, it has been shown that peri vascular cells, which are 
present in the adventitial layer of mesenteric vessels have increased number of activated 
macrophages expressing inducible NOS. Thus paracrine effect of inflammatory cells 
producing NO may augment portal hypertension (82).The relative contribution of the 
various NOS isoforms are still being debated. In rodent models of pre sinusoidal portal 
hypertension using the portal vein ligation (PVL) model, it is clear from various studies, 
that endothelial NOS (eNOS) is the predominant contributor of NO production the 
mesenteric circulation (83).However in the studies using Bile Duct Ligation (BDL) model 
inducing biliary cirrhosis and portal hypertension, there is evidence to show that there is 
increased expression of aortic iNOS after administration of LPS (84). 
The role of the gut liver axis in propagating splanchnic vasodilatation has been 
investigated. Patients with advanced cirrhosis produces increased systemic NO and 
endotoxemia post TIPSS and there is also evidence to show increased in iNOS activity in 
these group of patients (85). Flouroquinolone antibiotics like norfloxacin had been used 
in cirrhotic patients to show there is reduction in the endotoxin load, improvement in the 
mean arterial pressure, and systemic vascular resistance as well as reduction in NO 
mediated mid arm vasodilatation (86), (87). In cirrhotic rats, pro inflammatory cytokines 
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like TNFa and IL6 are reduced by down regulation of eNOS phosphorylation by Akt upon 
treatment with norfloxacin (88) 
Studies from iNOS and eNOS knockout studies have suggested there are agents other than 
NO that are implicated in the pathogenesis of splanchnic vasodilatation in cirrhosis (83). 
Microparticles (MP), membrane vesicles that can affect the vascular and inflammatory 
signaling pathways have been found to be increased in cirrhotic patients and their levels 
co-relate to disease severity and inflammation. They have also been shown to impair the 
vasoconstrictor effect on cultured rat aorta rings (89). 
All the above factors are implicated in the modulation of inflammatory pathways in the 
regulation of splanchnic vascular tone. 
 
 
1.4 Bacterial Translocation and Portal Hypertension 
Due to the unique anatomical location the liver and its vascular blood supply, there is 
significant exposure to intestinal bacteria and bacterial products in the context of cirrhosis. 
The role of gut microflora in the pathogenesis of complications of cirrhosis including 
spontaneous bacterial peritonitis and hepatic encephalopathy is well recognised. Recently 
there has been renewed interest in the concept of bacterial translocation in the 
pathogenesis of portal hypertension and complication of cirrhosis. 
Bacterial Translocation (BT) is defined as the passage of viable and non-viable products 
of microbes and microbial particles from the intestine into the mesenteric lymphnodes 
and other organs.BT has become an increasingly interesting focus for many complication 
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of cirrhosis. Bacterial cultures are positive in mesenteric lymph nodes in 30.8% of Child 
C cirrhotic patients as compared to 6.8% of non cirrhotic patients (90). Similarly the 
surrogate marker of BT, lipopolysaccharide (LPS)-binding protein (LBP), was observed 
to be increased in 42% of cirrhotic patients (86).  It has also been recognized that bacterial 
infections are associated with a poorer prognosis from variceal haemorrhage (VH) (91)).  
BT is associated with other portal hypertension-related  complications, such as hepatic 
encephalopathy and spontaneous bacterial peritonitis (SBP) (92). 
The downstream mechanism of BT is complex but the most preserved pathway of innate 
immunity signals is via the exposure to microbial products or pathogen associated 
molecular patterns (PAMP) leading to activation of toll like receptors (TLR), which are 
most commonly expressed in Kupffer Cells (KC) although they are expressed in all types 
of parenchymal and non parenchymal cells. The kupffer cells in turn become activated by 
the TLR pathway and adopt a pro inflammatory phenotype releasing cytokines like TNFa, 
IL 6 and IL 2 (93). This pro-inflammatory cytokine response to BT is associated with 
severe portal hypertension in cirrhosis. Serum bacterial DNA levels, as a surrogate marker 
of BT, are correlated with severity of inflammation and portal hypertension in cirrhosis 
(94). Moreover, in patients with SBP, elevated levels of catecholamines and TNFa are 
associated with higher HVPG (95).In rodent studies, it has been shown that injection of 
LPS increases the portal pressure (96) and antibiotics have been used to reduce the 
occurrence of bacterial translocation (97). In humans, use of antibiotics have been shown 
to improve the haemodynamic abnormalities in the cirrhotic patient proving the notion 
that reduction of the bacterial translocation has a beneficial effect on the portal pressure 
(87). Direct inhibition of TNFa in patients with severe alcoholic hepatitis showed 
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significant reduction in portal pressure both immediately and also sustained till day of 
discharge of patients. This was associated with improvement in the hepatic and renal 
blood flow. This study suggest that targeting inflammation may be an important target to 
reduce portal pressure and improve outcome of patients (71).Several pro inflammatory 
cytokines like CRP and IL 6 have been shown to be raised in patients with cirrhosis and 
the level of the cytokine load co-relates with the portal pressure (98) (99). Therefore, 
bacterial translocation is a major mediator of inflammation induced portal hypertension 
in advanced cirrhosis. 
 
1.5 The link between inflammation, sympathetic 
nervous system   and portal hypertension 
The relationship between sympathetic nervous system and inflammation has been known 
for a long time. In the mid-1980s, it was well recognised that secondary lymphoid tissues 
is highly innervated by sympathetic nervous fibres in close proximity to immune cells 
(100). These immune cells express adrenoreceptors which are functional and translate 
neuronal signals into immune cell signal (101).The activation of the SNS in the context 
of an active immune system results in release of sympathetic neurotransmitters. 
Sympathetic influence on immune cells can be direct via adrenergic receptors on immune 
cells or via regulating blood or lymph flow (102).One of its main function is to modulate 
the release of pro inflammatory peptides (103) 
High levels of catecholamines in the portal venous plasma of patients with cirrhosis were 
reported by Shaldon et al. in 1961 (104). Patients with a high Child score, more 
pronounced portal hypertension, avid fluid-sodium retention, and the hepatorenal 
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syndrome have the highest plasma levels of NA and adrenaline. Selective catheterisation 
techniques and tracer kinetic methods have disclosed that the increased circulating 
noradrenaline in patients with cirrhosis is caused by sympathetic nervous overactivity in 
a number of organs (105). The very high noradrenaline from the kidney accords with the 
conception of a preferential renal sympathetic nervous over activity in patients with 
advanced liver disease (106) 
Several investigators have found a direct relation between the size of the portal/sinusoidal 
pressure and the circulating level of noradrenaline. This may suggest that sympathetic 
over-activity is involved in the pathogenesis of the portal hypertension in such patients. 
 
There is a large body of evidence to suggest that a decrease in the central and arterial 
blood volume of patients with cirrhosis (107).Moreover, it is already known that inverse 
relationship between the size of the central and arterial blood volume (i.e. the volume in 
the heart cavities, lungs, and central arterial tree) on the one hand and arterial and renal 
venous NA on the other (108). This suggests to us that central and arterial hypovolaemia 
is a significant afferent stimulus to overall and renal sympathetic over activity. Moreover, 
the increased arterial level of noradrenaline is directly related to the increased portal 
venous pressure and azygos blood flow. Various experiments have been done to block 
central and peripheral adrenoreceptors which lowers systemic and portal pressures. These 
findings suggest that the sympathetic nervous system plays a role in the genesis and 
perpetuation of portal hypertension (109). A close relation has been demonstrated 
between circulating noradrenaline and survival, and the level of plasma noradrenaline is 
an independent prognostic factor in cirrhosis. 
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In the recently published prospective CANONIC study, acute on chronic liver failure 
patients can be differentiated from acute decompensation of cirrhosis by the presence of 
organ failure, a marked systemic inflammatory response and higher short term mortality. 
Systemic inflammation appears to the most important prognostic factor as it rises with the 
progression of disease. However, the key precipitants for acute decompensation and acute 
on chronic liver failure were similar, suggesting that the major determinant for the 
development of ACLF is host response to injury rather the nature of the precipitant (72).  
There is increasing evidence that norepinephrine modulates the activation of kupffer cells 
by pro inflammatory cytokines via the adrenergic receptors (110). Gut derived bacteria or 
bacterial products activate pathogen associated molecular patterns which secrete pro 
inflammatory cytokines to activate kupffer cells. NE is thought to upregulate TNFα 
production in KC through the adrenergic receptor pathway (111). Extra hepatic tissue and 
cells also have been shown to secrete catecholamine in an acute inflammatory 
environment via the alpha 2a receptors (112) 
The close relationship between noradrenaline levels, SIRS and intrahepatic resistance 
leads to the hypothesis that modulation of the sympathetic nervous system will reduce 
intra hepatic resistance and provides a valid target for the management of portal 
hypertension. 
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1.6 Adreno-receptors in the hepatic vasculature 
The adreno receptors are a group of transmembrane receptor in the class of G-protein 
coupled receptors that are targeted by catecholamine. A significant number of cells 
possess these receptors and stimulation by catecholamine will provoke the activation of 
downstream pathways and stimulation of the sympathetic nervous system. 
Up to now, several different adreno-receptors have been identified. They have been 
divided into two main groups – α and β adrenergic receptors. They have been further sub 
divided into α1 and α2 and the β adrenergic receptor has been sub divided into β1, β2 and 
more recently β3.The α adrenergic receptors are further divided into sub groups. Alpha 1 
adrenergic receptors are have three highly homologous subtypes –α1a, α1b, α1d. Alpha 2 
adrenergic receptors are also further sub divided into three sub types. They are α2a, α2b 
and α2c. These are homologous subtypes with main action being inhibition of insulin 
release and induction of glucagon release and more importantly giving pre-synaptic 
negative feedback for the release of noradrenaline. 
Adrenaline or noradrenaline are receptor ligands to either α1, α2 or β-adrenergic receptors. 
α1 couples to Gq, which results in increased intracellular Ca2+ and subsequent smooth 
muscle contraction. α2, on the other hand, couples to Gi, which causes a decrease in 
neurotransmitter release, as well as a decrease of cAMP activity resulting in smooth 
muscle contraction. β receptors couple to Gs, and increases intracellular cAMP activity, 
resulting in e.g. heart muscle contraction, smooth muscle relaxation and glycogenolysis. 
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There is presence of adrenergic receptors in the liver, the predominant ones being α1 and 
β2 adrenergic receptors. The α1 adrenergic receptor is primarily responsible for the 
vasoconstriction in the resistance vessels which includes the venules whereas the β2 
adrenergic receptors are primarily responsible for vasodilataion of the arterial side of the 
hepatic vasculature. The evidence for the presence of α2 adrenergic receptor and in 
particular α2a adrenergic receptor is scarce, especially in the normal liver. However, there 
is definite proof of its presence in kupffer cells (111) and other migratory cells (113). 
This makes it an attractive target for modulation in the diseased state. 
 
1.7 Arginine metabolism in liver disease 
The previous section of the thesis focused on targeting the sympathetic nervous system in 
order to modulate inflammation and thereby reduce portal hypertension. Another aspect 
of modulation of the intra and extra hepatic vascular tone is the vasoactive substance nitric 
oxide. Inflammation is both directly and indirectly involved in the metabolism of nitric 
oxide in the hepatic vasculature. L-Arginine is the sole substrate for the production of 
nitric oxide and had immunological properties that merit further investigation in the 
context of liver cirrhosis and portal hypertension. In order to understand the metabolic 
pathways that are implicated in this process, I have started this section of the thesis with 
a literature review and have attempted to highlight the rational of studying this pathway 
in more detail as my alternative strategy for the modulation of inflammation for the 
reduction of intra hepatic resistance in portal hypertension. 
46 
 
Arginine is a semi essential amino acid which acts a sole substrate of enzyme eNOS for 
oxidation into NO and citrulline (114). As discussed previously, NO has become an 
important vasoactive agent both in the intra  and extra hepatic circulation which modulates 
vascular tone. There is a growing body of research into modulation of NO in order to 
reduce intra hepatic resistance but very little effort has gone into the understanding of the 
metabolism of L-Arginine in liver disease. Most of the studies related to arginine 
supplementation in humans have been done as part of immunonutrition in intensive care 
patients and therefore the outcomes are confounded by the presence of other amino acid 
constituents in the packet.  
Moreover, therapeutic interventions based on both stimulation and inhibition of arginine 
metabolism has given contradictory results. The metabolism of L-arginine in normal and 
disease state are influenced by many factors and therefore it will be important to 
understand these pathways before a rational strategy can be applied to modulate 
inflammation in order to lower portal pressure. 
1.7.1 Normal arginine metabolism 
 
Muscle derived glutamine starts the pathway for arginine synthesis by converting to 
citrulline in the small intestines via the glutamine- ornithine pathway (115). Most of the 
released citrulline (83%) in turn is absorbed by the kidney (116). Arginine is synthesised 
proximal renal tubules in the kidney from the citrulline (117) (118).About 10-15% of 
whole body arginine is produced by this pathway. Alternative pathways for arginine 
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availability include protein breakdown and diet intake with the jejunum as the major site 
of intestinal absorption (119). 
There are four major metabolic pathways of arginine. Firstly, arginine is metabolised by 
the enzyme Arginase. There are two isoforms of Arginase, Arginase I being the cytosolic 
enzyme which is expressed in the liver and Arginase II which is present in the 
mitochondria and present in the intestines, kidney and brain. Arginase I mainly involved 
in the metabolism of ammonia and urea whereas arginase II is used up in the synthesis of 
ornithine, proline and glutamine (120). Arginase II plays an important role in the 
degradation of intestinally absorbed arginine (121).  
Second major pathway for arginine metabolism is by the synthesis of NO. NO is produced 
by the oxidation of L-arginine by the enzyme NOS (Nitric oxide synthetase). There are 
three isoforms of the enzyme which are endothelial NOS (eNOS), neuronal NOS (nNOS) 
and inducible NOS (iNOS).All the three isoforms produce NO which have different 
functions (119). 
Besides these two important pathways, a large portion of L-arginine is used up in the 
synthesis of proteins and agmatine. L-arginine is also utilised in the biosynthesis of 
creatine which is the pre cursor of creatinine (122). 
1.7.2 Arginine metabolism in disease state 
There is a paucity of data for arginine metabolism in liver disease itself but a surrogate to 
this would be to understand the metabolism of arginine in sepsis, which is 
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pathophysiologically akin to liver disease. Plasma arginine concentration have been found 
to be consistently low in the humans and animal models when they are under stress or 
septic and the prognosis was significant worse in patients with low arginine levels along 
with low levels of other amino acids (123).The whole body plasma level of arginine , 
which is the total volume of arginine synthesised from protein breakdown and de novo 
arginine production via the intestinal-renal axis remains the  same in the septic patients 
and non septic intensive care patients (124). The main impetus for maintenance is on the 
de novo arginine synthesis of arginine through the intestinal-renal axis (125), (126). 
 
However, in critically ill patients the net amount of plasma arginine may be reduced 
because of impaired intestinal function, which is the main site for production of citrulline 
(119).Therefore, de novo arginine production is the main pathway for the maintenance of 
the balance of plasma arginine levels. 
The reduction of plasma arginine levels may suggest that there is a shift of arginine to the 
intra cellular compartment. In order to facilitate transport, there are certain conditions that 
have to be met like availability of a transport system of which there are many. The most 
important transport system is the y+ is the most important and high affinity transport 
system. These transport system are associated with transport proteins called Cationic 
Amino Acid Transporters (CAT), of which there are three, namely CAT1, CAT2 (B) and 
CAT3. The uniqueness of these transport system is that they may be co-localised with a 
NOS enzyme in the plasma membrane (127). More specifically, eNOS is co localised with 
the CAT1, which helps to regulate the flux of arginine inhibitors into the cell. 
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Furthermore, some endogenous inhibitors like ADMA also compete for the same 
transport system, therefore may be able to regulate the arginine flux across the cells (128). 
1.7.3 Catabolism of Arginine 
1.7.3.1 Arginase Pathway 
Arginase is a binuclear manganese mettaloenzyme, which is an integral part of the urea 
cycle in the liver and is the main enzyme for the catabolism of L-Arginine into ornithine 
and urea. There are two isoforms of arginase Arginase I and Arginase II, which share 60% 
homology (129).Arginase I is a cytosolic enzyme which is present primarily in the liver 
and Arginase II is a mitochondrial enzyme present in the extra-hepatic tissue including 
the vascular smooth muscle cells (120). It is suggested that Arginase will compete with 
NOS for the substrate L-Arginase but on consideration of their biochemical properties, it 
is evident that the L-arginine has greater affinity for the purified NOS than arginase 
although there is a suggestion that there is similar rate of substrate utilisation at 
physiological levels of L-Arginine (122). However, early studies on activated 
macrophages reveal that majority of substrate are being consumed by the arginase 
pathway to produce urea and inhibition of arginase (130), (131). Apart from depleting L-
arginine as a substrate for NO production, arginase also inhibit the expression of iNOS 
repressing the translation and stability of the protein (132) and by production of urea 
(133).On the other hand, the intermediate product of L-Arginine by the NOS pathway, N-
Hydroxy-L-Arginine is a potent inhibitor of arginase and therefore there is presence of a 
reciprocal inhibition pathway (134). Apart from depleting the substrate L-Arginine, 
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arginase also sensitise the endothelial cells to the endogenous NOS inhibitor ADMA, 
which will prevent the formation of NO (135).There is also suggestion in the literature 
that depletion of arginine results in uncoupling of the eNOS protein leading to the 
formation of oxygen free radical, which can directly inactivate any NO formed. Thus 
indirectly increased arginase activity can have a negative impact on NO generation. In 
addition, superoxide in combination with NO forms peroxynitrite, which causes increased 
vascular reactivity and endothelial damage (136).  
Apart from causing endothelial dysfunction as a result of depletion of substrate L-
Arginine for the production of NO by various mechanisms mentioned above, there is also 
growing evidence that increased arginase activity causes vascular smooth muscle 
dysfunction. Urea produced by the arginase pathway is eliminated via the kidney, 
however ornithine is used up in the formation of polyamine and L-proline, which are 
important component for the proliferation of vascular smooth muscle and essential for the 
formation of several structural proteins including collagen (137), (138).Pharmacological 
inhibition of arginase leads to reduction in vascular smooth muscle proliferation. 
Increased arginase activity can directly stimulate smooth muscle cell proliferation and 
polyamine synthesis and can be associated with the decrease in NO as it is a known 
inhibitor of smooth muscle cell proliferation (138).In the context of cirrhosis, recent data 
suggest that both isoforms of Arginase is regulated differently as there is increased 
expression of arginase II and decrease expression of arginase I, which suggest that they 
are involved in different processes in cirrhosis. Arginase I being utilised by the urea cycle 
in the liver and the arginase II being used up in the synthesis of ornithine, polyamine and 
L-proline which lead to proliferation of vascular smooth muscle cells (139) 
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In conclusion, arginase has established itself as a major regular of NO in the vasculature. 
It can cause both endothelial and vascular dysfunction by modulation the intra cellular 
metabolism of L-arginine. More specifically, arginase compete with NOS enzyme for the 
substrate  
L-arginine, depleting it significantly by various mechanisms and causing reduced NO 
production. In the vasculature arginase depletes NO generation by directing the utilisation 
of L-arginine in the production of ornithine and polyamine, which is responsible for 
smooth muscle cell proliferation and causing vascular dysfunction.  
1.7.3.2 Arginine - NO Pathway 
L-Arginine is the sole substrate for the production of NO and citrulline by NOS (140). 
This is the second most important pathway of arginine metabolism after the arginase 
pathway. There are three types of NOS that have been identified. Endothelial NOS (eNOS 
or Type 3) which is the major NOS involved in the vasodilation and neuronal NOS (nNOS 
or Type 2) found in the nerve endings have been designated as constitutive NOS and 
inducible NOS (iNOS or Type 2) is the other NOS which is induced by cytokines and 
endotoxins (141).In order for the reaction to take place, NOS enzyme requires NADPH 
and O2 in stoichiometric quantities. The NOS enzyme also requires important co-factors 
including Flavin-adenine dinudestide (FAD), flavin mononucleotide (FMN), 
tetrahydrobiopterin and glutathione (142). In addition electron transfer to the haeme group 
is mediated by calmodulin and calcium is required for the calmodullin binding in the 
constitutive NOS enzymes although it is not a necessary condition for the iNOS reaction 
to take place (143). 
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Various alterations in the availability of these co-factors will impact on the reaction of 
these NOS enzymes. The NOS enzymatic reaction is also regulated by arginase by 
multiple mechanism as detailed above and by methylarginine, which will be detailed in a 
separate section. 
1.7.3.3 ADMA pathway 
There is a dichotomy in the amount of NO present in the circulation. In the splanchnic 
and peripheral circulation, there is an abundance of NO which may be due to the 
continuous induction of iNOS through endotoxins, which have been translocated through 
the gut barrier. However in the intra hepatic circulation, there is a deficit in NO as a 
consequence of endothelial dysfunction. This deficiency in NO may be due to arginine 
depletion as a consequence of presence of large amount of arginase and Asymmetrical 
Dimethyl Arginine in the liver, which will compete with the same transport system as 
arginine and therefore leads to its intracellular depletion and hence reduction on NO 
production (144),(145). From the sepsis literature, it is clear that ADMA is an independent 
risk factor for intensive care mortality and has been shown to be associated with hepatic 
dysfunction (146). This increased ADMA level will alter the Arginine to ADMA ratio in 
the intra cellular compartment, therefore provide a rationale to supplement arginine to 
alter this ratio. 
1.7.4 ADMA  metabolism 
Asymmetrical Dimethyl Arginine (ADMA) are methylated  L-arginine residue in protein 
produced during proteolysis that freely circulate in the plasma and excreted in the urine 
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and present in cells and tissues (147).It is the most important endogenous inhibitor of 
endothelial nitric oxide synthesise and therefore has been implicated in endothelial 
dysfunction (145) 
ADMA is synthesised when arginine residue of protein are methylated by the enzyme 
protein arginine methyltransferase (PRMT) Type I. Type II PRMT methylate protein to 
form  symmetrical dimethyl arginine (SDMA), whereas both Type I and type II can 
monomethylate the arginine residue to form N-monomethyl L-arginine (L-NMMA). Both 
ADMA and L-NMMA can inhibit NOS but SDMA does not (148).PRMT type I are 
expressed in the heart, smooth muscle cells and the endothelium. The expression of PRMT 
Type I can be increased due to shear stress and inhibited by suppression of the IκB kinase 
or by using a peroxisome proliferated-activator receptor gamma(PPARγ) activator, 
troglitazone, suggesting that the ADMA levels can be regulated by modulating the PRMT 
Type I receptor expression (149) 
The most important target for ADMA is the NOS enzyme and it can inhibit all three 
isoforms of NOS with equal potency. There is a suggestion that ADMA can also cause 
uncoupling of the NOS enzyme however it is still unclear whether this is a true effect 
(150). Another target for ADMA would be the y+ transport system , wherein it would 
compete with L-Arginine for its transport to the intra-cellular compartment but this occurs 
when there is a significant rise in the ADMA level which almost become physiologically 
irrelevant(151) 
The major metabolic pathway for degradation of ADMA is by Dimethylaginine 
Dimethylamino Hydrolase (DDAH) to citrulline and dimethylamine (152)There are two 
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isoforms of DDAH that have been identified with different tissue localisation. DDAH I 
has been encoded from the genes expressed in Chromosome 1 and DDAH II in 
chromosome 6 (153). Both the enzymes are expressed abundantly in the vascular tissues 
but with a preponderance to DDAH II (154). 
The concern of an increased plasma level of ADMA relates to its concentration to the 
plasma arginine concentration. In physiological states the level of ADMA is about 
0.45µmol/L to 0.65µmol/L and in diseased states, it can go from 0.69µmol/L to 
0.85µmol/L. In comparison, the arginine levels are in the range of 30-100µmol/L in the 
plasma and 1-2mmol/L in the intra-cellular compartment (155) (122). 
As such, it is logical to assume that that the vast amount of arginine outcompetes with the 
cellular ADMA, however there is evidence that in disease states such as cirrhosis, there 
is a relative increase in ADMA which is disproportionate to the normal arginine to ADMA 
ratio and hence can inhibit the NOS enzyme. This phenomenon is known as the arginine 
paradox.  
We and others have shown that the plasma ADMA level rises significantly in cirrhosis in 
humans and rats (156) (32). The rise in the level of ADMA and the relative deficiency of 
arginine confirms the presence of the ‘arginine paradox’ which implies that although the 
total amount of arginine is greater than the plasma ADMA level, the increase in ADMA 
level alters the ratio. This paradox provides a rational for the supplementation of L-
arginine to reverse the ratio and benefit from the effects of increased nitric oxide 
production, especially in the intra-hepatic circulation. 
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1.7.5 Protein synthesis and energy source 
Arginine is necessary for the production of various proteins. In sepsis, there is an increase 
in the level of acute phase proteins and antibodies (157). There is also some evidence of 
increased muscle protein synthesis. In children with sepsis, there is an increase in arginine 
oxidation, which suggests that arginine is also needed for energy production. 
1.7.6 Arginine and Immune Function 
Evidence from studies in sepsis and endotoxaemia suggest that this is a L-arginine 
deficiency state (158). The arginine deficiency is as a result of decreased uptake, reduced 
de novo production of L-arginine and rapid metabolism of L-arginine by arginase both in 
the liver and in other organs in sepsis. This is inspite of the fact that there is more arginine 
production from protein breakdown. This turns arginine into a semi-essential amino acid. 
Arginine deficiency has been noted in endotoxaemic murine models and patients admitted 
to ITU ((159), (160). Decreased nitric oxide production during sepsis is probably due to 
the reduced activity of the Nitric oxide synthetase 3. This reduction in nitric oxide results 
in endothelial dysfunction. There is also evidence that the cationic amino acid transporter, 
which is the main transporter for arginine is altered and CAT2b is upregulated. This 
transporter is particularly important for activated macrophage which imports large amount 
of L-arginine for the production of nitric oxide (161). Besides the observed deficiency of 
L-arginine and nitric oxide in sepsis, there is also documented deficiency of citrulline, 
which in turn worsens arginine availability and nitric oxide production (162). However, 
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the main pathway for the metabolism of L-arginine in the context of sepsis remains via 
the arginase pathway.  
During inflammatory conditions both arginase I and arginase II activity are induced by 
specific cytokines with preferential activation of Arginase I ((119), (163), (164). 
Replenishing the plasma arginine level would be important to maintain all the cellular 
function including its immune function. This could be achieved by either replacing L-
arginine directly or indirectly by replacing citrulline. All these evidence suggest that there 
is an overall inverse relationship of L-arginine with sepsis and other inflammatory 
condition.  
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1.7.7 Discussion  
Therefore, in conclusion, arginine concentration is significantly reduced in the context of 
inflammation and sepsis. The deficiency is determined by the regulation of the various 
metabolic pathways in sepsis. Arginase metabolic pathway is the most important pathway 
for the degradation of arginine. The plasma ADMA levels are high relative to the plasma 
arginine concentration in inflammatory or sepsis therefore providing an imbalance in the 
arginine: ADMA ratio. This provides an opportunity to test a hypothesis that 
supplementation of L-arginine would alter the ratio and also act as a regulator of 
inflammation in liver diseases 
 
 
 
 
. 
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1.8 Hypothesis 
 
In cirrhosis, portal hypertension is propagated by systemic inflammation and upregulation 
of the sympathetic nervous system. Modulation of the sympathetic nervous system will 
reduce inflammation which thereby  reduces the intra hepatic resistance and  portal 
pressure. 
Aim of the studies: 
1. To define the relationship between inflammatory mediators and the sympathetic 
nervous system and haemodynamic abnormality in a rodent model of portal 
hypertension. 
2. To antagonise the alpha 2a receptor in a rodent model of biliary cirrhosis and 
portal hypertension and to assess its effect on inflammatory parameters and 
haemodynamic abnormalities. 
3. To explore the importance of arginine in liver failure and portal hypertension and 
to understand the implication of arginine supplement as an anti-inflammatory 
strategy in the treatment of portal hypertension. 
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                            Chapter 2  
                  Materials and Methods 
2.1 Animals  
All animal experiments were conducted according to the Home Office guidelines under 
the UK Animals in Scientific Procedures Act 1986. This study was performed in male 
Sprague-Dawley (SD) rats (Charles-rivers), weighing 220–250gms  were obtained from 
the Comparative Biological Unit at University College London. All rats were housed in 
the respective unit and given free access (ad libitum) to standard rodent chow and water, 
with a light/dark cycle of 12 hours (the dark phase extended from 1900–0700 hours), at a 
temperature of 22–23°C and humidity of approximately 50%. 
2.1.1. Bile-duct ligation (BDL):  
 The bile duct ligation of the rats were done as described. Following induction anesthesia 
(1L/min oxygen containing 5% isoflorane), anesthesia was maintained with 2% isoflorane 
in air, delivered at 0.5L/min to a facemask. Rectal temperature was maintained at 36±1oC 
using a heating pad. A midline laparotomy was performed and the common bile duct 
(CBD) was isolated by blunt dissection. The CBD tied off with triple ligatures (4-0 silk), 
before transecting the CBD between the  distal two ligatures. 4 weeks BDL was allowed 
for the development of secondary biliary cirrhosis often with observed hepatic 
decompensation (e.g. ascites). 
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2.1.2 Sham operation: 
These  operations as described were performed in the same manner as described in Section 
2.1.1 but no ties were placed and the duct was not ligated. The surgery was completed 
within 15 min, and rats were returned to individual cages after cessation of anesthesia 
where feeding and water ingestion resumed.  
2.2 Study design 
Male Sprague Dawley rats weighing 220-250 g were randomly assigned to receive sham 
or bile duct ligation (BDL) surgery as described above and  previously (165). Four weeks 
later haemodynamic measurements were performed and samples collected for analysis. 
For the BRL44408 study, treatment with either 10 mg/kg BRL44408 maleate (Sigma-
Aldrich Company Ltd., Dorset, UK) dissolved in sterile water or saline (control, equal 
volume) by subcutaneous  (s.c.) injection was given on the last 2 days of the study. In the 
second part of the experiments, the rats were injected for the last 10 days of the experiment 
using the same protocol. Previous pre clinical studies have shown that the sub cutaneous 
route as the best route at the dose of 10mg/kg (166).  
  For the L-arginine supplementation studies, treatment with either 30gm/kg L-Arginine 
(Damor Pharma, Italy) dissolved in sterile water or saline (control, equal volume) by oral 
gavage was given on the last 7 days of the study. The dose regime and route was chosen 
from previous studies (167). Rats were randomly assigned to the different treatment 
groups.  
at the rate of 0.33mg/kg. 
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All rats were exsanguinated under terminal anesthesia (2% isofluorane). Within seconds 
blood was withdrawn from the descending aorta and immediately put into ice cold 
heparin/EDTA containing tubes (until full exsanguination), centrifuged at 3000 rpm and 
4oC for 10 min, and the plasma collected and stored at -80°C until assayed. Liver tissue 
was also removed immediately harvested and snap frozen for storage at -80°C until 
analyzed. Liver tissues were also fixed with 10% formalin for further histological 
analysis. 
 2.3 Haemodynamic measurements 
Haemodynamics were measured under anesthesia (2% isofluorane in air). Mean arterial 
pressure (MAP) was measured pre-laparotomy by direct cannulation of the right carotid 
artery. Portal pressure (PP) was measured by direct cannulation of the portal vein post 
laparotomy. Pressures were transduced to a Powerlab 4SP data acquisition device (AD 
Instruments Ltd., Oxford, UK) analysed using BioPac Student Lab v4 software (BioPac 
Systems Inc., Goleta CA, USA). Hepatic arterial and portal venous blood flow were 
measured using a doppler flow probe connected to a TS420 transit-time perivascular 
flowmeter (Transonic Systems Inc., Ithica NY, USA). Intrahepatic resistance was 
calculated by dividing the portal pressure by the sum of the hepatic arterial and portal 
venous flows.  
 
 2.4 Echocardiography 
Rats are placed in the supine position and transthoracic echocardiography performed 
under 1.5% anesthesia using a commercial echocardiography machine (Vivid 7 
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Dimension™, GE Healthcare, Bedford, UK) with a 14 MHz probe recording at a depth 
of 0-2 cm. End diastolic and systolic diameters were determined from a parasternal long-
axis view using two-dimensional B-mode with the diameter measured from the apex to 
the aortic. Left ventricular dimensions during diastole and systole were also determined 
from a parasternal short-axis view using time-motion (M)-mode.  Measurements were 
taken of the internal dimension of the cavity, the anterior and posterior wall.  Stroke 
volume was determined as the product of the velocity time integral (VTI) and the vessel 
cross-sectional area (π x [0.5 x diameter] 2). Prior studies in rats of this age showed the 
aortic diameter to be 0.26 cm, thus a cross sectional area of (0.13)2 x π was assumed for 
all animals studied. As heart rate ranges from 350-500 beats per minute and respiration 
rate from 60-100 breathes per minute, the theoretical number of cycles needed to account 
for the variation in flow with respiration ranges from 3.5 (350/100) to 8.3 (500/60).  In 
practice, an average of 5-6 consecutive cycles was enough to account for this variability.  
Heart rate was determined by measuring the time between 5-6 consecutive cycles from 
the start of each Doppler trace.  Cardiac output was calculated as the product of stroke 
volume and heart rate.  
 2.5 Measurement of plasma biochemistry 
All basic chemical reagents were purchased from Fisher Scientific (Loughborough, UK), 
Sigma-Aldrich Company Ltd. (Dorset, UK), or VWR International Ltd. (Lutterworth, 
UK). 
All biochemical parameters (ALT, ALP, albumin, total protein, ammonia, bilirubin, urea 
and creatinine, lactate) were analyzed using 200μl of respective plasma samples using a 
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Cobas Integra 400 multianalyzer with the appropriate kits (Roche-diagnostics, Burgess 
Hill, West Sussex, UK). 
 2.6 Plasma and liver tissues cytokines 
Snap frozen (-80°C) and stored plasma and liver samples were later analyzed for cytokine 
profiles. Prior to analysis, 100μg of liver tissues was homogenized and deproteinized in 
300µl of ice-cold cell lysis buffer solution. After centrifugation at 12,000 x g for 10 
minutes at 4°C, the supernatants were collected for processing. Following protein 
concentration quantification of equilibrated liver protein samples and plasma supernatants 
(50µl) were analyzed for TNF-α cytokine levels (pg/ml) and IL-6  levels (pg/ml) by flow 
cytometry using the Becton Dickinson (BD™ biosciences, San Diego, CA) rat 
inflammation cytometric bead array (CBA) kit as described by the manufacturer's 
instructions. Samples were analysed by measuring the fluorescence produced by the CBA 
beads on a ‘FACS Canto™ II flow cytometry system (BD™ Sciences) and the data 
analyzed with BD™ CTA software. 
 2.7 Western blot analysis 
Frozen liver was homogenised in RIPA buffer (Pierce Biotechnology Inc., Rockford IL, 
USA) with complete ultra mini protease inhibitors and phostop phosphatase inhibitors 
(Roche Diagnostics Ltd., Burgess Hill, UK) using 7mm steel beads with a tissue lyser 
(Qiagen Ltd., Manchester, UK). Proteins were extracted by incubating for 2 hours at 4 
degC with continuous rotation and insoluble cell debris was removed by centrifugation at 
16,000rpm x for 20 mins, 4 degC. Protein concentration was measured using a BCA assay 
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kit (Pierce Biotechnology Inc., Rockford IL, USA) for liver lysates. Equal amounts of 
protein were separated on 4–12% NuPAGE Bis-Tris gel under reduced denaturing 
conditions using either MES or MOPS running buffer (Life Technologies, Renfrew, UK) 
depending on the molecular weight of the protein of interest. The molecular weight 
markers, Novex Sharp pre-stained protein standards and MagicMark XP Western protein 
standards (Life Technologies, Renfrew, UK), were combined in 1 lane. Separated proteins 
were transferred on to PVDF membranes (Invitrogen, Paisley, UK) and successful 
blotting was confirmed with Ponceau S stain (Sigma-Aldrich Company Ltd., Dorset, UK). 
Following transfer, membranes were blocked for 1 hr at room temperature in TBS/0.1% 
Tween-20/5% BSA then incubated overnight at 4 deg C in the appropriate primary 
antibody diluted in TBS/0.1% Tween-20/5% BSA. The primary antibodies used were 
specific to the protein of interest. The primary antibodies used were:rabbit anti Adra2a 
(1:1000 dilution, PA1-048, Pierce Biotechnology Inc., Rockford IL, USA), mouse anti 
eNOS (1:1000 dilution, 610297, BD Biosciences, Oxford, UK), rabbit anti phospho-
eNOS (Ser1177) (1: 1000, #9571, Cell Signalling Technology, Inc., Danvers MA, USA), 
and mouse anti GAPDH (1:1000 dilution, ab6046, Abcam plc., Cambridge, UK). 
Secondary detection was performed by incubating for 1 hour at room temperature with 
the appropriate HRP-conjugated secondary antibody diluted in TBS/0.1% Tween-20/5% 
BSA. The secondary antibodies used were donkey anti mouse IgG (human and rat IgG 
cross-adsorbed, 1:10,000 dilution, A16017, Life Technologies, Renfrew, UK), goat anti 
Rabbit IgG (human and rat IgG cross-adsorbed, 1:10,000 dilution, sc-2054, Santa Cruz 
Biotechnology, Inc., Dallas TX, USA. The bands were visualized using an enhanced 
chemiluminescence detection kit and quantified by densitometry. Loading accuracy was 
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evaluated via membrane rehybridization with antibodies against mouse and rabbit anti-α 
tubulin (1:1000; Upstate Biotechnology, Albany, NY) or mouse anti GAPDH (1:1000 
dilution, ab6046, Abcam plc., Cambridge, UK). Densitometry was measured using 
Alphaview SA v3.4.0 software (ProteinSimple, San Jose CA, USA). 
 
 2.8 Histology 
Formalin fixed liver tissue was processed through graded alcohol and xylene and 
embedded in paraffin. 3-5mm sections were dewaxed in xylene, stained with hematoxylin 
and eosin (for assessment of routine liver histology) or picrosirius red (for assessment of 
collagen deposition), and mounted in DPX. Liver tissue was processed in accordance with 
standard protocol and Haematoxylin and Eosin together with Sirius Red staining was 
performed. Histological staging was conducted by a consultant histopathologist using a 
14 point secondary biliary cirrhosis scoring system. Sirius red staining was quantified 
using computer assisted digital image analysis. A circular polarising filter was used for 
picrosirius red stained slides. Collagen proportionate area was determined using Zeiss 
KS300 image analysis software.  
 
2.9 Radiometric analysis of hepatic NOS activity 
The conversion of 14C L-arginine to 14C L-citrulline was used as an index of NOS activity. 
Snap frozen liver tissue was homogenised and measured for protein content as above. For 
NOS activity determination, 5µl of supernatant was incubated with 40µl of a reaction 
medium [Tris-HCL buffer (50mM, pH 7.4); NADPH (1.25mM); 14C-arginine (10µCi/ml, 
Amersham, UK); norvaline (5mM); and either CaCl2 (400µM) or EGTA (600µM)] at 
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30oC for 30 minutes, and the reaction stopped with 500ml of ice-cold citrate buffer (50mM 
pH5) containing EDTA (1mM). The arginine:citrulline ratio were determined by 
separating the amino acid components using thin layer chromatography on silica plates 
(Kieselgel 60, Merck, Darmstadt, Germany). Non-tritiated amino acids were added to aid 
spot detection, and the components separated using a running mixture of 
CHCl3:MeOH:NH4OH:H2O (ratio of 10:45:20:10). The individual spots were removed 
and the scintillation activity measured as for DDAH activity assay above. The activity 
was expressed as µmoles citrulline made/ mg protein/ min. The difference in the measured 
NOS activities between the calcium present / calcium chelated (EGTA present- for iNOS 
activity determination) assays described above, were interpreted as representing eNOS 
activity. 
 2.10 Plasma Renin Activity 
Plasma renin activity was assessed using a FRET assay specific for rat renin (SensoLyte 
520 Rat renin assay kit; AnaSpec, EGT Group, Seraing, Belgium). Briefly, plasma 
samples (EDTA as anticoagulant) were incubated with a 5-FAM/QXL520 FRET peptide 
corresponding to a part of rat angiotensinogen. Kinetic measurements (every 5 minutes 
for 1 hour, 37degC) of fluorescence intensity at ex/em 490 nm/520 nm were taken using 
a fluostar omega plate reader (BMG Labtech Ltd., Aylesbury, UK) with excitation and 
emission filters of 485/12 nm and 520/20 nm. The initial velocity (V0) in RFU/min was 
calculated from the linear portion of the kinetic curves using Omega MARS data analysis 
software v11.31277.0 (BMG Labtech Ltd., Aylesbury, UK) 
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2.11 Plasma Noradrenaline Levels 
Plasma noradrenaline concentration was measured using a competitive ELISA (LDN 
Labor Diagnostika Nord GmbH & Co. KG, Nordhorn, Germany). Briefly, noradrenaline 
was extracted from plasma samples (EDTA as anticoagulant), standards, and controls 
using a boronate affinity gel coated plate. The extracted noradrenaline was acylated and 
enzymatically derivatised. The concentration of derivatised noradrenaline was measured 
using a competitive ELISA with a HRP-conjugated secondary antibody and TMB as 
substrate. The absorbance spectrum from 350 to 850 nm was measured using a Fluostar 
Omega plate reader (BMG Labtech Ltd., Aylesbury, UK). The absorbance at 450nm for 
the standards was used to generate a 4-parameter non-linear regression (y linear, x 
logarithmic) from which the concentrations of the samples was calculated using Omega 
MARS data analysis software v11.31277.0 (BMG Labtech Ltd., Aylesbury, UK). 
 2.12 Cyclic AMP ELISA 
96 well plates pre-coated with mouse monoclonal anti-rabbit IgG and blocked with a 
proprietary formulation of proteins (Cayman Chemical,AnnArbor,USA). To prepare the 
plasma, to 500 μl plasma  2 ml ice cold ethanol is added and vortexed. The supernatant 
obtained after centrifugation at 1,500 x g for 10 minutes is  transferred to a clean 10 ml 
test tube. The supernatant is dried then resuspended in 500 μl of ELISA Buffer. 
Supernatants of these cultures were applied to the ELISA plates in 3 step dilutions and 
incubated for 3 hrs at room temperature. Plates were washed and incubated with an HRP 
coupled secondary goat anti-mouse Ig antibody Southern Biotechnology) for one hour at 
room temperature. Thereafter Ellman’s reagent is reconstituted and 200µl pipetted into 
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each well. The plate is then incubated for 90 minutes in a orbital shaker. The plate is read 
in a colour absorbance wavelength range between 405-420nm in a sphectrophotometer 
using  the Endoscan V software. 
 
2.13 Cell culture 
Rat hepatic stellate cells were a kind gift from Jonathan Fallowfield. Rat HSCs were 
cultured in DMEM (high glucose, with sodium pyruvate & glutamax) with 10% FBS (Life 
Technologies, Renfrew, UK). All treatments with agonist or antagonist were performed 
in serum free medium. 
 
2.14 Gel contraction 
Rat hepatic stellate cells were cultured within 3D collagen gels (Fibroblast-populated 
collagen lattices; FPCL). 24 well cell culture plates were pre-coated with sterile 2% BSA 
(Sigma) in PBS (Sigma). Ice cold neutral collagen solution was made by mixing 1 part 
0.2M HEPES pH 8.0 (life tech), 4 parts >2mg/ml rat tail collagen type I (First Link (UK) 
Ltd., Wolverhampton, UK), and 5 parts DMEM (high glucose, with sodium pyruvate and 
glutamax; Life tech). For FPCL, equal volumes of the neutral collagen solution and 
hepatic stellate cells resuspended at  10cells/ml in DMEM were mixed. 1ml of the FPCL 
was added to each well and allowed to polymerise for 1 hour at 37degC 5% CO2. After 
polymerisation, 1ml of serum free medium with or without 50uM guanfacine was added 
causing detachment of the FPCL from the plate. After 6 hours the contracted gels were 
imaged using a Fluorchem M ccd (Protein simple) with white light transillumination. 
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2.15 Isolation of Liver Non-Parenchymal Cells and 
circulating cells. 
The isolation of Liver non parenchymal cells was performed in the following manner. 
Perfused liver tissue was dissected with a scalpel and homogenized in Hanks balanced 
salt solution (with calcium and magnesium + collagenase 0.01% and DNAse I (0.01%). 
The homogenate was then transferred to a 50ml Falcon tube and incubated at 37’C prior 
to filtration through a 100mcm cell strainer.  
Thereafter it was centrifuged at 500rpm for 5 minutes at 4’C and the supernatant 
subsequently centrifuged at 2000rpm for 10 minutes at 4’C. The supernatant was 
discarded and the pellet resuspended in PF4 (HBSS with no calcium or magnesium, 
DNAse I 0.01%, bovine serum albumin (0.25%) and centrifuged at 2000rpm for 10 
minutes at 4’C. The pellet was then resuspended in 3.9ml of RPMI 1640 and mixed gently 
with 2.1ml (RPMI and optiprep 22%). RPMI was then layered on top followed by 25 
minute centrifugation (2800rpm without brake at 4’C). The non-parenchymal cells were 
then isolated from the interface, resuspended in an equivalent volume of PF4 and 
centrifuged at 2000’C at 4’C for 10 minutes. 10 x 106cells were used in all subsequent 
assays.  
The peripheral circulating cells were suspended over a polymorphoprep solution and 
centrifuged at 500rpm for 10 mins at 4’C . The layer of interest (neutrophils at the bottom 
layer and the monocyte at the middle layer) are pipetted out and resuspended in a 10ml 
HBSS solution without Ca+/Mg+.. A further centrifuge at 350rpm for 10 mins produced a 
pellet. A red cell lysis buffer is added to the pellet and resuspended with vortex. After 
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removing the supernatant, 250 µl of HBSS is added to the solution and cell count is made 
by FACS after appropriate gating. 
 
2.16 Phagocytic function of Non parenchymal and 
circulating cells 
The phagocytic function of non parenchymal and circulating cells was assessed by the 
following method. The neutrophils and monocytes were isolated by the method described 
above in Section 2.15. The cells were centrifuged at 2000rpm for 5 minutes at 4ºC and 
the supernatant discarded. 200ul of latex beads containing media were added to the pellet 
and incubated at 37’C in the dark for 20 minutes. 5ml of ice cold PBS was then added and 
centrifuged at 2000rpm for 5 minutes at 4ºC. The pellet was then washed with 5ml of cold 
PBS and centrifuged. Fc blocker was then added and incubated for 10 minutes at 4’C. 
Cell surface markers for neutrophils (Anti CD32 antibody)  and kupffer cells (Anti-
CD163 antibody) was then added and incubated for 30minutes at 4’C in the dark. The  
phagocytic function was assessed with the help of the FACS canto machine after the cells 
were  washed with 1ml of FACS buffer, centrifuged and resuspended in 100ml FACS 
buffer solution. 
2.17 Kupffer cell ROS production 
To assess Kupffer cell ROS production, 20ug/ml of E.coli endotoxin was added to 1x 106 
non-parenchymal cells sample and incubated for 30minutes at 37’C. ROS inducer at a 
final concentration of 200-500uM was used for the positive control. The samples were 
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then centrifuged at 500g for 5 minutes and the supernatant discarded. The cells were then 
resuspended in 5ml of wash buffer, centrifuged at 500g for 5minutes and the supernatant 
removed. The cells were re-suspended in 500ul of ROS detection solution and incubated 
for 30 minutes at 37’C in the dark. Following centrifugation, the cells were resuspended 
in 100ul of FACS buffer, Fc blocker added (1:25) and incubated for 10minutes at 4’C.  
Anti-CD163 antibody was added and the cells incubated for 30minutes at 4’C in the dark. 
The cells were then washed with 1ml of FACS buffer, centrifuged and resuspended in 
100mcl FACS buffer solution.  
2.18 Limulus amoebocyte Lysate (LAL) endotoxin assay 
The chromogenic limulus amoebocyte lysate kinetic assay (Charles River Laboratories) 
was used for the detection of endotoxin. Portal venous plasma (100mcl) was diluted 1:10 
with endotoxin-free water and incubated at 75’C for 30 minutes. 100mcl of sample and 
100mcl of LAL reagent were mixed in a 96-well plate and analysed at 405nm with 
spectrophotometer using the Endoscan V software. Results are expressed as EU/ml. 
2.19 Brain water Measurement 
Brain water content was measured 24 hour post surgery. At the time of sacrifice, the rat 
brain was immediately removed and the right frontal lobe was excised with a sharp scalpel 
and inserted into a plastic tube and weighed in a electronic digital weighing machine. 
They are placed in an oven at 105 degrees for 48 hours. The percentage of water content 
was calculated as [(wet weight-dry weight)/wet weight] x 100%. 
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2.20 Arginase activity assay 
Liver tissue was suspended in a TRIS/HCL buffer containing a protease inhibitor cocktail 
(Sigma-Aldrich) and PMSF, and manually macerated with a glass mortar and pestle. The 
suspension was then centrifuged, and the clear homogenate was collected leaving the 
precipitate behind. 20 μl liver homogenate or serum was then combined with 20μl MnCl 
(10 mM), 150 μl Tris Buffer (pH 7.4, 50 mM), and 100μl of l-arginine (50 mM; Sigma-
Aldrich) for 30 min at 37° C. Arginine hydrolysis was stopped with 0.5 ml Tungstic acid 
solution (150 mM) containing concentrated hydrochloric and sulphuric acid (100 mM 
each). Unwanted particulate matter was pelleted by centrifuging at 5,000 RPM for 10 min 
at 4° C. 200μl of clear solution was used for detection of urea on a COBAS INTEGRA 
400 using a UREAL kit assay (Roche). To subtract background serum urea levels, each 
experiment was duplicated substituting the l-arginine substrate with 100 μl water. 1 U of 
arginase activity is defined as the amount of enzyme required to catalyze formation of 
1μM urea per minute. To avoid any bias in arginase activity attributable to baseline 
differences in protein content of the liver sections, protein content for each sample was 
determined by the Biuret test. This allowed arginase activity to be standardized against 
protein content, expressed as IU/liter serum or IU/mg protein. 
 
 
 
2.21 RNA isolation and qRT-PCR  
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Frozen liver was homogenized in TRI reagent (Sigma-Aldrich Company Ltd., Dorset, 
UK) using 7mm steel beads with a tissue lyser (Qiagen Ltd., Manchester, UK). After 
extraction with chloroform total RNA was isolated using an RNeasy mini kit (Qiagen 
Ltd., Manchester, UK). RNA concentration was measured using a nanodrop (Labtech 
International Ltd., Uckfield, UK). Reverse transcription was performed on 1ug RNA per 
sample with combined polyT and random hexamer primers using a Quantitect reverse 
transcription kit (Qiagen Ltd., Manchester, UK). 
qPCR was performed using hydrolysis probe assays (Integrated DNA Technologies, 
BVBA., Leuven, Belgium) and Taqman Fast Advanced marmix (Life Technologies, 
Renfrew, UK) on a 7500 Fast qPCR machine (Life Technologies, Renfrew, UK) 
 
2.22 Statistics 
Data are expressed as mean ± SEM or median [range] as appropriate. Significance of 
difference was tested with student T-test or Mann-Witney comparisons test; p<0.05 was 
taken to be statistically significant. Comparison between multiple groups was by analysis 
of variance (ANOVA) with a Bonferroni correction for multiple comparisons. Software 
used included Microsoft Excel 2007 (Microsoft Corp., Redmond, WA) and GraphPad 
Prism 4.0 (GraphPad Software, Inc., San Diego, CA) 
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                                    Chapter 3 
Characterisation of the Bile duct ligated rat as a model 
of Portal Hypertension and biliary cirrhosis 
3.1 Introduction 
The effect on hepatic morphology after traditional  bile duct ligation has been studied 
extensively since the original publication by Cameron and Oakley et al in 1932.The timing 
of development of cirrhosis varied between various studies. Some reported evidence of 
cirrhosis in 3-5 weeks post bile duct ligation. Biliary obstruction for 15 days or  more led 
to cirrhosis and after 4 weeks , this was found to be the majority of the rats. It was 
associated with extra hepatic cholestasis , with a narrow zone of oedema and ductular 
proliferation at the junction of the parenchyma and the septa which is characteristic of 
biliary cirrhosis in man (168) 
Systemic and splanchnic haemodynamics of the chronic bile duct-ligated rat were 
previously characterized by radioactive microspheres. The conscious bile duct ligated rats 
had a significantly more hyperdynamic circulation as compared to sham operated animals 
with increased cardiac output and portal venous blood flow (169).The chronology of 
evolution of portal hypertension , sodium handling and hyperreninaemia in a bile duct 
ligated rat model was studied by Poo et al (170). They showed that the portal pressure 
increases at week 1 and the mean arterial pressure remains the same until week 4, when 
it drops in the bile duct ligated group as compared to the sham operated animal. A 
significant reduction in sodium excretion and hyperreninaemia was also noted in the bile 
duct ligated rats as compared with control rats. However there is a suggestion that the 
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characteristic hyperdynamic circulation and increase portal pressure in the bile duct 
ligated rats occur earlier than the reduction in the sodium excretion and hyperreninaemia 
, suggesting that these are secondary phenomenon (171) In bile duct ligated rats, increased 
levels of pro inflammatory cytokines were found as compared to the control rats (171). 
BDL-induced cirrhosis was corroborated by the elevated liver damage markers and 
histopathological analysis. Chronic BDL significantly increased most of plasma and 
hepatic cytokine levels and diminished the hepatic IFN-gamma amount (172) 
 
When bile duct ligated rats and sham operated are challenged with lipopolysaccharide 
(LPS), there was increased sensitivity in the bile duct ligated rats as compared to the sham 
operated rats. This was associated with increased cytokine release and plasma 
nitrate/nitrite levels. It also was associated with increased liver injury and mortality in the 
bile duct ligated rats (165) 
 
The aim of our study was to establish that the bile duct ligated model with or without 
lipopolysaccharide had all the necessary vascular and biochemical parameters to test my 
hypothesis. 
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3.2 Animals 
The animals were cared for as per standard protocol as described in section 2.1 
 
3.2.1. Animal models: Physical appearance 
Male Sprague Dawley rats (Charles River, UK) were housed in a temperature and light 
controlled (12 hours light/dark cycle) facility at the Comparative Biology Unit, UCL. Rats 
received standard chow and water ad libitum. All procedures were performed in 
accordance with UK Home Office Animals (Scientific Procedures) Act 1986.  
3.2.2 Weight Changes 
 
  
  
Sham BDL BDL + BRL44408 
Weight gain (%) 43.0 (21.6) 25.8 (14.8) 20.4 (10.3) 
Liver weight (g) 14.6 (1.62) 27.9 (3.84) 24.5 (5.29) 
Table 3.1 : Weight Changes in the three groups of animals. 
All the animals studied were male Sprague Dawley rats supplied by Charles Rivers. Their 
initial weights were between 220-250 gms. Both Sham operated rats and BDL rats gained 
weight albiet at different rates of gain. The chart above denotes the percentage change in 
their weight from baseline up to the time of exsanguination. The liver weights were also 
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calculated in each group. I have included the intervention arm in this table as it shows the 
liver tends to gain weight upon treatment with an ADRA2a adrenergic receptor antagonist. 
3.2.3 Biochemistry Profile 
 
 
 
 
        Sham 
 
        BDL 
 
   BDL + LPS 
 
      Albumin (g/L) 
 
       32.4±0.76 
  
      24.41±0.93*** 
 
  24.80±0.80 
 
     Bilirubin       
       (µmol/L) 
 
      1.00±0.62 
 
      183.80±21.02 
 
  190.1±10.20 
 
      ALT (IU/L) 
 
     70.27±9.07 
 
     100.10±13.26* 
 
    130.3±24.40 
 
          AST (IU/L) 
 
      131.70±17.37 
 
      444.50±58.3*** 
 
    587.5±56.48 
 
      Lactate        (mg/dL) 
 
       2.74±0.52 
 
 
      7.05±0.42 
   
   10.23±0.24 
 
 
 Creatinine (mmol/L) 
 
     31.50±1.75 
 
      33.47±1.63 
 
  40.90±1.96 
 
Table 3.2: Shows the plasma biochemistry parameters in the three groups, Sham, 
BDL and BDL + LPS. These parameters include serum albumin, alanine 
transaminase, Aspartate transaminases, Lactate and Creatinine levels. (*** 
p<0.0001; * p<0.01) 
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The serum biochemistry was measured as per method described in section 2.5.The serum 
albumin was significantly different between the sham operated with saline and BDL 
animals treated with saline (32.4 v 24.4 g/L,p<0.0001) . There was no significant 
difference between BDL animals treated with saline or LPS. 
Similarly, there was a significant increase in the serum bilirubin the BDL rats as compared 
with the sham operated rats ( 183.80±21.02 v 1.00±0.62, p<0.0001). But there was no 
difference between the BDL animals treated with saline or LPS. 
There was a non statistical increase in the BDL rats as compared with the sham operated 
rats in the alanine aminotransferase (ALT) levels (100.10±13.26 v  70.27±9.07). There 
was a further increase in the ALT levels in the BDL rats treated with LPS as compared 
with saline, however, this was not statistically significant (130.30±24.46 v 100.10±13.26). 
There was a significant increase in the plasma AST level in the BDL rats treated with  
saline as compared to the sham operated rats treated with saline ( 444.50±58.3 v 
131.70±131.70, p<0.05). Although there was a further increase in the BDL rats treated 
with LPS as compared to the BDL rats treated with saline, it was statistically not 
significant. 
 Moreover, the plasma lactate was also significantly higher in the BDL animals treated 
with saline as compared to the Sham operated rats (7.65± 0.96 v 2.74± 0.52, p<0.05) and 
serum creatinine was not significantly raised in the BDL rats treated with saline as 
compared with the sham operated rat. 
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3.2.4.  The Mean Arterial Pressure   
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Fig 3.1:  Mean Arterial Pressure (MAP)  in the three groups (Sham , BDL and BDL 
rats treated with LPS). It shows that the MAP is reduced significantly in the BDL 
rat treated with saline as compared to the Sham operated rat (p=0.02).There was no 
further decrease in the MAP in the BDL rats treated with LPS. (Sham=16, BDL=20, 
BDL+LPS=6) 
The mean arterial pressure was measured in all the three groups as described previously 
in section 2.3. (Sham, BDL, BDL+LPS). There was significant reduction in the MAP in 
the BDL group as compared to the Sham operated rats ( 89.63 ± 1.91 v 103.3 ± 2.75, 
p=0.02) . There was however no significant difference in the MAP between the BDL rats 
with or without LPS (99.02 ± 3.4 v 89.63 ± 1.91). 
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3.2.5 Plasma Renin Activity  
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Fig 3.2: Plasma Renin Activity in Sham and BDL animals. This shows that there is 
a significant elevation of PRA in the BDL rats as compared to the Sham animals 
(p<0.0001). 
The plasma renin activity is measured by an ELISA test in sham and BDL rats as described 
in section 2.10. There is a significant increase in the plasma renin activity in the BDL rats 
as compared to the sham rats (234.4 ± 23.39 v 45.5 ± 11.7, p<0.001). 
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3.2.6  Portal Pressure measurements 
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Fig 3.3: Portal pressure measurement in the three groups (Sham, BDL and BDL  
animals treated with LPS). This shows that there is a significant increase in the 
portal pressure in the BDL rats as compared to the Sham animals 
(p<0.001).However, there was no difference in the portal pressure in the BDL rats 
treated with LPS as compared to BDL rats treated with saline. (Sham=16, BDL=21, 
BDL+LPS =6) 
The portal pressure was measured in all the three groups ( Sham, BDL and BDL + LPS) 
as described in section 2.3. There was significant increase in the portal pressure in the 
BDL group as compared to the Sham operated rats (14.79± 0.72. v 6.67±0.72). However 
on injection of LPS to the BDL rats, there was no difference in their portal pressure  
(14.79± 0.72 v 13.86 ± 1.47) 
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3.2.7: The relation between the portal pressure and plasma 
noradrenaline levels. 
 
Fig: 3.4: Relationship between the portal pressure and plasma noradrenaline 
levels.Shows a scatter plot diagram of the Noradrenaline levels in relation to the 
Portal pressure between the Sham and the BDL group.It shows that there is a 
significant linear co-relation between the two variables (p=0.02). (Sham=9, BDL=12) 
The plasma noradrenaline levels was measured by ELISA in sham and BDL rat plasma 
as described in section 2.11. There is a significant difference between the plasma 
noradrenaline levels in the sham and BDL animals. The BDL animals had significantly 
more noradrenaline levels as compared to the Sham operated animals. On plotting the 
noradrenaline levels to the portal pressure, there is a direct co relation between the plasma 
noradrenaline levels and the portal pressure. 
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3.2.8  Hepatic tissue TNFα levels 
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Fig 3.5 : Liver tissue TNFα levels in Sham, BDL and BDL rats treated with LPS. The 
FAC cytokine bead array test shows that the TNFα levels is significant increase in 
the BDL rats as compared to the sham rats (p=0.01). And it rises significantly in 
BDL rats treated with LPS as compared to BDL rats treated with saline (p=0.007) 
(Sham=8,BDL=7, BDL+LPS = 6) 
The liver tissue TNFalpha cytokine levels were measured by FAC cytokine bead array as 
described in section 2.6. The TNFalpha levels was significantly increased in the bile duct 
ligated animals as compared to the sham operated animals (73.23±31.26 v 49.41±22.31, 
p=0.01). However on injecting  LPS to the BDL rat, there is a  further significant rise in 
the TNFα levels as compared to the BDL group without LPS (990.6±227.7 v 73.23±31.23, 
p=0.007). 
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3.2.9  Plasma TNFα levels  
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Fig 3.6  The plasma TNFα in Sham and BDL animals. This shows that there is a 
significant inthe plasma level of TNFα in the BDL rats as compared to the Sham 
operated animals (p=0.003) (Sham+N/S =6, BDL+N/S=6) 
The plasma level of cytokine TNFα is measured by an ELISA test as described in section 
2.6. This shows that the plasma TNFα level increases significantly in the BDL rats as 
compared to the Sham operated rats (19.5±7.84 v 55.26±16.80, p=0.003). 
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3.2.10 Presence of the ADRA 2a receptor in the liver tissue 
To analyse the protein expression of  alpha 2a receptor in the liver, western blot analysis 
were undertaken on liver homogenate. This showed a significantly increased protein 
expression in the bile duct ligated rats as compared with the sham rats (p=0.01,fig 1a). 
Alpha 2a receptor protein was detected  at 68 kilodalton. GAPDH was used to correct for 
protein loading. 
 
 
 
 
 
 
Fig 3.7: Protein expression of alpha 2a adrenoreceptor showing a significant increase 
expression in the BDL rat as compared to the Sham operated rats (p<0.01,t-test) 
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Fig 3.8: mRNA expression of ADRA 2a receptors in Sham, BDL and BDL animals 
There is a significant difference in the number of ADRA 2a receptors in the two 
groups with a significant number which is more in the BDL rats as compared to the 
sham operated rats (p=0.03) 
The receptor density in the liver is shown in the figure above as quantified by qPCR. The 
method of isolation of mRNA was undertaken as per the method described in section 2.20. 
There is a significant difference in the number of receptors in the BDL rats as compared 
to the Sham operated animals.  
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3.3 The effect of inflammation on structure 
The initial elements of the study were to determine the impact of inflammation on the 
structure and function in a rodent model of bile duct ligated rats with reference to liver 
structure and measureable variables of biochemical function and inflammatory 
parameters. 
3.3.1 Structural changes in the liver due to inflammation  
  Histological presentation of the bile duct ligated rat: 
 
   
   
Fig 3.9: Histological assessment in the three groups. The top panel shows the 
Haematoxylin and Eosin stain in the Sham, BDL and BDL+LPS in the top panel. 
The bottom panel shows the Pico Sirius Red staining in the three groups –Sham 
,BDL and BDL+LPS. 
     BDL BDL+LPS    Sham 
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The histological assessment of the rat liver tissue were prepared as described in section 
2.8. As seen in patients with cirrhosis, BDL rats undergo significant loss of the normal 
liver architecture .The sham operated rats show that the normal lobular architecture is 
intact. In bile duct ligated rats, there is increasing loss of defined portal tracts. There is a 
significant increase in the proliferation of cholangiocytes. There is loss of liver 
architecture with early nodule formation. This distortion and loss of liver architecture is 
further augmented by the addition of lipopolysaccharide (LPS), as an inflammatory 
stimulus to BDL animals with greater parenchymal loss. With the Pico Sirius Red 
staining, it is evident that there is preservation of normal architecture in the sham rats , 
whereas there is increased collagen deposition in the in the BDL rats and the BDL rats 
treated with LPS. There is no clear difference in the level of collagen deposition between 
the BDL and the BDL rats treated with LPS. 
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3.4 Discussion  
Improved understanding of the pathogenesis of chronic liver disease and development of 
novel diagnostic, prognostic and therapeutic tools depend on development of appropriate 
reproducible animal models. However, no single animal model has been deemed to be 
perfect for the study of a diverse range of pathological processes leading to acute and 
chronic liver disease. Cholestatic liver injury is one of the major causative factors for the 
development of liver fibrosis and cirrhosis in patients with chronic liver disease. 
Therefore, experimental models have been generated that mimic various aspects of the 
complex mechanisms that lead to hepatic inflammation, fibrosis and cirrhosis. (173). 
Surgical BDL is one of the most widespread experimental models that is used to induce 
obstructive cholestatic injury in mice and rats. (174). We and others have already used 
this model in experiments involving inflammation and portal hypertension. However, 
there are discrepancies in the acceptance of the optimum time for the establishment of 
fibrosis in this model. In a recent study by Tarcin et al, it was demonstrated that collagen 
formation was optimum at week 3 and thereafter there is reduction in the amount of 
collagen content (175).This implied that the fibrosis in this model is at its peak at week 3 
post bile duct ligation and thereafter there is gradual reduction in fibrosis. Therefore it 
was important to validate this model to justify using this model to study this area. 
There can be several important conclusions that can be made from the results of this study. 
We have been able to show that there is a significant difference in the biochemical 
characteristics between the sham operated rat and the bile duct rats. The sham operated 
rats have a significantly higher albumin than the BDL rats, however, the bilirubin is 
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significantly higher in the BDL rats as compared to the sham operated animals. There was 
significant increase in aspartate transaminase in the BDL rats as compared to the sham 
operated rats and there was a trend towards increases in the serum alanine transaminase 
in the BDL rats as compared to the sham operated rats. There was no different in the 
results when the BDL rats were treated with Lipopolysaccharide. From the literature 
review, it is clear that in chronic hepatocellular injury, ALT is more commonly elevated 
than AST; however, as ﬁbrosis progresses, ALT activities typically decline, and the ratio 
of AST to ALT gradually increases, so that by the time cirrhosis is present, AST is often 
higher than ALT (176) (177). In my BDL model, at the end of 4 weeks we already note 
that the liver architecture has changed significantly with evidence of evolving fibrosis. 
This may help to explain why there is no significant difference in the ALT levels between 
the sham and BDL rats in my study. 
 
 The histological slides provide further proof of the progressive nature of liver injury that 
is seen in the bile duct ligated rat model as compared to the sham rats. This is characterised 
by the increased proliferation of cholangiocyte and septa formation in the BDL rats as 
compared to absence of these features in the sham operated rats. On assessment of the 
Sirius red staining of each of the group, it reveals that there is a significant increase in the 
deposition of collagen in the liver disease as compared to the sham operated animals. 
There is no increase in the collagen deposition by the BDL rats treated with LPS as 
compared to untreated BDL rats. 
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This is further supported by the finding of the significantly increased pro inflammatory 
cytokine TNFα in the liver tissue of the BDL rats treated with LPS as compared to the 
BDL rats. There was also significant increase in the TNFα level both in the plasma and 
liver tissue in the BDL rats as compared to the sham operated rats.. This indicates that the 
inflammation is propagated significantly by the addition of LPS. This supports the finding 
of increased cytokine release and plasma nitrate/nitrite levels associated with increased 
liver injury and mortality in the bile duct ligated rats noted by  Harry et al. (165). The 
timing of 3 hours post LPS injection and the dose of 0.33mg/Kg via intra peritoneal route 
has  a major impact on the study. In a recent study by Chou et al, it has been demonstrated 
that there is maximum stimulation of the pro-inflammatory cytokines at 3 hours both in 
the liver tissue and plasma when they used a 0.5mg/kg dosage regime given by a tunnelled 
biliary line(178). There is significant increase in the TNFα  in the plasma however there 
was reduction in the TNFα level in the liver tissue in this study. In our study, we used a 4 
week old BDL model with a lower dose of LPS (0.33mg/Kg) given via the intra peritoneal 
route. The bioavailability of LPS may be variable because of this choice of route and 
probably has led to the finding of no significant difference in the Sham and BDL groups. 
Although we have demonstrated that there is change in the cytokine profile in the BDL 
rats as compared to the Sham rats, this dose and route may not have been adequate to 
effect a haemodynamic change. 
The other significant finding is the upregulation of the ADRA 2a receptor protein in the 
BDL rats as compared to the sham operated animals. There is no evidence of presence of 
ADRA2a receptors in the normal livers. There is increased protein expression of the 
ADRA 2a receptor in the BDL rats. I am able to show this difference between the sham 
92 
 
and BDL both by protein expression and mRNA.  In the context of a bile duct ligated rat 
model, the addition of LPS worsens the pro inflammatory cytokine load. This predisposes 
the migrating macrophages to be activated and translocated to the liver. 
In this characterised BDL model we are able to show that the portal pressure is 
significantly raised as compared to the sham operated rat. There is no further 
augmentation of the portal pressure in the BDL rats treated with LPS. The study design 
consisted of giving one dose of LPS by the intra peritoneal route three hours before 
exsanguination. This probably impacted on the fact there was no significant  difference in 
the portal pressure in the BDL rats treated with LPS as compared to the untreated BDL 
ones. In clinical practice the secondary insult is usually over a longer period of time and 
therefore is able to influence the portal pressure in a more significant way.  We have also 
shown that the noradrenaline levels in the BDL rats were significantly increased as 
compared to the sham operated animals. It is well known that production of noradrenaline 
may be from a multitude of sources including the adrenal glands and the circulating 
immune cells which have been shown to have the mechanism to produce noradrenaline 
on its own in a paracrine effect. Intestinal translocation of bacteria and its products 
stimulate the adrenergic receptors in the migrating immune cells. These cells in turn 
stimulate the transmembrane receptors present in each cell to produce the increased 
amount of noradrenaline that is observed in this study.  
There is a reduction of the mean arterial pressure in the BDL rats as compared with the 
sham operated rats. There is no difference in the MAP when LPS is injected to the BDL 
rats. The same early effect of the LPS effect is probably in play as a cause for the non 
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difference in the haemodynamic outcome post injection of LPS.  As a compensatory 
mechanism, we are also able to show that the plasma renin activity is increased in response 
to the low MAP found in the BDL rats as compared to the sham operated animals.  
In conclusion, This model provides me with all the necessary haemodynamic, 
biochemical and cytokine characteristics that will enable me to carry out the studies that 
I have planned for.  The increased protein expression of the ADRA 2a receptor is an 
important finding in the BDL rat. The fact that ADRA2a receptor was not found in the 
sham operated rat suggest that is produced by the migrating immune cells provide a 
rational target to reduce intra hepatic and systemic inflammation and thereby mitigate the 
haemodynamic dysfunction. The next phase of the study will attempt to reduce the high 
inflammatory load in this model by using an ADRA2a adrenergic receptor antagonist and 
thereby reduce intra hepatic resistance and portal hypertension. 
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                                      Chapter 4 
The effect of ADRA2a adrenergic receptor antagonism 
in hepatic and systemic haemodynamics in a BDL rats  
4.1 Introduction. 
Portal hypertension is the clinical syndrome which is implicated in the complication of 
liver cirrhosis. The onset of clinically significant portal hypertension defines disease 
progression. It is responsible for a spectrum of consequences which lead to acute 
decompensation of the liver by way of ascites, variceal bleeding, hepatic encephalopathy 
and hepato-renal syndrome (68). Portal hypertension is characterized by both increased 
intra hepatic resistance and splanchnic vasodilatation. The primary haemodynamic 
change that occurs in portal hypertension is increasing being accepted as increased intra 
hepatic resistance. This increased intra hepatic resistance was originally thought to be as 
a consequence of established fibrosis and nodule formation. However, increasingly it is 
being recognized that there is a reversible component to intra hepatic resistance (179). 
This consist of the vascular tone and activation and contractility of hepatic stellate cells. 
The splanchnic and systemic haemodynamic changes are thought to be a consequence of 
the increased intra hepatic resistance (180) 
It is well established in the literature that the sympathetic system is upregulated in portal 
hypertension. It has been shown in several studies that the plasma norepinehrine is 
elevated in patients with high Childs-Pugh score and severe portal hypertension, with the 
level co relating to disease severity (181-183). Catecholamine are thought to play a role 
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in the pathogenesis of portal hypertension as in experimental models of cirrhosis, they 
have been shown to increase intra hepatic resistance (184).  
Adrenergic receptors have been studied in great detail in the control of vascular regulation 
(185). The main strategy for treatment of portal hypertension is currently a non selective 
beta blocker (186).It is poorly tolerated in about 30% of patients due to side effects and is 
effective in another 30% of patients only. Various other adrenergic receptors have been 
investigated for the treatment of portal hypertension. However, most of them have not 
been used in routine clinical practice because of concerns about systemic hypotension. 
ADRA2a adrenergic receptor is a specific receptor, which is subtype of G-protein related 
peptide which are present as transmembrane protein receptors. It is present in various 
densities in the central and peripheral nervous system and its mechanism of vascular 
regulation has been studied in detail (187). In the sepsis literature, it has been used as a 
target to reduce the inflammatory cytokines produced by the migrating macrophages 
including the kupffer cells (110). Although there is no evidence of significant receptor 
density in the liver, the migrating macrophages and the resistance vessels present a valid 
target in liver disease to assess the modulation of the sympathetic receptor in improvement 
of intrahepatic resistance in the context of cirrhosis of the liver 
The aim of this study is to assess whether that antagonism of the ADRA2a adrenergic 
receptor reduces the intra hepatic resistance and thereby decrease portal pressure. This 
study will also investigate on the possible mechanisms by which the antagonism of the 
ADRA2a adrenergic receptor modulates intra hepatic resistance. 
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4.2 Methods: 
4.2.1 Study design  
Male Sprague Dawley rats weighing 220-250 g were randomly assigned to receive sham 
or bile duct ligation (BDL) surgery as described previously (165). Four weeks later 
haemodynamic measurements were performed and samples collected for analysis. For the 
BRL44408 study, treatment with either 10 mg/kg BRL44408 maleate (Sigma-Aldrich 
Company Ltd., Dorset, UK) dissolved in sterile water or saline (control, equal volume) 
by subcutaneous (s.c.) injection was given on the last 2 days of the study 
 Rats were randomly assigned to the following treatment groups: 
i. Sham group: sham surgery, s.c. saline 
 
ii. Sham+BRL group, s.c BRL 44408 
 
iii. BDL group: BDL surgery, s.c. saline 
 
iv. BDL+BRL group: BDL surgery, s.c. BRL44408 
 
All rats were exsanguinated under terminal anesthesia (2% isofluorane). Within seconds 
blood was withdrawn from the descending aorta and immediately put into ice cold 
heparin/EDTA containing tubes (until full exsanguination), centrifuged at 3000 rpm and 
4oC for 10 min, and the plasma collected and stored at -80°C until assayed. Liver tissue 
was also removed immediately harvested and snap frozen for storage at -80°C until 
analyzed. Liver tissues were also fixed with 10% formalin for further histological 
analysis.  
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All the four groups were used for the haemodynamic assessment. However, in subsequent 
analysis, only the Sham+Saline, BDL+Saline, BDL+BRL were only used. The rationale 
for omitting the Sham+BRL group was that as there was no haemodynamic difference in 
the Sham animal treated with BRL as compared with the Sham animal treated with normal 
saline, it was assumed that it would not have an impact on the results of the other 
experiments. The focus of this set of experiment was to assess the impact of the proposed 
treatment on the diseased animals, therefore the analysis was based on the effect of 
treatment on diseased animal as compared to non treated diseased animals. 
 
4.2.2  Haemodynamic measurement 
All haemodynamic measurements were undertaken exactly as described previously in 
section 2.3. 
4.2.3. Biochemical Parameters 
All biochemical parameters (ALT, ALP, albumin, total protein, ammonia, bilirubin, urea 
and creatinine) were analyzed using 200μl of respective plasma samples using a Cobas 
Integra 400 multianalyzer with the appropriate kits (Roche-diagnostics, Burgess Hill, 
West Sussex, UK). 
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4.2.4  Plasma and tissue Cytokine Assays 
All cytokine assays were undertaken in a similar method as described previously in 
section 2.6. 
4.2.5  Western Blot Analysis 
All the western blot analysis was undertaken in exactly the same technique as previously 
described in section 2.7.  The primary antibody that have been used in this study are 
Adra2a (1:1000 dilution, PA1-048, Pierce Biotechnology Inc., Rockford IL, USA), ), 
mouse anti eNOS (1:1000 dilution, 610297, BD Biosciences, Oxford, UK), rabbit anti 
phospho-eNOS (Ser1177) (1: 1000, #9571, Cell Signalling Technology, Inc., Danvers 
MA, USA), mouse anti ACTA2 (alpha-SMA; 1: dilution, M0851, Dako UK Ltd., Ely, 
UK) and mouse anti GAPDH (1:1000 dilution, ab6046, Abcam plc., Cambridge, UK), 
mouse anti DDAH1 (1:1000 dilution ab2231,abcam plc, Cambridge,UK) mouse anti 
NFkB p65 (1:1000, dilution, 2A12A7,Invitrogen,UK). Loading accuracy was evaluated 
via membrane rehybridization with antibodies against mouse and rabbit anti-α tubulin 
(1:1000; Upstate Biotechnology, Albany, NY) or mouse anti GAPDH (1:1000 dilution, 
ab6046, Abcam plc., Cambridge, UK). 
4.3 Results. 
Following surgery all animals continued to gain weight. From the final body weight taken 
before termination, cirrhotic rats were found to be significantly lower than that of sham 
rats (350 ± 5g vs. 472 ± 9g, respectively; P < 0.001). 
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4.3.1 Biochemical Profile 
Table 4.1 Biochemical Profile 
 
  
Sham+Saline 
 
        BDL+Saline 
 
   BDL + BRL 
 
     Albumin  (g/L) 
 
       33.05±0.84 
  
      26.06±0.93*** 
 
  25.88±1.29 
 
      Bilirubin       
     (µmol/L) 
 
     44.16±15.46 
 
  132.20± 21.02*** 
 
123.40 ± 11.61 
 
      ALT (IU/L) 
 
     60.75±8.81 
 
   90.73±5.49* 
 
    94.73±4.90 
 
       AST (IU/L) 
 
    131.70±17.37 
 
564.30±59.64*** 
 
  589.30±56.32 
Fig 4.1 Shows the biochemical parameters in the three groups (Sham, BDL and 
BDL+BRL) (*** p<0.001, *p<0.01) 
The serum albumin was no different between the sham operated with saline or BRL 
44408. There was a significant reduction in the serum albumin levels in the BDL rats as 
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compared to the sham operated rats (26.06± 0.93 v 33.05±0.84,p<0.001) . This did not 
alter after treatment with BRL 44408 (26.06±0.93 v 25.88±1.29)  
Similarly, the serum bilirubin was not difference between the sham operated animals 
treated with saline and BRL44408.There was a significant increase in the serum bilirubin 
the BDL rats as compared with the sham operated rats (132.2±2.02 v 44.16±15.46, 
p<0.001). However there was no difference between the BDL rats treated with saline or 
BRL 44408 (123.40±11.61 v 132.20±21.02). 
There was a significant increase in the plasma ALT levels in the BDL rats as compared 
with the sham operated rats (90.73±5.49 v 60.75±8.81, p<0.001). There was a trend 
towards a reduction in the plasma ALT levels in the BDL rats treated with BRL as 
compared to the BDL rats treated with saline (94.73±4.90 v 90.73±5.49). 
There was a significant increase in the plasma AST level in the BDL rats treated with  
saline as compared to the sham operated rats treated with saline (564.30±59.69 v 
131.70±17.37,p<0.001). However, there was no reduction in the plasma AST level in the 
BDL rats treated with BRL 44408 as compared with the BDL rats treated with saline 
(589.30±56.32 v 564.30±59.64). 
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4.3.2  Mean Arterial Pressure Measurement 
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Fig 4.2 : Mean arterial pressure measurement of all four groups There is a significant 
increase in the MAP in the BDL rats treated with BRL 44408 as compared to the 
BDL rats treated with saline (p=0.01) (Sham + N/S =16, Sham + BRL =9, BDL+N/S 
= 24, BDL+BRL=21) 
The mean arterial pressure (MAP) was measured in all the groups as described in the 
methods section 2.3. The MAP in the  bile duct ligated rats is significantly lower than 
sham operated rats treated with saline (93.28±3.45 mmHg vs 109.9±3 
mmHg.,p<0.0001).However on treatment with BRL 44408, there is a significant increase 
in the MAP in the treated group as compared with BDL rats (93.28±3.45 mmHg vs 
99.67±4.38 mmHg, p=0.05, Fig 4.3).  
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4.3.3 Portal Haemodynamic outcome 
4.3.3.1 Portal Pressure Measurement 
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Fig 4.3: Portal pressure measurement of all four groups. The portal pressure was 
significantly increased in the BDL rats treated with saline as compared to the Sham 
operated rats treated with saline (p<0.001).The portal pressure is significantly 
reduced in the BDL rats treated with BRL 44408 as compared with the BDL rats 
treated with saline (p<0.001). (Sham + N/S =16, Sham + BRL =9, BDL+N/S = 24, 
BDL+BRL=21) 
The portal pressure  was measured in all the groups as described in section 2.3. The portal 
pressure was significantly increased in the bile duct ligated rat as compared to the sham 
operated rats (18.24±1.0 vs 7.6±0.6 mmHg,p<0.0001).The portal pressure was 
significantly reduced in the BDL rats treated with BRL 44408 as compared to the BDL 
treated with saline (11.61±0.9 vs 18.24±1.0 mmHg, p<0.0001 Fig 4.4).  
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 4.3.3.2: Hepatic Blood Flow          
A.                                                                                           
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Fig 4.4(A): Portal Vein Blood Flow                 
B. 
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      Fig4.4(B): Hepatic Artery  Blood Flow 
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Fig 4.4(A) and Fig 4.4(B): Hepatic blood flow in all the four groups). The portal vein 
blood flow reduces significantly in the BDL rat as compared to the sham operated 
rat (p<0.001), whereas there is a significant increase portal vein blood flow in the 
BDL rats treated with BRL 44408 as compared to the BDL rats treated with saline 
(p=0.05). A similar pattern was observed in the hepatic artery blood flow with 
reduced blood flow in the BDL rat as compared to the sham operated rat ( 
p=0.0006).However the blood flow goes up on treatment of the BDL rats with BRL 
as compared to BDL rats (p=0.004) (Sham +N/S=12, Sham+BRL=3, BDL+N/S=9, 
BDL+BRL=12) 
 
The portal vein in the BDL rats showed a significant drop in the blood flow as compared 
to the sham operated rats (68.98±19.23 vs 179.1±59.08,p<0.001). The blood flow in the 
portal vein was increased significantly in the BDL rats treated with BRL 44408 as 
compared to the BDL rats treated with saline alone ( 93.16±30.31 vs 68.98±19.23, 
p=0.05). The blood flow in the hepatic artery ( HABF) was also decreased in the BDL 
rats as compared to the sham operated rats ( 24.35±8.04 vs 11.18±5.63,p<0.001), however 
the blood flow increased significantly in the hepatic artery in the BDL rats treated with 
BRL 44408 as compared with the BDL rats treated with saline ( 11.18±5.63 vs 22.09± 
8.29, p<0.01) 
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4.3.4.  Cardiac Haemodynamic outcomes:  
4.3.4.1 Cardiac Output 
A. Cardiac Output 
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Fig 4.5(A): Cardiac output data in all the four groups. The cardiac output increases 
significantly in the BDL rats treated with saline as compared to the sham operated 
rats treated with saline (p=0.001).This was further increased in the BDL rats treated 
with BRL as compared to the BDL rats treated with saline (p=0.001). (Sham+N/S=3, 
Sham+BRL=3, BDL+N/S=6, BDL+BRL=6) 
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4.3.4.2 Stroke Volume  
B. Stroke Volume 
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Fig 4.5(B): Stroke volume data in all the four groups. The stroke volume increases 
significantly in the BDL rats treated with saline as compared to the sham operated 
rats treated with saline (p=0.004).There was no further increased  in the stroke 
volume in the BDL rats treated with BRL as compared to the BDL rats treated with 
saline. (Sham+N/S=3, Sham+BRL=3, BDL+N/S=6, BDL+BRL=6) 
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4.3.4.3  Heart Rate  
C. Heart Rate 
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Fig 4.5(C): Heart rate data in all the four groups. The heart rate  reduces 
significantly in the BDL rats treated with saline as compared to the sham operated 
rats treated with saline (p=0.03).There was a non significant increase  in the heart 
rate in the BDL rats treated with BRL as compared to the BDL rats treated with 
saline (p=0.08). (Sham+N/S=3, Sham+BRL=3, BDL+N/S=6, BDL+BRL=6) 
 
The echocardiogram was undertaken in all the groups of animals as described in section 
2.4. There was no difference between the cardiac output in the sham operated group 
treated with either saline or BRL 44408. However the cardiac output increased 
significantly in the BDL rats as compared to the sham operated rats (156.0 ± 3.055 v 126.3 
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± 5.044, p<0.001). . Further, on treatment with  BRL 44408, the BDL rats increased their 
cardiac output significantly as compared to the BDL rats treated with saline (188.5 ± 7.154 
v 156.0 ± 3.055, p<0.001). The stroke volume was increased significant in the BDL rats 
as compared to the sham operated rats. However, the heart rate was significantly reduced 
in the BDL rats as compared to the sham operated rats. This was improved significantly 
in the BDL rats treated upon treatment with BRL 44408. Overall, the cardiac output is 
increased in the BDL rats treated with BRL 44408 as compared to the BDL rats treated 
with saline. However, the increased output is more significantly determined by the heart 
rate and not by the stroke volume. This indicates that actual cardiac output is not 
increased. 
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4.3.5  Reduction of Intra Hepatic Resistance : 
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Fig 4.6: The calculated intra hepatic resistance for all the four groups. The intra 
hepatic resistance in the BDL rats was significantly greater as compared to sham 
operated rats (p=0.003). This was significantly reduced in the BDL rats treated with 
BRL 44408 as compared to the BDL rats treated with saline (p=0.02) 
The intra hepatic resistance is calculated by the dividing the portal pressure by the total 
hepatic  blood flow. In our experiment, there is no significant difference in the intra 
hepatic resistance between the sham operated animals treated with saline or BRL 44408. 
However, there is a significant increase in the intra hepatic resistance in the BDL rats 
treated with saline as compared to the sham operated animals treated with saline. This 
increased resistance is in the BDL rats treated with saline is significantly reduced with the 
treatment of the  BDL rats with BRL 44408. 
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4.3.6  Plasma renin activity levels 
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Fig 4.7: Plasma renin activity in the three groups. The plasma renin activity was 
significantly increased in the BDL rats as compared to the Sham rats 
(p=0.001).However, the renin activity goes down significantly in the BDL rats treated 
with BRL 44408 as compared to BDL rats treated with saline.( Sham+N/S =11, 
BDL+N/S =10, BDL+BRL=8) 
The plasma renin activity measured by ELISA as described in the methods chapter 2.10 
was compared between the sham operated, BDL rats treated with saline and BDL rats 
treated with BRL.The plasma renin activity was significantly increased in the BDL rats 
as compared to the sham operated rats ( 297.6±4.89 v 45.15±4.89, p=0.001). However 
after treatment with BRL 44408 , BDL rats reduced their plasma renin activity 
significantly as compared to the BDL rats treated with saline ( 178.2±11.0 v297.6±4.89 , 
p=0.009) 
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4.3.7 Plasma Noradrenaline Levels in the three groups 
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Fig 4.8: Plasma noradrenaline levels in the three groups. This shows that the plasma 
noradrenaline is significantly increased in the BDL rats as compared to Sham 
operated rats (p=0.01). This was further increased in the BDL rats treated with BRL 
44408 (p=0.04) (Sham+N/S =9, BDL+N/S =14, BDL+BRL=11). 
The plasma Noradrenaline level was measured by an ELISA assay as described in section 
2.11. This shows that the plasma noradrenaline level goes up in the BDL rats as compared 
to the sham operated rats (286.8±70.40 v 95.40±28.22, p=0.01). This was further 
augmented by treatment of the BDL rat with BRL 44408 (526.22 ±84.69 v 286.8±70.40, 
p=0.04) 
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4.3.8 Reduction of inflammation in BDL rats with BRL 44408 treatment.  
4.3.8.1 Liver Tissue TNFα level                    
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Fig 4.9(A):Liver tissue TNFa levels in the three groups ( Sham, BDL and 
BDL+BRL).The TNFα level goes up significantly in the BDL rats as compared to the 
sham rats (p=0.01). However, on treatment of the BDL rats with BRL 44408, there 
is significant reduction in the liver tissue TNFα level (p=0.03) (Sham+N/S =8, 
BDL+N/S =7, BDL+BRL=5) 
The liver tissue TNFalpha cytokine levels were measured by FAC cytokine bead array as 
described previously in section 2.6. The TNFalpha levels was increased significantly in 
the bile duct ligated animals as compared to the sham operated animals(149.50±73.67 v 
72.80±5.56,p=0.01) However, on treatment with BRL 44408 , the liver tissue TNFalpha 
cytokine levels were significantly reduced as compared with the saline treated BDL rats 
(93.11±16.32 v 149.50±73.67,p=0.03). 
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 4.3.8.2: Plasma TNFa levels in the three groups  
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Fig 4.9(B): Plasma TNFα level for the three groups (Sham, BDL and 
BDL+BRL).The plasma TNFα level was significantly raised in the BDL rat as 
compared to the sham rats (p=0.003) and the level was significantly reduced with 
treatment of the BDL animal with BRL 44408 (p=0.02). (Sham+N/S =6, BDL+N/S 
=7, BDL+BRL=5) 
The plasma TNFalpha cytokine levels were measured by FAC cytokine bead array as 
described previously in section 2.6. The  plasma TNFalpha levels was increased 
significantly in the BDL rats treated with saline as compared to the sham operated rats 
(48.12±4.08 v 20.06±6.06, p=0.003).However, the TNFalpha was significantly reduced 
in the BDL rats treated with BRL 44408 as compared to the BDL rats treated with saline 
(31.11 ±6.08 v  48.12±4.08, p=0.02)  
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4.3.8.3  Liver Tissue NFkB protein expression  
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Fig 4.10: NFkB levels in liver tissue in the three groups). It shows that the NFkB 
levels go up in the liver tissue in the BDL rats as compared to the sham animals 
(p=0.001). This level goes down when BDL rats are treated with BRL 44408 as 
compared to the BDL rats treated with saline (p=0.05)  
The nuclear factor kappa B is a transcription factor which acts a final common pathway 
for a multitude of inflammatory mediators. The western blot analysis of the protein 
expression of the nuclear factor kappa B shows that the expression goes up significantly 
in the BDL rats as compared to the sham operated rats (0.4826 ± 0.04642 v 0.8082 ± 
0.05441,p=0.001).This protein expression goes down  in the BDL rats with treatment with 
BRL 44408  as compared with the BDL rats treated with saline (0.5946 ± 0.07793 v 
0.8082 ± 0.05441, p=0.05) 
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4.3.9 Pathways that have been implicated in the improvement in portal 
pressure. 
4.3.9.1 Cyclic AMP activity after treatment with BRL 44408. 
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Fig 4.11: Cyclic AMP levels measured in the three groups. The cAMP levels in the 
BDL rats was reduced in the BDL rats as compared to the Sham operated rats. 
However, upon treatment with BRL , the BDL rats have increased cAMP activity 
(p=0.01). (Sham+N/S=7, BDL+N/S=6, BDL+BRL=7) 
The cAMP activity was measured from the liver homogenate by a ELISA method as 
described section 2.12. The cAMP activity was non significantly increased in the BDL 
rats as compared with the sham operated rats (276.6 ± 16.48 v 318.7 ± 16.88,p=0.10 ).The 
cAMP activity was however reduced significantly in the BDL rats treated with BRL 
44408 (340.3 ± 15.78  v 276.6 ± 16.48, p=0.01) 
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4.3.9.2  Hepatic Stellate Cell Activation: 
 
 
 
 
Fig 4.12: Rat hepatic stellate cells contraction assay. Rat hepatic stellate cells grown 
in the presence of 5uM Guanfacine show greater contraction in a 3D collagen gel 
than cells grown in the absence of guanfacine  
Gel contraction assay was undertaken as per method detailed in section 2.14. I sought to 
determine whether adrenergic signalling could enhance hepatic stellate cell activation to 
a myofibroblast phenotype. Rat hepatic stellate cells (a gift from Jonathan Fallowfield) 
were seeded into serum-free 3D collagen gels. They were incubated in serum-free medium 
or in the presence of 5uM Guanfacine (an ADRA2a adrenergic receptor agonist). 
Stimulation with Guanfacine caused an increase in the contraction of the 3D collagen gel 
compared to serum free medium.  
Subsequent experiments beyond the remit of this thesis has confirmed this finding in 
human hepatic stellate cells , wherein experiments conducted in this laboratory showed 
that the human stellate cells grown in 5uM of guanfacine showed greater contraction as 
compared to serum free medium. However, on addition of BRL 44408 to the Hepatic 
Stellate Cells and Guanfacine, there was definitive relaxation.  Downstream signalling 
Serum Free Guanfacine 
Rat 
HSC 
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pathway was also analysed to confirm that this pathway was involved in the contraction. 
Western blot analysis of erk-1/2 phosphorylation was increased in guanfacine stimulated 
cells. Although , a numerical assessment of the number of cells was not done, the above 
experiments confirm the involvement in the contraction of the gel by way of reversibility 
of contraction by addition of the ADRA2a antagonist. 
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4.3.9.3  Alpha Smooth Muscle Actin protein expression in the three groups 
 
 
Fig 4.13:  αSMA  protein expression in Sham, BDL  and BDL rats treated with BRL 
44408. This shows that the protein expression of αSMA is significantly increased in 
the BDL liver as compared to the BDL rat liver. However, this expression was 
significantly reduced in the BDL treated with ADRA2a as compared to BDL rats 
treated with saline. GAPDH was used as a control for the western blot. 
The Alpha Smooth Muscle Actin (αSMA) is a surrogate marker for Hepatic Stellate Cell 
activation. The protein expression in this study suggest that there is significant increase 
in the HSC activation in the BDL rats as compared to the sham operated animals as 
evidenced by the increased protein expression of  αSMA in the BDL rats . However, this 
protein expression was significantly reduced in the BDL rats treated with BRL 44408 
suggesting that there is reduction in HSC activation with ADRA2a antagonism.  
It is well established that there is increased production in the cytokine production in the 
BDL rats as compared to the sham animal. These are propagated by increased bacterial 
translocation from the gut. These cytokines in turn activate the hepatic stellate cells as 
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they reach the liver through the portal circulation. The alpha smooth muscle actin protein 
expression is upregulated by the activated hepatic stellate cells. However, on treatment 
with the ADRA2a antagonist, there is reduction in the cytokine production in the liver. 
This in turn deactivates the hepatic stellate cells and thereby indirectly reduces the protein 
expression of the alpha smooth muscle actin. 
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4.3.9.4 Endothelial Nitric oxide Synthetase protein expression in the three groups 
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Fig 4.14: eNOS protein expression in the three groups of animals. This shows that 
the  eNOS  protein expression is  increased significantly in the BDL rats    as 
compared to the sham operated rats (p<0.0001) . However, the protein expression of 
eNOS  is down regulated in the BDL rats treated with BRL as compared with the 
BDL rats treated with saline (p<0.01) 
The protein expression of eNOS protein reveal that the expression goes up in the BDL 
animal as compared to the Sham operated  rat (2.313 ± 0.06395 v 0.7588 ± 0.2095, 
p<0.0001) .However, there is reduced protein expression of  eNOS in the BDL rats treated 
with BRL 44408 as compared to the BDL rats treated with BDL(1.892 ± 0.07007 v 2.313 
± 0.06395, p<0.01) 
 
α tubulin 
eNOS 
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4.3.9.5 Phosphorylated endothelial Nitric oxide synthetase protein expression in the 
three groups 
 
 
 
Fig 4.15: Phosphorylated eNOS and total eNOS protein expression in all the three 
groups. The expression of total eNOS protein is increased in BDL rats compared to 
sham operated rats whereas the level of eNOS phosphorylation is reduced. 
Treatment with BRL44408 reduces the expression of total eNOS protein and 
increases the level of eNOS phosphorylation. 
The expression of total eNOS protein was increased in BDL rats compared to sham 
operated rats but despite this the level of eNOS phosphorylation was greatly reduced. 
Treatment with BRL44408 both reduced the expression of total eNOS protein and 
increased the level of eNOS phosphorylation. 
Sham BDL BDL+ BRL 
BDL+ BRL p-eNOS (Serine 1117) 
  
GAPDH 
Total eNOS 
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4.3.9.6  DDAH 1 levels in the three groups of animals 
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Fig 4.16: DDAH1 protein expression in the three groups. This shows that the protein 
expression of DDAH1 in the liver tissue is decreased non significantly in the BDL 
rats as compared to the sham operated rats. However, on treatment of the BDL rats 
with BRL 44408, there is a significant increase in the protein expression of DDAH1 
in the liver tissue as compared to the BDL rats treated with saline (p=0.03) 
The DDAH1 protein expression in the liver tissue shows there is non significant reduction 
in its expression in the BDL rats as compared to the sham operated rats (1.955 ± 0.1854 
v 2.164 ± 0.1353). However, on treatment with BRL 44408, the BDL rats had significantly 
increased DDAH1 protein expression (2.363 ± 0.04553 v 1.955 ± 0.1854, p=0.03). This 
signifies that there is less inhibition of eNOS enzyme, which in turn lead to increase NO 
production in the BRL 44408 treated animals. 
α tubulin  
DDAH1 
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4.3.10 Histological assessment in the three groups  
Fig 4.17: Histological assessment of all the three groups. Liver architecture and 
fibrosis in Sham, BDL, and BDL + BRL rats was assessed by H&E and picrosirius 
red (PSR) staining, respectively. 
Sham rats demonstrate a normal liver architecture. BDL rats show a loss of acinar 
structure and number of hepatocytes, along with the development of fibrous bands, 
significant cholangiocyte proliferation, and some cholestasis. BDL rats treated with BRL 
show the same features with no visible reduction in the level of injury. Representative 
images of the same region of liver stained with picrosirius red imaged by both bright field 
and circular polarised light microscopy are also shown. Under brightfield microscopy, 
sham livers show strong collagen staining surrounding vessels but very little visible 
throughout the parenchyma. BDL livers show a large amount of collagen staining 
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throughout the whole section coinciding with the ductular proliferation. In sham livers, 
polarised light microscopy reveals yellow staining (indicating medium thickness collagen 
fibres) surrounding vessels with some green staining (indicating thin collagen fibres) 
within the parenchyma. BDL livers show both yellow and green staining (suggesting 
medium thickness maturing fibres and thin newly synthesized fibres) throughout the 
section. BDL rats treated with BRL show the same types of collagen fibres without any 
visible reduction in fibrosis 
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4.3.11 Other Organ involvement: 
4.3.11.1 Reduction in brain water  
A. Brain  Water 
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Fig 4.18(A): Brain water changes in all the three groups. Shows the percentage 
change in the brain water in the three groups. The brain water percentage change is 
significant in the BDL rats as compared to the Sham rats (p=0.005). There is 
significant reduction in the brain water content in the BDL rats treated with BRL 
44408 as compared to the BDL rats treated with saline (p=0.03). (Sham+N/S =5, 
BDL+N/S =7, BDL+BRL=7) 
The brain water content is a surrogate marker for cerebral inflammation that occurs in 
cirrhosis. The brain water content was measured as described in section 2.19. The brain 
water content is increased in the BDL rat as compared to the sham operated rat (85.64 ± 
1.235 v 71.20 ± 2.605, p=0.005). However, on treatment with BRL 44408, the brain water 
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content in the BDL rats reduces significantly as compared to the BDL rats treated with 
saline (78.47 ± 2.540 v  85.64 ± 1.235,p=0.03)  
 .4.3.11.2  Plasma Lactate levels  
B.Plasma Lactate Levels 
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Fig 4.18(B):Plasma lactate levels in the three groups. The Plasma lactate level goes 
up significantly in the BDL rats as compared to the sham operated rats( p=0.003). 
However, upon treatment with BRL 44408, there was significant reduction in the 
plasma lactate levels as compared to the BDL rats treated with saline (p=0.02). 
(Sham+N/S=5, BDL+N/S=7, BDL+BRL=7) 
The plasma lactate level is a surrogate marker for peripheral ischemia, which in turn is a marker 
for adequacy of systemic circulation. In this model, the plasma lactate level was significantly 
increased in the BDL rats as compared to the sham operated animals (7.053 ± 0.4239 vs 2.74 ± 
0.52,p=0.003) However,upon treatment with BRL 44408 , the plasma lactate level decreased 
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4.3.11.3  Renal Function 
C.Renal Function 
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Fig 4.18(C): Serum creatinine levels in the four groups. This shows that the serum 
creatinine increases in the BDL rats as compared to the sham operated rats (p=0.04). 
This level goes down with treatment of the BDL rats with BRL 44408 as compared 
to the BDL rats treated with saline (p=0.02). (Sham+N/S=8, Sham+BRL = 
3,BDL+N/S=7, BDL+BRL=5) 
The serum creatinine is a marker for renal function. The level gives an indication whether 
there is renal impairment. In this study, the serum creatinine did significantly rise as 
significantly in the BDL rats as compared to the  BDL rats treated with saline ( 2.61 ± 0.24 vs 
7.053 ± 0.4239, p=0.02) 
 
 
128 
 
compared to the sham operated animal (32.55±1.46 v 24.55 ± 2.573, p=0.04). However this 
reduced significantly in the BDL rats treated with BRL 44408 as compared to the BDL 
rats treated with saline (27.55±1.76 v  32.55±1.45, p=0.02) 
 
4.4 Discussion 
I was able to make several observations based on the results of this study. Firstly, the 
results show that treatment of the bile duct ligated rats with BRL 44408, an ADRA2a 
adrenergic receptor antagonist, results in significant improvement in the haemodynamic 
abnormalities. In particular, there is significant reduction in the portal pressure in the BDL 
rats treated with BRL 44408 as compared to the BDL rats treated with saline. In addition, 
there is an increase in the mean arterial pressure  and increased portal and hepatic blood 
flow in the BRL 44408 treated rats as compared to the BDL rats treated with normal 
saline. Secondly, the results show that there is also a significant reduction in the 
inflammatory markers including plasma and tissue TNFα level and Nuclear Factor Kappa 
B protein expression in  the BDL rats treated with BRL 44408 as compared to the BDL 
rats treated with saline. Thirdly, the results also show various pathways that are implicated 
in the reduction of intra hepatic resistance. This includes the liver tissue cAMP activity 
which is increased in the BRL 44408 treated rats as compared to the BDL rats treated with 
saline, implying that there is relaxation of vasomotor tone thereby improved hepatic blood 
flow. The Hepatic stellate cells (HSC) displays increased contractility with an ADRA2a 
agonist suggesting that the antagonism of this receptor will induce HSC relaxation thereby 
facilitating intra hepatic vasodilatation. Lastly, ADRA2a antagonism improves 
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endothelial dysfunction as evidenced by improvement in the pNOS protein expression, 
indicating increased nitric oxide production in the intra hepatic circulation.  
  Intrahepatic resistance (IHR) was classically thought to be as a result of the mechanical 
effects of cirrhosis including fibrosis, thrombosis and nodule formation which leads to 
abnormal architecture of the sinusoidal space and hence distortion to the laminar flow of 
blood (12). The exact site of intra hepatic resistance is variable and can change according 
to etiological factors and disease process. Chronic hepatitis appears to have both pre-
sinusoidal and sinusoidal vascular abnormalities which contribute towards the increased 
resistance (13) where as there is abnormal architecture in the sinusoidal and post 
sinusoidal site (14), when liver disease is caused by injury. As the disease progresses, 
there is terminal vein fibrosis, reduction in sinusoidal space by enlarging hepatocyte and 
deposition of collagen in the space of disse, all of which contribute to the increased 
vascular resistance. However, the seminal paper by Mittal and Groszmann in 1984 gave 
the first indication into the presence of a modifiable component in the intra hepatic 
vasculature (16).Bhathal and Grossman in 1985 confirmed this perspective and led to the 
theory of presence of a pharmacologically modifiable vascular element in addition to the 
mechanical factors that influence intra hepatic resistance (17). A significant body of 
research has been undertaken and published since then to understand and apply this 
principle to modify intra hepatic resistance as a treatment of portal hypertension. 
It is clear from the literature that reduction of portal pressure to below 12 mmHg or 20% 
below the basal reading has shown to have clear benefit in patients outcome by reducing 
the risk of first bleeding episode to less than 10% (5). In our study, we show that the portal 
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pressure rises to 16.45±3.49 mmHg in the bile duct ligated rats as compared to the portal 
pressure in the sham operated rats which have a portal pressure of 7.36±1.31 mmHg. 
However on treatment with BRL 44408, the BDL rat dropped the portal pressure to 
12.05±2.74 mmHg. This shows that the BRL 44408, a ADRA2a adrenergic receptor 
antagonist lowers portal pressure significantly (27%) from the baseline. The portal blood 
flow was increased in the BDL treated with ADRA2a antagonist as compared to the BDL 
rats treated with saline. This implies that the liver is able to accommodate increased blood 
volume. These results are even more significant in the context of an increased mean 
arterial pressure in the BDL rats treated with BRL 44408. This was complimented by the 
results of the plasma renin activity results which shows that treatment with ADRA2a 
antagonist reduces the plasma renin activity, suggesting increased systemic vascular tone. 
Overall, all the haemodynamic findings in this study suggest that there is significant 
reduction in the intra hepatic resistance in the BDL rats treated with ADRA2a antagonist 
as compared to the BDL rats treated with saline. 
It is well established that the mean arterial pressure and the peripheral resistance is lower 
in rats with established portal hypertension as compared with controls (188)and this has 
been noted in human studies as well(189, 190) . The various treatment strategies that have 
been applied in the clinical trials settings have had a major issue with the systemic blood 
pressure as the drugs which are used to vasodilate the intra hepatic circulation also dilates 
the systemic vasculature and hence causes a deleterious effect on the clinical outcome due 
to significant systemic hypotension. This is due to the presence of a dichotomy between 
the blood vessel caliber in the intrahepatic and systemic and splanchnic circulation. In the 
intrahepatic circulation there is vasoconstriction, whereas in the splanchnic circulation, 
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there is significant vasodilatation as a result of an imbalance between the vasoactive 
substances in the different vasculature beds(191). The observed increase in the mean 
arterial pressure is obviously desirable in the setting of cirrhosis and portal hypertension. 
The cardiac haemodynamic results in this study demonstrate that the BDL rats have a 
hyperdynamic circulation with higher cardiac output as compared to the sham rats. 
However, although the cardiac output was increased in the BDL rats treated with BRL 
44408, the actual increase was due to a non significant increase in the heart rate, which 
may be due to the action of BRL 44408 itself.  
These observations are further supported by the increased noradrenaline levels that have 
been found in my experiments. The plasma noradrenaline is significantly higher in the 
BDL rats as compared to the sham operated rats. The noradrenaline level remains at a 
high level in the BDL rat treated with BRL 44408. The fact that the noradrenaline remains 
high even on treatment of  BRL 44408 into the BDL rats suggest that the free 
noradrenaline are being not able to bind to their receptors as they have been saturated by 
the receptor antagonist. We can speculate that the mechanism of action for this 
observation is the presence of high density ADRA1 adrenoreceptors, which in turn are 
stimulated by the increased noradrenaline level that is produced by the  ADRA2a 
adrenergic receptor antagonist (BRL 44408) used in this study. This causes 
vasoconstriction of the large vessels and thus increases the mean arterial pressure. We 
have not measured the ADRA1 adrenoreceptor density in the aorta in this study but it has 
been suggested in other reviews. (192). .  
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 The other significant observation made in our study was significant increased hepatic 
blood flow after treatment of the BDL rats with BRL 44408 in comparison to the BDL 
rats treated with saline. The forward flow theory of portal hypertension hypotheses’ that 
the splanchnic vasodilatation results in increased blood to the liver with the hepatic arterial 
buffering for the decreased blood flow to the liver. The net effect is an increased hepatic 
blood flow which helps to propagate and maintain the portal hypertension. The above 
findings are more relevant taking into account that the portal pressure was significantly 
reduced in the BRL 44408 treated BDL rats as compared to the BDL rats treated with 
normal saline. The fact that the cirrhotic liver is able to accommodate an increased blood 
flow is evidence of modulation of the reversible component of the intra hepatic resistance. 
The vascular tone forms a significant part of this reversible part of the intrahepatic 
resistance. We show in our study that the cyclic AMP activity in the liver tissue is 
significantly increased in the BDL rats treated with BRL 44408 as compared to the BDL 
rats treated with saline. This implies that there is an increase in the calcium flux into the 
myosin which helps to relax the vascular smooth muscle cells which in turn help to 
vasodilate the intrahepatic vasculature leading to reduction in intra hepatic resistance.  
One of the most important observation in this study is the significant increase in the 
ADRA2a receptor density in the liver of the BDL rats as compared to the Sham operated 
rats. From the sepsis literature , it is clear that the ADRA2a receptor has got significant 
increased expression in the migrating macrophages  in the ceacal ligation and puncture 
rat model and this theory might help to explain the increased receptor expression in the 
BDL rats as compared to the Sham operated rats (193). To compliment this finding, there 
is also increased inflammatory markers including tissue and plasma TNFα and Nuclear 
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Factor in the BDL rats as compared to the sham operated rats. These markers show a 
significant reduction in the level of TNFα, both in the tissue and plasma and also in the 
protein expression of NF kappa B in the BDL rats upon treatment with BRL 44408.It is 
probable that the migrating macrophages from the portal circulation in the BDL rats have 
increased cytokine load and therefore provoke an inflammatory response with the rise of  
TNFα in the plasma and liver tissue. This pro-inflammatory cytokine drive is ameliorated 
by treatment with BRL 44408, demonstrating its anti-inflammatory properties. 
 In order to interrogate the possible pathways that are implicated in the reduction of 
intrahepatic resistance with the ADRA2a antagonism, I also assessed the cyclicAMP 
levels in the three goups of animals. There is significant reduction in the cyclicAMP levels 
in the ADRA2a antagonist treated BDL rats as compared to the BDL rats treated with 
saline. This suggests that this pathway is involved in the vasodilatation process in the intra 
hepatic vasculature. cyclicAMP is a second messenger in the adenyl cyclase pathway 
which is a G-protein receptor dependent signaling cascade which is used in cell 
communication. When a GPCR is activated by its extracellular ligand, a conformational 
change is induced in the receptor that is transmitted to an attached intracellular 
heterotrimeric G protein complex. This in turn stimulate the cyclic nucleoside gated 
calcium channel, which is necessary in the steps for the vasomotor relaxation which in 
the case of intra hepatic circulation reduces intra hepatic resistance.  Till date the various 
treatment strategies have targeted this increased blood flow towards the liver with an aim 
of reducing the total hepatic blood flow. However, there is some conflicting  evidence that 
in cirrhosis with refractory ascites, there may be an adverse effect by adopting this strategy 
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as there is already an existent intense vasoconstriction of the intrahepatic vasculature and 
further restriction of blood flow has a deleterious clinical outcome (10). 
The hepatic stellate cells are contractile cells located in the peri-sinusoidal space with 
elongated protrusion which encircle more than one sinusoid. The stellate cells become 
contractile in the face of chronic liver injury and manifest as fibrotic band of collagen 
which regulate the pre-sinusoidal blood flow. They also express various receptors which 
endothelin 1, angiotensin 1 which induce generation of contractile force by contractile 
cell types (194, 195). In my study, I demonstrate that upon incubation of rat hepatic 
stellate cells in a serum free medium as compared to a medium containing guanfacine 
(ADRA2a agonist), there is increased contractility in the guanfacine containing gel plate. 
This suggest that the hepatic stellate cells also express ADRA2a receptor and provides 
another target cell to reduce the contractility of these cells in order to improve hepatic 
blood flow. 
Alpha Smooth Muscle Actin (αSMA) is a marker of hepatic stellate cells activation. This 
indicates that the HSC modify to form myofibroblasts which impact on the contractibility 
of the sinusoidal cells. In my study, I looked at the protein expression for the αSMA 
protein in the three groups within the experiments. The results reveal that there is a 
significant expression of  αSMA in the BDL rats as compared to the sham operated rats. 
However, on treatment with BRL 44408, there is significant reduction in the αSMA 
expression. This suggest that there is deactivation of the HSC upon treatment of the BDL 
rats treated with BRL 44408. This leads to reduction in the sinusoidal contraction, in turn 
reducing intra hepatic resistance in the treated group. 
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Based on the haemodynamic observations. I have elicited mechanistic pathways that may 
be involved in these observations. Previous studies from our research group has shown 
that the endothelial nitric oxide protein expression is increased in the BDL rats as 
compared to the sham operated rat. In this study, I have been able to validate that 
observation. Further to that, following treatment with BRL 44408, the ADRA2a 
adrenergic receptor antagonist, the protein expression of eNOS is significantly reduced. 
In contrast, the phosphorylated endothelial nitric oxide which is a marker for the enzyme 
activity is reduced in the BDL rats as compared to the sham operated rats. This is increased 
significantly in the BDL rats treated with BRL 44408. This implies that there is increased 
production of intra hepatic nitric oxide, which facilitates reduced vascular tone and 
thereby reduce intra hepatic resistance in the BDL rats treated with BRL 44408. 
Although the treatment protocol for this set of experiment was over two days, I have made 
a histological assessment of the liver tissues from the rats involved in this experiment. I 
have shown that there is significant architectural changes noted in the BDL rats as 
compared to the Sham operated rats. This was evidenced by increased number of 
cholangiocytes in the BDL rats with architectural distortion of the hepatic lobule in the 
BDL rat as compared to the Sham operated animal. This changes are similar to previous 
finding during the establishment of the model in my laboratory and therefore data is not 
shown. However, there was no difference between the BDL rats treated with BRL 44408 
as compared to the BDL rats treated with saline. This indicates that there was no structural 
influence on the haemodynamic changes that is observed in the experiments.  
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Apart from these results related to the effect of ADRA2a antagonism on the porto-
systemic vasculature, I also show some preliminary data on improvement of perfusion to 
other organs including the brain and the kidney. First of all, I show that there is significant 
improvement in the plasma lactate levels in the ADRA2a antagonist treated BDL rats as 
compared to BDL rats treated with saline. This indicates that there is improvement in the 
perfusion of end organs with ADRA2a antagonism. In the brain, there is significant 
reduction in the brain water in the ADRA2a antagonist treated rats indicating that there is 
less brain swelling in this group of animal as compared to the saline treated BDL rats. As 
brain swelling can initiate transcription of cytokines, it is also possible that reduction in 
brain water following treatment with ADRA2a led to a reduction in brain inflammation. 
Studies from our lab have shown that using an anti-inflammatory strategy, there is 
reduction of neuroinflammation and restoration eNOS activity (196). I also show that 
there is significant improvement in the serum creatinine in the BDL rats treated with 
ADRA2a antagonist as compared to the BDL rats treated with saline. I accept that serum 
creatinine does not accurately reflect renal function but it highlights an important signal 
to justify further investigation of the renal effect of ADRA2a antagonism.  
In conclusion, in this study I was able to show an alternative strategy to reduce portal 
pressure. The beneficial effect of an increased mean arterial pressure and increased 
hepatic blood are both desirable in the setting of cirrhosis and portal hypertension. These 
data provide a rationale for considering ADRA2a adrenergic receptor antagonism as a 
legitimate strategy for lowering portal pressure. 
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Taking into account all the above findings, it is clear that the intra hepatic resistance is 
propagated by a combination  of the architectural distortion as a result of nodule formation 
and micro thrombi and a reversible vascular component. This reversible vascular 
component is modifiable with various intervention. Inflammation, mainly propagated by 
the gut-liver axis has been given its due importance as a main proponent of progression 
of intra hepatic resistance. The migratory immune cells from the gut to the liver have been 
implicated in the production of inflammatory cytokines. There has been some suggestion 
in the literature, especially from the sepsis literature about targeting these circulating 
immune cells as a strategy to reduce the inflammatory burden (197). It poses an interesting 
question as to whether targeting these set of circulating immune cells in the context of 
liver disease will have a positive effect on portal hypertension. The next section of studies 
will attempt to answer some of these questions. 
  
138 
 
                               Chapter 5 
The modulation of the immune system by ADRA2a     
adrenergic receptor antagonism 
 
5.1 Introduction  
The relationship between inflammation and portal hypertension has now been shown in 
several studies. Mortensen et.al. have shown that there is a close linear relationship 
between the highly sensitive C-Reactive Protein and the portal pressure (99). Pro-
Inflammatory cytokines like IL-6 have been found to be increased in patient with portal 
hypertension and alcoholic hepatitis (98). We have previously shown that on treatment 
with an anti-TNF agent, the portal pressure improves significantly in patients with 
alcoholic hepatitis, suggesting that targeting the inflammatory cytokines are a valid 
target to reduce portal pressure (198), albeit their clinical translation has been limited by 
serious adverse effects. 
 
The understanding of the pathophysiology of gut derived catecholamine release has 
improved significantly in the last decade. Many inflammatory molecules have been 
identified and these have been noted to be increased in a septic model. There is evidence 
to suggest that the central nervous system receives messages from the immune system 
and vice versa.  Messages from the brain modulate immune function in health and 
disease (199). There is also evidence that noradrenaline levels are released by the 
sympathetic nervous system and modulate the immune function (200). It is already 
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known that the sympathetic nervous activity is increased in sepsis and this leads to 
increased release of noradrenaline.. Previous studies have shown that the level of NE 
release is directly co-related to the level of cytokine (TNFα) and other cytokine release 
(201). 
Similarly, intra-portal infusion of NE in vivo or in isolated livers increased TNFα 
synthesis and release which was inhibited by co-infusion of yohimbine. Furthermore, 
the increased cellular levels of TNFα in Kupffer cells after in vivo administration of NE 
was also blocked by yohimbine (ADRA2 adrenergic receptor antagonist). These results, 
taken together, suggest that gut-derived NE upregulates TNF-α production in Kupffer 
cells through an  α2 adrenergic pathway, which appears to be responsible at least in part 
for the increased levels of circulating TNF-α observed during early sepsis (111) 
Further experiments shows that the enhanced pro inflammatory cytokine release in early 
sepsis in kupffer cells is via the ADRA2a adrenoreceptors. More specifically, it has been 
found that the NE increased the release of TNF-a in cultured KCs, which was specifically 
inhibited by the ADRA2a  antagonist BRL-44408.This suggest that ADRA2a adrenergic 
receptor provides a viable target for the treatment of sepsis (193) 
Therefore, the above studies have provided evidence that in the context of sepsis, gut 
derived NE produces TNFα from the kupffer cells and liver derived macrophages causes 
liver dysfunction. This phenomenon is reversible by antagonism of the ADRA2a 
adrenergic receptor. The ADRA2a adrenergic receptor has been shown to have a 
significant role in the propagation of this inflammatory cascade. Therefore the ADRA2a 
adrenergic receptor would be an ideal target to explore in the context of liver disease and 
portal hypertension  
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The aim of this study was to assess the relevance of the ADRA2a adrenergic receptor in 
the modulation of inflammation in the circulating immune cells and to address the 
hypothesis that the ADRA2a receptor is a valid target for reduction of portal pressure by 
ameliorating inflammation.  
 
5.2 Methods and Materials: 
5.2.1 Study design 
Four weeks after bile duct-ligation or Sham-operation, rats were randomized in to six 
groups. The treatment regime for both placebo (N/Saline) and BRL 44408 (ADRA2a 
antagonist) included daily subcutaneous injection at the rate of 10mg/kg. These injections 
were given once a day from day 18 till day 28 when the haemodynamic experiments were 
carried out. Lipopolysaccharide (E.coli,Sigma Aldrich) was injected at 0.33mg/kg per rat 
as a intra peritoneally 3 hours prior to start of the haemodynamic measurement. The rats 
were monitored in a temperature controlled incubator for three hours and then were 
exsanginated as per prescribed method. The groups that were set up were: 
Sham +N/S         (n=16) 
Sham+LPS         (n=3) 
Sham +BRL       (n=3) 
BDL+ N/S          (n=20) 
BDL+LPS          (n=9) 
BDL+BRL          (n=21) 
BDL+LPS+BRL (n=7) 
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5.2.2  Haemodynamic measurement 
All haemodynamic measurements were undertaken exactly as described previously in 
section 2.3. 
5.2.3. Biochemical Parameters 
All biochemical parameters (ALT, ALP, albumin, total protein, ammonia, bilirubin, urea 
and creatinine) were analyzed using 200μl of respective plasma samples using a Cobas 
Integra 400 multianalyzer with the appropriate kits (Roche-diagnostics, Burgess Hill, 
West Sussex, UK). 
5.2.4  Tissue Cytokine Assays 
All cytokine assays were undertaken in a similar method as described previously in 
section 2.6. 
5.2.5 FACS analysis 
Whole liver tissue was taken and homogenized as per protocol and population studies and 
functional studies on various cell types were conducted after cell isolation. The details of 
the methods used for the FACS analysis in various cell types are described in section 2.15 
till 2.17. 
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5.2.6  Endotoxin Assay 
 The chromogenic limulus amoebocyte lysate kinetic assay (Charles River Laboratories) 
was used for the detection of endotoxin. The method used is described in detail in section 
2.18. 
 
5.3 Results. 
Following surgery all animals continued to gain weight. From the final body weight taken 
before termination, cirrhotic rats were found to be significantly lower than that of sham 
rats (350 ± 5g vs. 472 ± 9g, respectively; P < 0.001). 
5.3.1 Biochemical paramenters in the different groups 
Six groups of animals were studied namely Sham operated (Sham), Sham + BRL, BDL 
and BDL+BRL, BDL+LPS and BDL+LPS+BRL. Bilirubin, creatinine, albumin and 
plasma aminotransferase were measured using standard kits on a Cobas Integra analyser 
(Roche Diagnostics Ltd, West Sussex, UK).  
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Table 5.1 Biochemical pattern in all the groups 
  Sham+N/S Sham+LPS BDL+N/S BDL+LPS BDL+BRL BDL+LPS+BRL 
ALT 
(IU/L) 
70.27±9.07 80.20±7.23 100.1±13.26* 130.3±24.46 82.12±6.26 69.10±5.19 
AST  
131.3±17.3 157.5±11.75 444.5±58.24* 587.5±52.48 406.2±64.82 488.4±8.36 
(IU/L) 
Bil 
(µmol/L) 
44.16±15.4 57.88±7.25 132.2±21.02* 136.2±20.11 123.4±11.61 130.2±16.14 
Albumin 
(gm/L) 
 
32.40±0.76 37.65±3.04 24.41±0.94 24.80±0.80 25.74±1.02 26.61±1.02 
  
Table 5.1: Shows the biochemical parameters in the six groups (Sham+N/S, 
Sham+LPS, BDL+N/S, BDL+LPS,BDL+BRL and BDL+LPS+BRL) ( *p<0.01) 
The alanine aminotransferase (ALT) level was no different between the sham operated 
rats treated with the saline or BRL 44408. However there was a significant increase in the 
plasma ALT levels in the BDL rats as compared with the sham operated rats (100.1 ± 
13.26 v 70.27 ± 9.07 , p<0.01). There was a trend towards a reduction in the plasma ALT 
levels in the BDL rats treated with BRL and with or without LPS as compared to the BDL 
rats treated with saline or LPS. 
The aspartate aminotransferase (AST) level was also no different between the sham 
operated rats treated with saline and BRL. There was a significant increase in the plasma 
AST level in the BDL rats treated with  saline as compared to the sham operated rats 
treated with saline (444.5± 58.24 v 131.3±17.3, p<0.01). However, there was no reduction 
in the plasma AST level in the BDL rats treated with BRL 44408 with or without LPS as 
compared with the BDL rats treated with saline or LPS. 
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Similarly, the serum bilirubin was not difference between the sham operated animals 
treated with saline and BRL44408.There was a significant increase in the serum bilirubin 
the BDL rats as compared with the sham operated rats (132.2±2.02 v 44.16±15.46, 
p<0.01). However there was no difference between the BDL rats treated with saline or 
BRL 44408 or LPS. 
The serum albumin was no different between the sham operated with saline or BRL 
44408.There was a significant reduction in the serum albumin levels in the BDL rats as 
compared to the sham operated rats (24.41.06 ± 0.94 v 32.40 ± 0.76 ,p0.01) . This did not 
alter after treatment with BRL and or LPS. 
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5.3.2 Mean Arterial Pressure 
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Fig 5.1: Mean arterial pressure measurement of all six groups ( Sham + N/S, Sham 
+ BRL, BDL + N/S and BDL +BRL,BDL+LPS,BDL+LPS+BRL ).There is a 
significant increase in the MAP in the BDL rats treated with BRL 44408 as 
compared to the BDL rats treated with saline (p=0.01). (Sham+N/S=16, 
Sham+BRL=3, BDL+N/S = 21, BDL+BRL=20, BDL+LPS=8, BDL+BRL+LPS=7) 
The mean arterial pressure (MAP) was measured in all the groups as described in section 
2.3.The MAP in the bile duct ligated rats is significantly lower than sham operated rats 
(89.64±1.91 mmHg v 103.3±2.75 mmHg, p=0.02).However on treatment with BRL 
44408, there is a significant increase in the MAP in the BDL treated group treated with 
BRL as compared to BDL rats treated with saline (89.64±1.91 mmHg v 94.84±1.8 mmHg, 
p=0.05). There is no difference in the MAP between the rats treated with an additional 
dose of LPS. 
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5.3.3 Portal Pressure Measurements: 
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Fig 5.2: Portal pressure measurement of all six groups (Sham + N/S, Sham + BRL, 
BDL + N/S and BDL +BRL, BDL+LPS and BDL+BRL+LPS).The portal pressure is 
significantly reduced in the BDL rats treated with BRL 44408 as compared with the 
BDL rats treated with saline (p<0.001) .The portal pressure was reduced in the BDL 
rats treated with BRL and LPS as compared to the BDL rats treated with LPS alone 
(p=0.04). There was no difference between the portal pressure in the sham operated 
rats. (Sham+ N/S=16, Sham+BRL=3, BDL+ N/S= 21, BDL+BRL=20, BDL+LPS=8, 
BDL+BRL+LPS=7) 
The portal pressure was significantly increased in the bile duct ligated rat as compared to 
the sham operated rats (14.21±0.43 mmHg v 6.71±0.36 mmHg, p<0.001).The portal 
pressure was significantly reduced in the BDL rats treated with BRL 44408 as compared 
to the BDL treated with normal saline (11.19±0.40 mmHg v 14.20±0.47 mmHg, p<0.001) 
in the study. Furthermore, there was a significant reduction the portal pressure of BDL 
rats treated with LPS and BRL 44408 as compared to the BDL rats treated with LPS alone 
(13.55±0.87 v 9.39±0.82). 
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5.3.4 Endotoxin Assay: 
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Fig 5.3:  Limulus Amebocyte Lysate Assay of the various groups of rats (Sham, BDL, 
BDL+BRL, BDL+LPS and BDL+BRL+LPS). The endotoxin shows a non-significant 
trend towards the improvement of the endotoxin load in the BDL rats treated with 
BRL with or without LPS.  (Sham+N/S=4, BDL+N/S=4, BDL+BRL=4, BDL+LPS=3, 
BDL+LPS+BRL=3) 
The Limulus Amebocyte Lysate Assay is an assay which reacts with bacterial endotoxin 
and lipopolysaccharide (LPS) which is a membrane protein in gram negative bacteria. 
This is used for the quantification of bacterial endotoxin load. In this set of experiments, 
the endotoxin load showed a non statistically significant trend towards the lowering of the 
endotoxin load in the BDL rats  treated with LPS and BRL 44408 treated rats as compared 
to the BDL rats treated with LPS alone (p=0.06). The  assay results described here do not 
show a  significant trend. This may be due to the variability within the assay itself and 
may have been improved if there was increased numbers of rats per group.  Therefore the 
results from this experiment have to be interpreted with caution. 
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5.3.5 Population studies 
 
A. FACS data on cell population in the portal circulation 
 
Sham 
 
BDL 
 
BDL +BRL 
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Sham + LPS 
 
BDL + LPS 
 
BDL + LPS + BRL 
 
Fig 5.4 : Population studies in the various groups. Gated Population study of the 
various cell types. The gated population in the different groups Sham, BDL, 
BDL+BRL, Sham+LPS, BDL+LPS and BDL+LPS+BRL.  
The population studies were done as described in method section 2.15. The Neutrophil 
count is increased in the BDL rats treated with Saline and LPS as compared to the Sham 
rats treated with Saline and LPS respectively. This was significantly reduced in the Sham 
and BDL rats treated with BRL 44408 with or without LPS. 
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5.3.5.1 The neutrophil population in the portal circulation 
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Fig 5.5(A): Neutrophil population in the portal vein in various groups (Sham, BDL, 
BDL+BRL, BDL+LPS, BDL+LPS+BRL). The neutrophil count is elevated 
significantly in the BDL rats as compared to the sham operated animals (p<0.001). 
The neutrophil count is reduced non-significantly in BDL rats treated with BRL 
44408. However, in BDL rats treated with LPS, BRL 44408 reduces the neutrophil 
count significantly (p=0.01). (Sham+N/S=7, BDL+N/S=5, BDL+BRL=5, 
BDL+LPS=5, BDL+LPS+BRL=5) 
The neutrophil population in the portal vein is shown in all the groups. The neutrophil 
population in the portal circulation was calculated by FACS analysis by a method 
described in section 2.15.  It shows that there is significant increase in the neutrophil 
count in the BDL as compared with Sham operated animals 11.12±1.41 v 1.42±0.24, 
p<0.001). However, after treatment with BRL, the neutrophil count is significantly 
reduced in the BDL animals with (6.08±2.03 v 13.86±1.41, p=0.01) or without LPS 
6.98±1.32 v 11.12±1.41, p=0.01)     
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 5.3.5.2 Neutrophil Population in the systemic circulation: 
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Fig 5.5(B): Neutrophil population in the systemic circulation in the various groups 
(Sham, BDL, BDL+BRL, BDL+LPS, BDL+LPS+BRL). The neutrophil count 
increases significantly in the BDL rats as compared to the Sham operated rats. There 
is a non- significant trend towards reduction in the BDL rats treated with BRL 
44408. However, in the BDL rats treated with LPS, BRL 44408 reduces the 
neutrophil counts significantly (p=0.04). (Sham+N/S =7, BDL+N/S =5, BDL+BRL=5, 
BDL+LPS=5, BDL+LPS+BRL=5) 
The neutrophil population in the systemic circulation is calculated in the various groups. 
The neutrophil population in the systemic circulation was calculated by  FACS analysis 
by a method described in section 2.15.  It shows that the neutrophil count significantly 
increases in the BDL animals as compared to the sham operated animals ( 8.86±1.51 v 
1.13±0.23, p=0.003) .However, The BDL rats treated with BRL 44408, there is a 
significant reduction in the rats with (7.16±1.43 v 12.71±1.74, p=0.04) or without LPS 
(5.60±0.85 v 8.86±1.51, p=0.04). 
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5.3.6 Phagocytic capacity of circulating cells: 
5.3.6.1 Phagocytic capacity of circulating neutrophils 
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Fig 5.6(A): Phagocytic capacity of circulating neutrophils. The phagocytic capacity 
increases in the BDL+LPS group treated with BRL44408 as compared to the  rats 
not treated with BRL (P=0.006). (Sham+N/S=7, Sham+LPS=5, BDL+N/S=5, 
BDL+BRL=5, BDL+LPS=5, BDL+LPS+BRL=5) 
The phagocytic capacity of the neutrophils were assessed for all the six groups of rats. 
The  phagocytic capacity of neutrophils was assessed by the method described in Section 
2.16. Although there was no significant difference in the animals treated with saline, there 
was a significant increase in the phagocytic capacity of the neutrophils in the BDL rats 
treated with BRL 44408 and LPS as compared to the BDL rats treated with LPS alone  
(78.70±1.5 v 45.60±8.06, p=0.006) 
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5.3.6.2 Phagocytic capacity of monocytes: 
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Fig 5.6(B): Phagocytic capacity of circulating monocytes (Sham, Sham+LPS, BDL, 
BDL+BRL, BDL+LPS, BDL+LPS+BRL). There is reduction in the phagocytic 
capacity of the BDL as compared to the Sham animals (p<0.001), whereas upon 
treatment with BRL 44408, there is significant improvement in the phagocytic 
capacity in BDL rats treated with (p=0.03) or without LPS (p=0.05)  (Sham+N/S=7, 
Sham + LPS=5,  BDL+N/S=5, BDL+BRL=5, BDL+LPS=5, BDL+LPS+BRL=5) 
The phagocytic capacity of the monocytes in the different groups of rats are shown above. 
The monocyte phagocytic capacity was assessed by the method described in Section 2.16. 
The monocyte phagocytic capacity is reduced in the BDL rats as compared with Sham 
animals (31.26± 4.35 v 73.43±4.82, p<0.001) However, this is increased in the BDL rats 
after treatment with BRL44408 with (85.07±6.67 v 60.65±6.33p=0.03), or without LPS 
(60.32±4.68 v 31.26±4.35, p=0.05). 
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5.3.7 Activation of Kupffer Cells: 
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Fig 5.7: Activated Kupffer cells in the various groups. The activated Kupffer cells 
are gated by the CD68 cell marker against the CD163 positive cells in all the groups 
(Sham, Sham+LPS, BDL, BDL+BRL, BDL+LPS, BDL+LPS+BRL). The kupffer 
cells are activated significant in the BDL rats as compared to the Sham operated rats 
(p=0.01). (Sham+N/S=7, Sham + LPS=5,  BDL+N/S=5, BDL+BRL=5, BDL+LPS=5, 
BDL+LPS+BRL=5) 
The activated kupffer cells are gated by the specific markers in all the groups. It shows 
that the kupffer cells are activated in the BDL animals as compared to the Sham operated 
animals (25.71±1.52 v 15.53±2.49, p=0.01). The BDL rats treated with BRL 44408 
showed a significantly reduced activated Kupffer cells in the rats treated with (9.54±1.69 
v 21.19±2.69, p=0.01) or without LPS (16.73±2.36 v 25.71±1.52, p=0.05)   
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5.3.8 Reduction of Reactive Oxygen Species in Kupffer Cells: 
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Fig 5.8:Reactive Oxygen Species in Kupffer Cells in various groups. The CD163 
gated ROS levels in all six groups (Sham, Sham+LPS, BDL, BDL+ BRL, BDL+LPS, 
BDL+BRL+LPS) . The ROS level is significantly increased in the BDL rats as 
compared to the Sham operated rats (p<0.001). The ROS levels are reduced 
significantly in the BDL rats treated with BRL with (p<0.001) or without LPS 
(p<0.001). (Sham+N/S=7, Sham + LPS=5,  BDL+N/S=5, BDL+BRL=5, BDL+LPS=5, 
BDL+LPS+BRL=5) 
The Reactive Oxidative Species (ROS) levels are done in all the six groups. It shows 
that the ROS level increases significantly in the BDL rats as compared to the sham 
operated rats (308.0±17.32 v 105.8±11.01, p<0.001). However, upon treatment with 
BRL 44408, the BDL rats have significantly reduced level of ROS in the rats treated 
with (127.5±15.56 v 222.5±28.06, p<0.001) or without LPS (79.56±6.49 v 308±17.32, 
p<0.001)  
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5.3.9 Reduction in Inflammatory cytokines with ADRA2a antagonism 
5.3.9.1 Liver Tissue TNFα level 
S
ha
m
+N
/S
B
D
L+
N
/S
B
D
L+
B
R
L
B
D
L+
LP
S
B
D
L+
LP
S
+B
R
L
0
500
1000
1500
p=0.03
Groups
p
g
/m
l
 
Fig 5.9(A): Liver tissue TNF levels in the various groups. The liver tissue TNFα levels 
were increased after administration of LPS (0.33mg/kg) , however, it was reduced 
significantly after treatment with BRL 44408 (p=0.03).There was no significant 
difference in the tissue TNFα levels in all the other groups. (Sham+N/S=7, 
BDL+N/S=6, BDL+BRL=5, BDL+LPS=6, BDL+LPS+BRL=6) 
The liver tissue TNFa levels were measured by cytokine bead array test done on the 
FACS machine as described in section 2.6. The liver tissue TNFa was shown to be 
significantly elevated in the BDL rats treated with LPS. However when treated with BRL 
44408, there was significant reduction in the TNFa levels in the BDL rats treated with 
LPS (111.1±35.32 v 990.6±277.7, p=0.03). 
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5.3.9.2 Liver Tissue IL-6 level 
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Fig 5.9(B):Liver tissue IL-6 levels in various groups. The IL-6 level is highest in BDL 
rats treated with LPS and this was reduced significantly after treatment with BRL 
44408 (p=0.03). (Sham+N/S=7, BDL+N/S=6, BDL+BRL=5, BDL+LPS=6, 
BDL+LPS+BRL=6)  
 
The liver tissue IL-6 levels is calculated in all the groups of animals. It shows that the 
liver tissue IL-6 level goes up in the BDL rats treated with LPS. However, on treatment 
with BRL 44408, there is significant reduction in the BDL rats treated with LPS 
(546.1±279.4 v 1251±198.5, p=0.03).There was no statistical difference in the level in 
the other groups. 
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5.4 Discussion: 
From the data presented I was able to conclude that the modulation of the innate immune 
system by blocking the ADRA2a adrenergic receptor improves the immune function and 
reduces the oxidative stress and inflammatory cytokines. This leads to reduction of the 
portal pressure in the bile duct ligated rats treated with or without lipopolysaccharide. 
The gut liver axis has been being accepted as an important pathophysiological pathway in 
the propagation of liver dysfunction in cirrhosis. It is well documented that there is 
increased bacterial translocation in cirrhosis and this in turn leads to an increased cytokine 
load in the portal circulation(202). The inflammatory reflex controls innate immune 
responses by a mechanism that targets the regulatory transcription factor nuclear factor-
κB (NF-κB). Ligand–receptor interactions activate innate immune responses and induce 
the secretion of pro-inflammatory cytokines. Molecular products of infection activate 
macrophages, monocytes and dendritic cells that interact with Toll-like receptors (TLRs), 
which transduce intracellular signals, ultimately leading to the activation of NF-κB and 
the increased release of pro-inflammatory cytokines (203) 
The results of the recently published CANONIC study shows that inflammation plays an 
important part in the pathophysiology and propagation of acute on chronic liver failure 
(72).  In this study, I show that there is a trend towards increase in the endotoxin load in 
the circulation of the bile duct ligated rats. This was further augmented trend upon 
treatment with LPS. This is complemented by the increase in the liver tissue pro –
inflammatory cytokine (TNF𝛼, IL-6). However, treatment with the ADRA 2a receptor 
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antagonist BRL 44408, there is trend towards reduction in the endotoxin levels in the BDL 
rats treated with LPS. 
From the sepsis literature, there is clear evidence that the pro-inflammatory cytokines in 
the portal circulation activate the migrating macrophages, which in turn produce more 
pro-inflammatory cytokines and reactive oxygen species. In this study I show that the 
macrophages (kupffer cells) gated by the CD163 shows an activated state (CD163 gated 
CD68 cells) in the BDL rats treated with saline. This is also noted to be significantly 
increased in the BDL rats treated by the addition of LPS. This was complimented by the 
significant increased production of Reactive Oxygen Species in the BDL rats and further 
increased in the BDL rats treated with LPS. This was again significantly reduced with 
treatment with BRL 44408.  
Rat lymphocytes and human peripheral blood mononuclear cell (PBMC) both have been 
shown to have increased level of expression of enzymes which results in increased 
production of dopamine, noradrenaline when stimulated(204).   Thus, it now is becoming 
clear that lymphocytes and phagocytes not only possess the ability to produce, store, 
release, and re- uptake catecholamines de novo, but that these cells also are capable of 
exquisitely regulating their catecholamine-synthesis in response to various extracellular 
stimuli. (113). 
In this study, I have assessed the function of the circulating neutrophils and macrophages. 
I show that the functional capacity of phagocytosis of these cells are significantly 
increased in the BDL rats treated with  LPS and BRL 44408 as compared to the BDL 
rats treated with LPS only. . Moreover, I also show that the absolute number of 
neutrophils in the portal and systemic circulation are significantly increased in the BDL 
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rats treated with or without LPS. This was reduced by treatment with BRL 44408 in BDL 
rats treated with or without the LPS. This implies that neutrophil migration to the liver 
that is noted in a setting of acute on chronic liver failure such as alcoholic hepatitis can 
be modified by this specific ADRA2a adrenergic receptor blockade. There is evidence 
of neutrophil dysfunction in cirrhosis and a study from our lab has previously shown that 
the neutrophils present in the setting of alcoholic hepatitis loses its function capacity to 
phagocytose the increased bacteria and bacterial products that are being translocated 
from the gut wall (71).  
 It is already known that the sympathetic nervous activity is increased in sepsis and this 
leads to increased release of norepinephrine. Yang et al has shown that the level of NE 
was lower in pre enterectomised rats where in sepsis was induced by ceacal ligation and 
puncture as compared to the non pre enterectomised rats. They also show that the level 
of pro-inflammatory cytokines TNFα and IL-6 were reduced and attenuated liver 
dysfunction in the pre enterectomised group (110). Furthermore, the increased cellular 
levels of TNF-α in Kupffer cells after in vivo administration of NE was also blocked by 
yohimbine. These results, taken together, suggest that gut-derived NE upregulates TNF-
α production in Kupffer cells through an α2-adrenergic pathway, which appears to be 
responsible at least in part for the increased levels of circulating TNF-α observed during 
early sepsis (111). In my study, I  have demonstrated that the Kupffer cells are activated 
as evidenced by the increased percentage of CD163 gated CD68 cells. This activated 
state also produced significantly more Reactive Oxygen Species in the BDL rats treated 
with or without LPS. However on treatment with BRL 44408, the percentage of activated 
kupffer cells were significantly reduced as well the amount of ROS production. 
161 
 
 
This study suggests that the ADRA2a adrenergic receptor plays an important role in the 
production of pro-inflammatory cytokines and elevation of portal pressure. By using a 
specific ADRA 2a adrenergic receptor antagonist we are able to demonstrate that it 
improves neutrophil and macrophage function, reduces inflammation, reduces activation 
of kupffer cells and its consequent ROS production and thereby reduces portal pressure. 
Based on these results, it can be postulated that ADRA2a adrenergic receptor may be a 
target for the modulation of inflammation and sympathetic tone in order to reduce portal 
pressure. However, further studies are required to validate our findings before clinical 
translation can be considered. 
 
In conclusion for this section of this research, I have been able to show that the ADRA2a 
adrenergic receptor is present in the BDL rat liver more significantly than in sham 
operated rats. By antagonising this particular receptor, I have been able to reduce the 
portal pressure in the BDL rats whilst maintaining their mean arterial pressure. These 
results are accompanied by the significant reduction of the pro-inflammatory cytokines. 
The mechanism of action was also explored and the results show that there is 
improvement in the cyclic AMP levels suggesting a possible vasorelaxing mechanism. 
There is also improvement in the eNOS activity suggesting that there is an improvement 
of endothelial dysfunction. I have also shown that the stellate cell contraction is also 
influenced by the ADRA2a adrenergic receptor pathway and its antagonism will relax 
the contractility of the stellate cells. While all these phenomenon are going on in the 
liver, I also show evidence of reduction of neutrophils from the portal circulation and 
162 
 
improvement in the functional capacity of the neutrophils and monocyte with treatment 
with an ADRA2a adrenergic receptor antagonist. This strategy will also reduce the 
activation of the kupffer cells and its consequent ROS production. Overall, these results 
prove that ADRA2a adrenergic receptor antagonism may be an important alternative 
strategy to reduce portal hypertension. 
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                                Chapter 6 
Role of L-Arginine supplementation in the modulation 
of intra hepatic resistance 
6.1 Introduction 
 
Over the past  few  decades, several studies have provided evidence that suggest 
supplementation of L-arginine was considered a logical therapeutic option to restore the 
decreased arginine levels in septic and critical ill patients, as increased arginine 
concentrations may restore the important physiologic processes, including organ 
perfusion, immune function, protein synthesis and wound healing (205), (206).Arginine 
supplementation between three to eight grams per day is very well tolerated but above 
nine milligrams causes patients to have side effects including diarrhoea and vomiting. 
There have been several meta analyses and reviews on this subject of arginine replacement 
in critically ill patients as part of their immune nutrition (207),(208). The results have 
been conflicting and may be compounded by the fact the diets are mixed with other 
compounds such as Omega 3 which will have an impact on the outcome. 
NO is formed by the oxidation of  sole substrate L-arginine, a semi essential amino acid 
by the enzyme Nitric oxide synthetase (NOS) (140). NO has been found be the main 
modulator of intra hepatic vascular tone (16) Since then a growing number of studies have 
proven that there is presence of endothelial dysfunction and low NO levels in cirrhosis 
(25) and that liver sinusoidal endothelial cells modulate NO levels (209).Therefore, it has 
been reasonable strategy to use vasodilators and NO donors to improve the intra hepatic 
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tone. However, most of them have not been accepted in routine clinical practice because 
of the systemic hypotensive effect. 
L-Arginine plays an important role in the modulation of intrahepatic tone by supplying 
NO, which acts as the most important vasodilator in the intra hepatic circulation. It has 
been proven that the increased intra hepatic vascular tone induced by L-NAME, a non-
specific NO inhibitor is reversed when L-arginine is supplemented (16). In cirrhosis and 
various other diseased states, arginine levels have been found to be high or low ((210), 
(211) and therefore supplementation of L-arginine have been reported with contradictory 
outcomes ((212), (213) 
L-Arginine has several metabolic pathways which may have an impact on the availability 
of substrate for NO synthesis (119).Among them Asymmetrical Dimethyl Arginine, 
(ADMA), an endogenous inhibitor of endothelial nitric oxide synthetase (147) and 
Arginase (214) which is an enzyme which converts L-arginine to urea and ornithine as 
part of the urea cycle has been mostly implicated in the regulation of L-arginine. We have 
previously shown in a devascularised porcine model of acute liver failure there is 
increased plasma arginase activity and ADMA levels. However, the arginine deficiency 
in this model was related to arginase related arginine clearance inspite of de novo arginine 
production (215). Therefore, in order to overcome the relative arginine deficiency because 
of increased ADMA levels and arginase activity in diseased states including cirrhosis, it 
was rational to supplement L-arginine exogenously to assess its effect on portal 
hypertension. 
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The aim of this study is to assess whether supplementation of L-arginine in the bile duct 
ligated rats lower their portal pressure. The secondary aim would be to investigation the 
underlying pathway involved in this process and whether there was an anti-inflammatory 
effect. 
6.2 Methods and Materials 
All animal experiments were conducted according to the Home Office guidelines under 
the UK Animals in Scientific Procedures Act 1986. This study was performed in male 
Sprague-Dawley (SD) rats (Charles-rivers), weighing 220–250g, were obtained from the 
Comparative Biological Unit at University College London. All rats were housed in the 
respective unit and given free access (ad libitum) to standard rodent chow and water, with 
a light/dark cycle of 12 hours (the dark phase extended from 1900–0700 hours), at a 
temperature of 22–23°C and humidity of approximately 50%. 
The rats underwent Bile duct ligation and sham operation as described in section 2.1.1 
and 2.1.2 respectively. 
6.2.1  Study design: 
Male Sprague Dawley rats weighing 220-250 g were randomly assigned to receive sham 
or bile duct ligation (BDL) surgery as described previously. Four weeks later 
hemodynamic measurements were performed and samples collected for analysis. For this 
arginine supplementation studies, treatment with either 30gm/kg L-Arginine (Damor 
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Pharma, Italy) dissolved in sterile water or saline (control, equal volume) by oral gavage 
was given on the last 7 days of the study. 
 Rats were randomly assigned to the following treatment groups: 
1.Sham  + N/Saline group: n = 8 
 
2.Sham+ L-Arginine group: n = 11 
 
3.BDL + N/Saline group: n =12  
 
4.BDL+ L-Arginine group: n = 13 
 
All rats were exsanguinated under terminal anaesthesia (2% isofluorane). Within seconds 
blood was withdrawn from the descending aorta and immediately put into ice cold 
heparin/EDTA containing tubes (until full exsanguination), centrifuged at 3000 rpm and 
4oC for 10 min, and the plasma collected and stored at -80°C until assayed. Liver tissue 
was also removed immediately harvested and snap frozen for storage at -80°C until 
analyzed. Liver tissues were also fixed with 10% formalin for further histological 
analysis. 
6.2.2  Haemodynamic measurement 
All haemodynamic measurements were undertaken exactly as described previously in 
section 2.3. 
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6.2.3 Biochemical Parameters 
All biochemical parameters (ALT, AST, albumin,  bilirubin,  ) were analyzed using 200μl 
of respective plasma samples using a Cobas Integra 400 multianalyzer with the 
appropriate kits (Roche-diagnostics, Burgess Hill, West Sussex, UK). 
6.2.4  Plasma and tissue Cytokine Assays 
All cytokine assays were undertaken in a similar method as described previously in 
section 2.6. 
6.2.5 Western Blot 
Proteins were isolated from snap frozen liver tissue using standard techniques as described 
in section 2.7. Equal amounts of protein extract were denatured and separated on 4-12% 
NuPAGE Bis-Tris Gels and transferred on to PVDF membranes (Lifetech, UK), The 
membranes were then incubated with different primary antibodies including a goat anti 
DDAH 1 (1:1,000; in-house preparation), mouse anti-ADMA (1:1,000; Acris Antibodies, 
Herford, Germany), mouse anti-eNOS (1:1000, Cell Signaling Technology, Beverly, 
MA), mouse anti NFkB p65 (1:1000, dilution, 2A12A7,Invitrogen,UK). The bands were 
visualized using an enhanced chemiluminescence detection kit and quantified by 
densitometry. Loading accuracy was evaluated via membrane rehybridization with 
antibodies against mouse and rabbit anti-α tubulin (1:1,000; Upstate Biotechnology, 
Albany, NY). 
168 
 
6.3 Results 
6.3.1 Biochemical parameters 
 
 
  
Sham  
(Mean±SEM) 
BDL  
(Mean±SEM) 
BDL + Arg 
(Mean±SEM) 
Significance  
*p<0.01, 
**p<0.001 
ALT 42.08±3.49 118.1±15.47** 81.83±5.54* 
** Sham v BDL  
*BDL v 
BDL+Arg 
AST 
 
76.76±9.45 500.7±81.58** 492.4±39.02 ** Sham v BDL 
Bilirubin 
 
1.75±1.077 118.3±14.61** 117.8±6.43 ** Sham v BDL 
Albumin 
 
32.93±3.10 21.59±1.27** 20.52±1.18 ** Sham v BDL 
 
Table 6.1: Plasma levels of ALT, AST, Bilirubin andAlbuminin the various groups. 
(**p<0.001, *p<0.01) 
The results of the biochemical analysis shows that apart from a significant reduction in 
the serum Alanine Amino Transferase level in the rats treated with L-arginine treated 
BDL rats, there was no significant difference between the groups.  
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6.3.2 Effect of L-Arginine supplementation on the Mean Arterial 
Pressure 
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Fig 6.1: Mean Arterial Pressure in the four Groups of Animals.  This shows that the 
Mean arterial pressure is significantly reduced in the BDL rats as compared to the 
sham rats (p=0.006).There was no change in the MAP after treatment of the BLD 
ratswithL-Arginine.(SHAM+N/S=14,SHAM+ARG=9,BDL+N/S=14, 
BDL+ARG=13) 
 
The results show that there was a  significant reduction in the mean arterial pressure in 
the BDL rats treated with L-Arginine as compared to the sham operated rats (84.96±2.87 
v 97.03±2.67, p=0.006).  However there was no significant difference between BDL rats 
treated with saline as compared to the BDL rats treated with Arginine. 
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6.3.3 Effect of L-Arginine supplementation on the portal pressure 
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Fig 6.2:  Portal Pressure in the four groups of animals. This shows that the portal 
pressure is significantly raised in the BDL rats as compared to the sham operated 
ones (p<0.001).There was reduction in the portal pressure in the BDL rats treated 
with arginine as compared to BDL rats treated with saline (p=0.03). 
(SHAM+N/S=14, SHAM+ARG=9, BDL+N/S=14, BDL+ARG=13) 
The portal pressure was measured on the day of the sacrifice after seven days of Arginine 
or equivalent amount of Normal Saline in sham and BDL rats. The results show that there 
was no significant difference between the sham animals treated with L-arginine or normal 
saline (6.6 ± 0.4 vs.  7.4 ± 0.7 p = 0.4). There was a significant increase in the portal 
pressure in the BDL rats as compared to Sham operated rats treated with saline (5.59 ± 
0.42 vs 15.25 ± 1.02, p <0.0001) However, treatment of the BDL rats with L-arginine 
significantly lowered the portal pressure as compared to the BDL rats treated with normal 
saline (12 ±1.2 vs. 15.8 ± 1.2, P<0.05). 
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6.3.4 Endothelial NOS protein expression: 
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Fig 6.3: eNOS protein expression in the three groups. This shows that the eNOS 
protein expression  is significantly raised in the BDL rats as compared to the sham 
operated ones (p<0.001).There was reduction in the eNOS protein expression in the 
BDL rats treated with arginine as compared to BDL rats treated with saline 
(p<0.001). (SHAM+N/S=5,  BDL+N/S=6, BDL+ARG=6) 
 Western blotting technique was used for the protein expression of eNOS in the various 
groups of animals. The results show that that there is a significant increase in the eNOS 
protein expression in the BDL group (p<0.0001) as compared to the sham group and it 
significantly goes down on treatment with L-arginine ((p<0.001) in the BDL group as 
compared to the BDL group treated with saline. 
e-NOS 
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6.3.5 Endothelial NOS protein activity 
 
Fig 6.4: eNOS protein activity in all the three groups (detected by the radioactive 
method). This shows that there is significant reduction in the eNOS activity in the 
BDL rats as compared to the sham rats (p=0.001). There was a trend towards 
increase in the eNOS activity in the BDL rats treated with L-arginine as compared 
to BDL rats treated with saline. (SHAM+N/S=5, BDL+N/S=6, BDL+ARG=5) 
 
The eNOS activity was measured by the radiometric analysis of hepatic eNOS activity as 
described in section 2.9. This shows that the BDL group has significant reduction in eNOS 
activity as compared to the sham. However upon treatment with L-arginine, the BDL rats 
will regain some of the activity of the enzyme, although this is not statistical significant. 
This was calculated by the radioactive method of conversion from citrulline to arginine 
as described in section 2.9. 
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6.3.6 Protein expression for ADMA 
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Fig 6.5: ADMA protein expression in all the three groups. The ADMA protein 
expression goes up significantly in the BDL rats as compared to the sham operated 
animal. This expression was significantly reduced in the BDL rats treated with L-
arginine. (Sham+N/S=5, , BDL+N/S=6, BDL+ARG=6) 
Western blot technique was used to elicit the protein expression of ADMA. The results 
show that there is a significant increase in the protein expression of ADMA in the BDL 
group (p<0.001) as compared to the sham group. However, on treatment with L-Arginine 
in the BDL group there is a significant reduction of the expression of ADMA as compared 
to BDL rats treated with saline (p<0.05). 
α-tubulin
 
 α-tubulin 
ADMA 
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6.3.7 Protein expression of DDAH1: 
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Fig 6.6: DDAH protein expression in all the groups. The DDAH1 protein expression 
is reduced in the BDL ratsa s compared to the sham operated rats. However, this 
expression is significantly increased in the BDL rats treated with arginine as 
compared to the ones treated with placebo. (SHAM+N/S=5,BDL+N/S=6, 
BDL+ARG=6) 
 The results show that there is a significant decrease in the DDAH1 protein expression in 
the BDL group as compared to the Sham group treated with saline (p=0.04) and on 
treatment with L-Arginine, the protein expression increases significantly in the BDL rats 
as compared to the BDL rats treated with saline(p=0.03). 
DDAH-1 band 
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6.3.8 Protein expression of Nuclear Factor kappa B (NFkB): 
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Fig 6.7: NFkB protein expression in all the three groups. The NFkB protein 
expression goes up in the BDL rats as compared to the Sham operated animal. This 
was however decreased upon treatment of the BDL rats with L-arginine as 
compared to the BDL rats treated with placebo. (SHAM+N/S=5,BDL+N/S=6, 
BDL+ARG=6) 
 The result shows that there is a significant increase in the protein expression of the NFkB 
protein in the BDL group as compared to the Sham group treated with saline(p<0.002). 
On treatment with L-Arginine, there is a significant reduction in the protein expression of 
NFkB in the BDL rats as compared to the BDL animals treated with normal saline 
(p=0.04). 
α tubulin 
NFkB 
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6.3.9 Tumour Necrosis Factor alpha (TNFα) cytokine levels 
S
H
A
M
+N
/S
B
D
L+
N
/S
B
D
L+
A
R
G
0
200
400
600
800
1000
p=0.01 p=0.06
p
g
/m
L
Groups
 
Fig 6.8: TNFα levels in the hepatic tissue in the various groups. The plasma TNFα 
level is increased significantly in the BDL rats as compared to the sham operated 
animals however this effect is abrogated by the treatment of the BDL rats with L-
arginine as compared to the placebo treated BDL rats. (Sham+N/S=5, , BDL+N/S=6, 
BDL+ARG=6) 
TNFα titre was measured by the BD bioscience Cytometric Bead Assay Kit and analysed 
in the FACS Canto II machine. The results show that there is a significant increase in the 
TNFα level in the BDL rats as compared with the Sham rats treated with saline (p=0.01). 
However the levels of TNFα are reduced in the BDL rats treated with L-Arginine as 
compared to the BDL rats treated with normal saline (p=0.06). 
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6.3.10 Liver tissue Arginase Activity: 
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Fig 6.9: Liver tissue arginase activity in all the group. This shows that the arginase 
activity is significantly increased in the BDL rats as compared to the sham operated 
rats. This was significantly reduced in the BDL rats treated with arginine as 
compared to the BDL rats treated with placebo. (Sham+N/S=5,BDL+N/S=8, 
BDL+ARG=8) 
The arginase activity was measured as per section 2.20. The above results show that the 
liver arginase activity is significantly increased in the BDL rats as compared with the 
sham operated rats treated with saline ( p<0.001) and the arginase activity in the liver is 
decreased significantly in the BDL rats treated with arginine as compared to the BDL rats 
treated with saline (p<0.05). 
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6.3.11 Plasma Arginine to ADMA ratio: 
 
B
D
L
B
D
L 
+ 
A
R
G
0
1
2
3
4
5
6
7
8
9
10
11
p<0.05
 
Fig 6.10:  Arginine to ADMA ratio between BDL and BDL animals treated with L-
Arginine animals. This shows that the ratio is increased in the BDL rats treated with 
L-arginine as compared to the BDL rats treated with saline ((p<0.05). 
The results show that the ratio of Arginine to ADMA is significantly increased in the BDL 
rats treated with L-Arginine as compared to the BDL rats treated with normal 
saline(p<0.05). The Arginine to ADMA ratio has been implicated in the synthesis of NO 
as a reduction in this ratio implies that there is relative increase in the ADMA level which 
inhibits eNOS and thereby reduces NO production. However on supplementation with L-
Arginine, there is an improvement in this ratio implying increase in the forward reaction 
for NO synthesis.  
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6.4 Discussion 
This result of this study reveals several important observations. Firstly, the results of this 
study show a significant reduction of portal pressure in the BDL rats treated with L-
Arginine as compared to the BDL rats treated with normal saline. This drop in portal 
pressure is noted in the context of the MAP without any significant difference between 
the BDL rats treated with L-arginine as compared to the BDL rats treated with saline. 
Secondly, the results of the protein expression studies reveal the involvement of the 
ADMA-DDAH pathway in the modulation of portal hypertension. Thirdly, the results of 
the biochemistry and the cytokine analysis, together with the NFkB protein expression 
show the involvement of the inflammatory pathway in the modulation of portal 
hypertension. 
Ever since the seminal paper by Mittal and Groszmann about the presence of a reversible 
component in the pathophysiology of portal hypertension in 1994, there has been a 
growing body of evidence about the various mechanistic pathways involved in the 
modulation of portal hypertension {Mittal, 1994 #1892. The focus of these strategies is to 
reduce intra hepatic resistance by modulating the various vasoactive agents but as there is 
no specific tools to assess it, portal pressure and portal blood flow can be taken as a 
surrogate indicators for the change in intra hepatic resistance. 
It is clear from the literature that reduction of portal pressure to below 12 mmHg or 20% 
below the basal reading has shown to have clear benefit in patients outcome by reducing 
the risk of first bleeding episode to less than 10%. Most of the strategies applied earlier 
have been to reduce the increased splanchnic inflow of blood to the liver including beta 
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blockers but recent data emerging suggest that this strategy may not be beneficial to 
patients in end stages of their disease process (10). Endothelial dysfunction has been the 
main feature of the pathobiology of intrahepatic resistance and reduction in the intra 
hepatic NO has been implicated in this process. In this study, I have used L-arginine as a 
treatment for portal hypertension. L-Arginine is the sole substrate for the production of 
NO with the help from the enzyme eNOS (140). L-Arginine metabolism is highly 
regulated and various pathways are compartmentalised (119). The rationale for using 
exogenous L-Arginine supplementation is to provide adequate substrate for eNOS to 
synthesis NO and reduce the intra hepatic resistance. Plasma concentration of L-arginine 
has been shown to have contradictory levels in various studies in humans and animal 
studies ((210), (216)). This suggests that L-Arginine supplementation has other important 
impact in the modulation of intrahepatic resistance. The finding from this study of 
reduction in portal pressure in the L-Arginine treated BDL rats by 18% from the BDL rats 
treated with normal saline is an important one. This finding is complemented by the 
finding that there is no difference between the two groups in terms of mean arterial 
pressure. Many of the  drugs  that have been tested until now to reduce portal pressure in 
animal models and clinical trial settings have not translated into routine clinical practice 
because of concerns with systemic hypotension (217), (218). Although, there is a risk of 
systemic hypotension with L-arginine supplementation, the studies done previously 
showed a significant reduction in MAP within the first thirty minutes of an intravenous 
bolus dose along with a peak plasma level of arginine within the same time. Whereas, 
after an oral dose, the peak plasma levels were reached at ninety minutes and the 
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bioavailability was around 70%, hence showed a less acute change in systemic 
haemodynamics (167) 
Endothelial Nitric Oxide Synthetase (eNOS) is the main enzyme involved in the oxidation 
of L-Arginine to produce NO and citrulline. In this study, I show that the protein 
expression of eNOS is increased in the BDL rats but is reduced upon treatment with L-
arginine. The enzyme eNOS requires cofactors like calcium, calmodulin and 
tetrahydrobiopterin (BH4) as necessary ingredients to function adequately. Therefore the 
finding of an increased protein expression of eNOS with a loss of activity in the BDL is 
not surprising as it suggest that the activity is lost due to a post translational modification. 
Hepatic eNOS activity regulation is multifactorial and literature suggest that impaired akt 
mediated phosphorylation and increased expression of caveolin I are implicated (28).The 
modification that has been shown to be most common is the reduction in the level of BH4 
which is reduced by increased oxidative stress that is known to be present in the diseased 
liver (219).Recently it has been shown that supplementation of BH4 helps to reduce portal 
pressure by increasing the eNOS activity and thereby increasing NO production (220). 
Asymmetrical Dimethyl Arginine is an endogenous inhibitor of eNOS. In normal 
physiological condition, there is a fine balance in the regulation of NO synthesis as it has 
about 10% inhibition effect on eNOS. However in the context of vascular injury which is 
akin to endothelial dysfunction, there is a significant rise in the ADMA levels, which in 
turn inhibit the eNOS mediated vasorelaxation (221). However, it has already been shown 
to have an increased level of ADMA in both patients (222)and animal models of 
cirrhosis(32)and act as marker for poor outcome (78).Elevated ADMA levels inhibit 
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eNOS and disturbs the ratio between the arginine and ADMA. In this study, I have shown 
that the ADMA protein expression is significantly increased in the bile duct legated rat 
but on treatment with L-Arginine, the protein expression is significantly reduced. The 
reason for the raised level of ADMA in the BDL rat may be multi factorial. ADMA is 
metabolised by Dimethylarginine Dimethylaminohydrolase (DDAH) in the intra-cellular 
compartment. In this study, I show that the DDAH protein expression is reduced in the 
BDL rat liver and goes up with treatment with L-Arginine. The reduced DDAH may play 
a significant part in its failure to metabolise ADMA in the BDL rats. There is a suggestion 
from the literature that the regulation of DDAH and L-Arginine may be intricately linked 
by a negative feedback mechanism and this mechanism may regulate the fine balance 
between the arginine and ADMA levels (223) 
In this study, I have conclusive proved that the inflammatory indices including serum 
ALT levels, TNFα pro-inflammatory cytokine and NFkB protein expression are all 
significantly increased in the BDL rats and goes down after L-arginine supplementation. 
This is further proof of earlier experiments wherein TNFα incubated with cultured 
endothelial cells showed a reduction in DDAH activity and increased in ADMA (224) and 
in vivo experiments done in our laboratory previously which showed that using an anti-
TNFα agent in a BDL rat decreased the portal pressure and ADMA protein expression in 
the liver (225). These results could also imply that L-Arginine might have an anti-
inflammatory property.  
Another important metabolic pathway of L-arginine is via the arginase pathway. In this 
study, I show that the arginase activity is increased in the BDL rats and goes down 
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significantly with treatment. There are multiple mechanisms that are involved in the 
modulation of vascular reactivity. The most important pathway for L-Arginine 
metabolism is via arginase and arginase also competes with eNOS for substrate although 
L-arginine has a natural preference of eNOS. Early studies on activated macrophages 
reveal that majority of L-arginine is consumed by arginase to produce urea and L-
ornithine.  The NO bioavailability is only increased by either supplementing L-Arginine 
or inhibiting arginase (130). Depletion of substrate L-Arginine for NO production leads 
to uncoupling of the eNOS leading to free radical formation, which in turn inactivates 
NO, thereby indicating that increase arginase activity indirectly leads to decreased NO 
bioavailability (136) Another alternative mechanism in which arginase works is by 
sensitising ADMA to eNOS either directly (135) or through the presence of inflammatory 
cytokines (226). 
The effect of an elevated ADMA level signifies an alteration in the arginine to ADMA 
ratio. In a recent study using a rat model where rats were randomised to receive normal 
saline as control, ADMA or a combination of arginase and ADMA as infusion shows that 
the group with the low arginine level with high ADMA had the most significant 
haemodynamic deterioration (227). In a previous study done from our group, it has been 
shown that in the presence of inflammation in cirrhosis, there is an increase in the ADMA 
levels and is associated with worse outcome (78). These result suggest that there is an 
alteration in the in the physiological balance between Arginine to ADMA which causes a 
reduction in NO synthesis and consequent haemodynamic abnormalities. The effect of 
this is found on the transporter system present in the transmembranous region. The 
cationic acid transporters are protein which transport the arginine into the intracellular 
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compartment also transport ADMA. When there is an increase in the level of ADMA, 
though it may be disproportionally small increase, it alters the transport mechanism and 
facilitates the transport of ADMA to the intra cellular compartment instead of arginine. 
Therefore, there is a relative deficiency of arginine in the intra cellular space, which in 
turn leads to reduced production of NO. The phenomenon of altered transport of Arginine 
and ADMA is known as the arginine paradox.  Although there is apparently abundant 
pool of arginine available, since it is all compartmentalised, not enough arginine may be 
available for the production of NO.  It is for this rationale that exogenous replacement 
may play a part in the regulation of intra cellular arginine levels and therefore has been 
used in our experiment. 
In conclusion, the results presented in this section of the thesis suggest that exogenous 
supplementation of L-arginine may be an important alternative therapeutic strategy for 
the treatment of portal hypertension. This has a significant effect on the inflammation that 
prevails in the bile duct ligated model and improvement in the endothelial dysfunction. I 
have been able to prove my hypothesis that L-arginine supplementation can be used an 
anti-inflammatory strategy for treatment of portal hypertension.  
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                                 Chapter 7 
                  Summary and Future Directions 
The modulation of inflammation in the reduction of 
portal hypertension 
7.1 Summary 
The onset of portal hypertension is an important clinical juncture for a patient with 
cirrhosis. This implies that the patient will be at risk of progression to severe and often 
fatal complications like ascites, spontaneous bacterial peritonitis, variceal bleeding and 
hepatic encephalopathy. Their mortality and morbidity with these complications goes up 
significantly. It has become clear that a decrease in portal pressure is not only protective 
against the risk of variceal (re)bleeding but is also associated with a lower long-term risk 
of developing complications and an improved long-term survival. Despite the high 
mortality associated with portal hypertension, there are a limited number of treatment 
options and a lack of consensus amongst physicians on their use. Treatment options for 
portal hypertension remain limited to non selective beta blocker (NSBB). These achieve 
a target reduction of > 20% reduction in hepatic venous pressure gradient (HVPG) in only 
40% of patients. About 20% of patients cannot tolerate the treatment because of easy 
fatigability and hypotension. Many other drugs have been able to show reduction in portal 
pressure in the research setting. However, many of these successes have not translated to 
their use in routine clinical settings. This may be because of the inability of overcoming 
the dichotomy of vasoconstriction in the intrahepatic circulation and vasodilatation in the 
splanchnic and systemic circulation.  
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Inflammation has been highlighted recently to play a major role in the propagation of 
portal hypertension by increasing intra hepatic resistance. This is mainly by inducing 
endothelial dysfunction. Anti-inflammatory strategies in portal hypertension have shown 
improvement in endothelial function and reduction in portal hypertension (228),(71). 
However, the exact mechanisms of these beneficial effects have not been elucidated in 
most of these strategies. There is therefore a significant clinical need to understand the 
impact of inflammatory mechanism on portal hypertension and the benefit of their 
modulation as a therapeutic target. 
The series of studies done as part of this thesis is an attempt to modulate inflammation as 
a strategy to reduce intra hepatic resistance and thereby portal hypertension. In the first 
section of the thesis in Chapter 3, I set out to validate the rodent model of bile duct ligated 
rat as a model suitable for study in this project. Bile duct ligated rats have been used in 
various studies on portal hypertension and cirrhosis. However, there is heterogeneity in 
the establishment of the model with some studies suggesting that there is evidence of 
portal hypertension from end of week 2 post bile duct ligation whereas other studies have 
shown that portal hypertension is fully established at the end of four weeks.  
In my study, this model provides characteristic features of secondary biliary cirrhosis 
induced by the bile duct ligation at the end of four weeks. This induces a significant 
architectural change in the liver with evidence of cholangiocyte proliferation and 
formation of septa, which could be translated to nodule formation in a cirrhotic human 
liver. Biochemically they show a low albumin and a high bilirubin as compared to the 
sham operated rat. The aminotransferase enzymes are raised non significantly in the BDL 
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rats as compared to the sham operated rats. The cytokine profile shows that there is a 
significant increase in the level of TNFα in the BDL rats as compared to sham operated. 
However, on injection of Lipopolysaccharide to the BDL rats, there is a further significant 
increase in the cytokine (TNFα) as well as increase in the aminotransferase levels. This 
indicates that the second hit with LPS injection provokes a more profound inflammatory 
reaction in the BDL rats. This is akin to the recently described concept of Acute on 
Chronic Liver Failure where a superadded infection or inflammatory insult provokes an 
exaggerated Systemic Inflammatory Response 
 There was a significant difference in the haemodynamic features between the sham and 
the BDL rats with the BDL rat having lower mean arterial pressure and higher portal 
pressure as compared to the sham operated animal. The heterogeneity of the model in our 
laboratory was less than 10%. These include the failed BDL rats and also variation in the 
haemodynamic measurements. With all these generated data, it was evident that this 
model would be a good model to undertake the proposed research project. 
Inflammation has been recently recognized as an important precipitant of acute on chronic 
liver failure. It is associated with significantly increased early mortality of patients. It is a 
well-established fact that the presence of inflammation in cirrhotic patients is associated 
with high portal pressure. Recently, we have shown that the presence of inflammation in 
patients with cirrhosis is directly related to the levels of sympathetic activation in these 
patients (229). Given the acknowledged reduction in beta-receptors with cirrhosis and 
evidence from the sepsis literature that suggests the  ADRA2a may be a target for 
reduction of inflammation and liver dysfunction, this lent itself to further study as of 
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potential mechanistic importance in portal hypertension. In my studies, I used the BDL 
rat as the portal hypertension model which also demonstrates an increase in inflammatory 
markers.  
In chapter 4, I demonstrated that there was a significant increase in the ADRA2a receptor 
(mRNA and protein) in the BDL rats as compared to the Sham operated animals.  By the 
use of a specific ADRA2a receptor antagonist, I was able to reduce portal hypertension 
by a clinically significant level. I also showed an increase in the cyclicAMP level and the 
endothelial NOS activity. These provide evidence of a link between increased ADRA2a 
and the development of endothelial dysfunction. In further experiments involving hepatic 
stellate cells, and following their challenge with Guanfacine, an ADRA2a adrenergic 
receptor agonist), there was a significant increase in the contractility of the HSC. This 
implied that antagonism of ADRA2a causes relaxation of the HSC, thereby promoting a 
reduction in intra hepatic resistance. This set of experiments provided a proof of concept 
that there was an alternative pathway for the treatment of portal hypertension other than 
targeting the beta adrenergic preceptor.  
The gut-liver axis has been well established as the main pathway for the propagation of 
inflammation by way of increased gut bacterial translocation. These bacterial products are 
carried by the circulating immune cells to the liver where in inflammatory cytokines are 
produced to affect changes to tissue resident macrophages (Kupffer cells), which in turn 
leads to increased  resistance vessels contraction and intra hepatic resistance.  
In the next set of experimentation in Chapter 5, I studied immune cells and their function 
in the setting of a BDL rat treated with or without LPS, thereby mimicking the clinical 
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picture of ACLF. I was able to demonstrate that there is an increase in the population of 
neutrophils and monocytes within the liver in the BDL rats treated with or without LPS 
as compared to sham operated rats. But more importantly, there is a significant 
improvement of functional capacity of the neutrophils and monocyte as evidenced by the 
improved phagocytosis and reduced Reactive Oxygen Species generated in the BDL rats 
treated with an ADRA2a antagonist. These findings are complemented by reduction in 
the inflammatory cytokine levels and significant reduction in portal pressure in the BDL 
rats treated with saline or LPS. This supports the contention that targeting the ADRA2a 
adrenergic receptor may be a valid target for the treatment of portal hypertension , 
especially in the context of added inflammation.  
Another area of interest is the impact of endothelial dysfunction in the pathogenesis of 
portal hypertension. In physiological conditions, the intact endothelium acts a natural 
barrier to the underlying vascular tissue and helps to maintain vascular equilibrium. The 
term endothelial dysfunction refers to impairment of the various functions of the 
endothelium, the most important amongst them being impaired release of vaso-relaxant 
like Nitric Oxide. L-arginine , an amino acid, is an essential substrate for the enzyme 
endothelial nitric oxide synthetase to produce nitric oxide. However, in the context of 
inflammation in liver cirrhosis, there is evidence of endothelial dysfunction leading to 
reduced intra hepatic nitric oxide and increased intra hepatic resistance. We have 
previously described the decrease in total body nitric oxide level in a devascularised 
porcine model and this may have been contributed by increase production of plasma 
arginase and ADMA levels. 
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 In the second section of my thesis in Chapter 6, my focus was in the importance of 
modulating Nitric oxide in maintaining intra hepatic vascular tone, in the context of 
inflammation. L-Arginine is the sole substrate needed for the production of nitric oxide. 
However, it is well established in the literature that there are multiple factors which alter 
the availability of L-Arginine for the production of NO. The two most important factors 
that have gained importance is that of increased ADMA levels and a more efficient 
arginase metabolic pathway. Both of these factors have been shown to be most activated 
in a  pro-inflammatory environment and it is already known that l-Arginine has significant 
anti-inflammatory properties.  
Therefore, in this section, I undertook a study of supplementation of L-Arginine in the 
BDL rats and explored whether this reduced portal hypertension and the potential 
mechanisms involved. Through this study , I was able to demonstrate that the portal 
pressure is significantly reduced in the BDL rats treated with L-Arginine as compared to 
the BDL rats treated with saline. This was not associated with any significant change in 
the MAP in the two groups. Moreover, there was also a significant drop in the 
inflammatory markers in the BDL rats treated with L-Arginine as compared to the BDL 
rats treated with saline. There was also increased eNOS activity in the arginine treated 
group in the context of decreased liver ADMA demonstrating the proof of concept that 
supplementation of L-arginine reverses the Arginine:ADMA  ratio to a favourable one, 
and thereby reduces portal pressure in these rats. 
Therefore, in conclusion, the studies described in this thesis confirm a clear association 
between inflammation and vascular dysfunction and more importantly increased portal 
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pressure. Furthermore, it is established that inflammation is a key factor in the propagation 
of portal hypertension. This leads to increased production of pro-inflammatory cytokines 
and significant reduction in eNOS activity. However with these two different anti-
inflammatory strategies, I have been able to show significant improvement of hepatic 
haemodynamics and eNOS activity indicating improvement in endothelial function. 
Based on the results presented in this thesis, both L-arginine supplementation and 
antagonism of ADRA2a provide potential new targets to treat portal hypertension. 
7.2 Limitations of the studies: 
7.2.1. ADRA2a study limitations:  
1).It should be acknowledged that although the data presented in this thesis strongly 
suggest that an anti-inflammatory pathway is definitely implicated in the BDL rats treated 
with a ADRA2a adrenergic receptor antagonist, there are other adrenergic receptors 
including the adrenergic receptor 2 subtypes B and C present in the systemic and portal 
vasculature. . Especially the ADRA2b have opposing physiological vasomotor effect 
which have not been studied in detail in these experiments. There is a potential that 
ADRA2a antagonism may have a significant unintended effect on the ADRA2b receptor 
which has not been accounted for in these studies. ADRA1 is another important receptor 
which has been antagonized in portal hypertension (230). ADRa2a antagonism increases 
the level of noradrenaline which will have a potential unintended effect on the ADRA1 
receptor which has not been studied as part of this thesis.  
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Moreover, as part of this thesis, I have demonstrated that there is presence of ADRA2a 
receptor in the Hepatic stellate cells and endothelial cells. However, there is some 
indication of modulation of inflammation by ADRA2a antagonism via the migrating 
immune cells. The exact contribution of each of these cell types have not been studied in 
detail as part of this thesis. 
2). The second most challenging aspect was the technical limitations of reliable ADRA2a 
adrenergic receptor  antibodies from which western blots and Immunohistochemistry  
analysis could be undertaken. Therefore, these had to be done multiple times in different 
test conditions and with different suppliers, in order to get an interpretable result. 
Ultimately, the most reproducible analysis was based on quantitative Polymerase Chain 
Reaction analysis.  
3). There were also a few logistical challenges in having to do several ex vivo experiments 
including haemodynamic experiments and cell separation assays simultaneously. 
However, I was fortunate enough to be able to avail the help offered by my co -research 
fellow colleagues in helping out at various stages of these studies. 
7.2.2. L-Arginine study limitations:  
1).The biggest limitation in this study was to work out the optimum method for Nitric 
oxide generation. I have attempted to do the Nox method to quantify generation of Nitric 
oxide. However, the results were very difficult to replicate. The eNOS activity assay also 
depends on experimental condition and the integrity of the tissue. The radioactive isotope 
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method is difficult to access and also operator dependent and therefore, difficult to 
generate reproducible results.  
2).Although, I have demonstrated that exogenous supplementation of L-Arginine alters 
the Arginine:ADMA ratio, the role of the cationic amino acid transporters have not been 
explored in this study. It is well established that a number of carrier proteins for amino 
acids have been identified on the molecular level. They belong to different gene families, 
exhibit overlapping but distinctive substrate specificities, and can further be distinguished 
by their requirement for the cotransport or counter-transport of inorganic ions. Uptake of 
amino acids by these transporters therefore depends largely on the intracellular substrate 
composition. Hence, there is a complex crosstalk between transporters for cationic and 
neutral amino acids. The transmembrane transporter Cationic Amino Acid Transporters 
(CAT ) are further divided into subtypes with CAT1, CAT2A/2B and CAT3. The 
transporting properties depend on several important parameters including the pH and 
substrate availability. As part of this study, I did not assess  the role of the individual sub 
type of co transporter in the BDL model and therefore it remains unclear as to the 
contribution it makes to alter the Arginine:ADMA ratio and thereby it’s influence in the 
improvement in endothelial dysfunction.  
However, inspite of these challenges, I have been able to present my finding with  data to 
prove the hypothesis and make an assertion that there is value in pursuing these strategies 
in the near future in the setting of a clinical trial. 
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7.3 Future Directions: 
The two  most important finding in the context of the studies presented in this thesis have 
been the reduction of portal pressure in the BDL rats treated with an ADRA2a receptor 
antagonist with a maintenance of the mean arterial pressure and the supplementation of 
L-arginine as an anti inflammatory strategy for the treatment of portal hypertension. I 
accept that these results have been generated using a single rodent model of secondary 
biliary cirrhosis with evidence of portal hypertension and inflammation. Therefore, it is 
important to address whether the observed findings can be reproduced in another model 
of liver injury such as a Carbon Tetrachloride induced liver injury rodent model. This 
would increase confidence in the data that the findings are more generalizable to 
modulation of inflammation in cirrhosis and not unique to the BDL model.  
There are several experimental questions that have arisen from the observations that have 
been made thus far. They are as follows: 
1).The experiments in these studies have been designed to specifically look at the role of 
ADRA2a in the  modulation of intra hepatic circulation. It is well established that other 
end organs, specifically the kidney and brain are critically involved in the evolution of 
decompensation of cirrhosis with advancing portal hypertension. I have shown some 
preliminary data on improvement in kidney function and brain inflammation in this BDL 
model using an ADRA2a antagonist. It has already been shown that the kidney and the 
brain have got abundance of ADRA2a receptors normally. It would be interesting to 
assess the effect of ADRA2a antagonism in these organs in the BDL model in more detail.  
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In order to address this question a BDL model can be used to particularly focus on the 
kidney and brain. In the kidney, haemodynamic assessment with flow measurements and 
functional assessment with ioxehol infusion can be measured in both the healthy and 
diseased (BDL) states. This is in addition to measuring the urine output from collections 
made in metabolic cages pre and post treatment, plasma creatinine and protein expression 
and  immunohistological assessment of Toll Like Receptor 4 expression as a marker of 
renal inflammation and the effect of treatment with ADRA2a antagonist. 
 In the brain, haemodynamic measurements could be assessed with functional MRI 
techniques which are being validated in animal models in our lab since the time I finished 
my practical experimentation. The functional study could be assessed by Barnes Maze 
experiments wherein working memory and learning could be assessed. This is in addition 
to measurement of brain tissue inflammatory markers and assessment of astrocyte 
swelling by brain water measurement and glutamine protein expression in pre and post 
treatment animals. These experiments will further our knowledge in the affected animals 
of progression of cirrhosis and portal hypertension, and the impact of modulating 
ADRA2a receptor in these models, in relation to effects on these major end organs.  
2).In these sets of experiments, I have  studied the effect of ADRA2a antagonism in portal 
hypertension in the BDL model. I accept that adrenergic antagonism may not completely 
block the effect of the ADRA2a adrenergic receptor. In order to elaborate further on the 
role of adrenergic receptor blockade in more detail, it would be interesting to study the 
impact of hepatic and vascular dysfunction in a heterozygous ADRA2a knockout model 
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treated with or without LPS. If the injury is non-lethal, it would be important to note if 
the dysfunction can be reversed by using a ADRA2a agonist.  
ADRA2a KO mice are now widely available on a commercial basis and with 
collaborators. These can be acquired so that further studies can be carried out to assess 
level of injury and dysfunction. In particular, all haemodynamic , biochemical and organ 
dysfunction parameters can be collected and analysed in all the groups. More specifically, 
markers of endothelial dysfunction including eNOS and nitric oxide production, 
inflammatory markers (TNFa, IL6) and liver architecture in wild type and diseased 
animals could be assessed. I would expect an abrogation of the inflammatory response 
and possibly improvement in liver architecture as compared to a wild type BDL rats with 
or without LPS.  
3).In these set of experiments , the design of the study was to only look specifically at the 
effect of ADRA2a antagonism. As alluded to previously, there will be some unintended 
effect on the ADRA 2 subtypes including the ADRA2b and ADRA2c adrenergic 
receptors. ADRA1a is a major sub set of adrenergic receptors that are present in 
abundance in the systemic vasculature and heart. The question that needs further 
investigation is  the role of the other adrenoreceptors in the  progression of liver disease. 
Does a specific ADRA2a antagonist have reciprocal effect in the other adrenoreceptors in 
the intra and extra hepatic vascular bed. 
By using the same model of BDL rats , the subtypes of ADRA adrenergic receptors can 
be assessed by protein expression and/or quantative PCR. These analysis could be co-
related to the plasma noradrenaline and haemodynamic results obtained from these studies 
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and specific conclusions regarding the role of these subtype of receptors in this model  can 
be addressed.  
4).In order to progress into the next steps of translating the findings from these 
experiments  into  clinical trial, there are several steps that needs to be achieved. Currently, 
the ADRA2a receptor antagonist is only available as a scientific compound in  powder 
form and therefore will not qualify as an  Investigational Medical Product under the Good 
Manufacturing Practice licence agreement. The closest compound that is already in use in 
the clinical context is Yohimbine (non selective ADRA2 antagonist) which has been 
produced in a GMP approved facility and therefore eligible to be used in man as part of a 
clinical trial. Preliminary data from our laboratory have shown a significant drop in the 
portal pressure in Bile duct ligated rats with preserved mean arterial pressure. These 
promising results appear to  suggest that it might be a suitable alternative to using a 
specific ADRA2a antagonist. 
In the second part of this thesis, I used L-Arginine as an anti-inflammatory agent for 
lowering portal pressure. It is clearly going to be important to validate these findings in 
other forms of liver injury. These observations have given rise to further research 
questions 
1).As previously highlighted, the experiments that have been designed as part of these 
studies focussed in the lowering of intra hepatic resistance by using an anti inflammatory 
strategy. Therefore , it will be important to understand the effect of treatment with L-
arginine on other end organs in this model , more specifically the kidney and brain.  
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To answer these questions,  a similar BDL model of portal hypertension can be used and 
the experimental design specifically focussed on  the kidney and the brain. Kidney and 
brain tissue can be collected and stored as fresh frozen samples. The haemodynamic 
parameters in the kidney can be assessed by flow probes and the function can be assessed 
by ioxehol clearance, as in the ADRA2a experiments, in both treated and untreated 
groups. Tissue based cytokine assays and immunohistochemical assessment of TLR4 
expression can be assessed to probe into the anti-inflammatory properties of L-arginine 
treatment in the kidney in this model.  
Similarly, assessment of haemodynamic parameters and functional activity status of the 
brain can be assessed with similar experiments as highlighted in the ADRA2a studies. It 
is interesting to note  since the end of my practical experiments, other researchers from 
my lab have published an paper using an anti inflammatory strategy in the BDL model 
showing an alteration of the Arginine:ADMA  in the brain tissue (196). Therefore, it will 
important to study the exact mechanism of L-Arginine supplementation which plays a 
role in the modulation of  inflammation in the brain and kidney.  
2).It is clear from the published literature that L-arginine supplementation strategies vary 
widely between studies. The heterogeneity is in relation to route, dose and method of 
supplementation. This has a bearing on the tissue bioavailability of L-arginine. There is 
an alternative strategy which would involve replacing citrulline in place of L-arginine, 
which might be a more effective strategy to increase intra hepatic NO and lower portal 
pressure as compared to direct L-arginine supplementation. 
199 
 
The rational basis of supplementing citrulline to increase arginine availability is that there 
is a significant degradation of arginine by way of first pass metabolism whereas the only 
fate of citrulline is conversion to arginine in the small intestine. Therefore it may be  a 
more efficient strategy to increase plasma arginine levels. A similar experimental model 
of portal hypertension has to be implemented to test this hypothesis. 
3).In order to overcome one of the major issues that I have highlighted in the limitation 
section is to address the best method of measuring Nitric oxide synthetase activity. The 
methods that have already been established have each got its own issues in the 
methodology and the interpretation of the results. I have attempted to do the Nox method 
to quantify generation of Nitric oxide. However, the results were very difficult to 
replicate. The eNOS activity assay also depends on experimental condition and the 
freshness of the tissue. The radioactive isotope method is difficult to access and also 
operator dependant and therefore, difficult to reproduce the results. 
In our lab, we have now used phosphorylated eNOS protein expression by western blot 
as the surrogate marker for Nitric oxide production. This method has previously been 
validated in other published studies. In order to assess this further, it would be ideal to use 
this protein expression study in other animal models to assess if we get the same results. 
4).If the availability of L-arginine can be circumvented, then an ideal clinical trial using 
L-Arginine infusion in cirrhotic patients would be able to be set up to assess if it would 
drop portal pressure by reduce the inflammatory burden in this cohort of patients. All 
involved end organs including the kidney and the brain can be assessed in the same study 
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to understand whether L-arginine supplementation has a beneficial effect in these organs 
too by way of improved hameodynamics and function.  
Overall, in conclusion of this thesis, I have been able to make several important 
observations by providing an alternative strategy to ameliorate portal hypertension. In 
pursuit of these answers to my hypothesis, I have been able to gather a significant amount 
of knowledge and understanding about the pathophysiology of portal hypertension. 
Moreover, as highlighted in the future directions section, these studies have been able to 
generate further important questions that needs to be pursued systemically as part of the 
ongoing studies to develop this area of research. I hope that I will be able to sustain my 
scientific and clinical inquisitiveness to undertake some of these studies and remain an 
integral part of this research group and to continue to contribute actively to achieve ground 
breaking research output. 
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